Review

Structure and Biological Activity of Ergostane-Type Steroids from Fungi

Vladimir N. Zhabinskii 1,* , Pavel Drasar 2 and Vladimir A. Khripach 1

1 Institute of Bioorganic Chemistry, National Academy of Sciences of Belarus, Kuprevich Str., 5/2, 220141 Minsk, Belarus; khripach@iboch.by
2 Department of Chemistry of Natural Compounds, University of Chemistry and Technology, Technicka 5, CZ-166 28 Prague, Czech Republic; pavel.drasar@vscht.cz
* Correspondence: vz@iboch.by; Tel.: +375-29-759-811

Abstract: Mushrooms are known not only for their taste but also for beneficial effects on health attributed to plethora of constituents. All mushrooms belong to the kingdom of fungi, which also includes yeasts and molds. Each year, hundreds of new metabolites of the main fungal sterol, ergosterol, are isolated from fungal sources. As a rule, further testing is carried out for their biological effects, and many of the isolated compounds exhibit one or another activity. This study aims to review recent literature (mainly over the past 10 years, selected older works are discussed for consistency purposes) on the structures and bioactivities of fungal metabolites of ergosterol. The review is not exhaustive in its coverage of structures found in fungi. Rather, it focuses solely on discussing compounds that have shown some biological activity with potential pharmacological utility.

Keywords: ergosterol; ergosteroids; fungi; mushrooms; anticancer; antiviral; cytotoxicity

1. Introduction

Fungi are a rich source of chemical compounds with a wide spectrum of biological activity [1]. To survive in the environment in which they exist, they need to protect themselves from fungal infections. Therefore, it is not surprising that antimicrobial or antiviral compounds beneficial to humans can be isolated from many fungi [2]. A large number of currently used drugs have their origins in fungi [3]. Steroids occupy an important place among fungal constituents. The vast majority of them are ergosterol metabolites. The latter is the main sterol of fungi involved in the regulation of membrane fluidity and structure as well as performing immunological functions [4]. Fungal ergosterol derivatives are often referred to as “ergostane-type steroids” [5–12] or “ergosteroids” [13–17]. One should bear in mind, however, that the application of the term “ergosteroids” can be confusing, as it was also suggested by Lardy et al. [18] to structurally different dehydroepiandrosterone derivatives based on their mode of action (influence on energy metabolism).

Ergostane-type steroids are characteristic not only of fungi but also of plants [19–21] and sponges [22]. These steroids are not a focus of the present paper. The purpose of this review is to highlight current knowledge on the structures and biological activities of fungal constituents, built on an ergostane skeleton 1 (Figure 1) or structures of which can be traced back to it. Currently, there are a number of reviews in this area dedicated to certain aspects or groups of ergostanes. A nice review on chemistry, biology, and medicinal aspects of rearranged ergostane-type natural products has been published recently by Heretsch et al. [23]. A detailed literature survey by Merdivan and Lindequist was dedicated to the consideration of biological activities of a single compound (ergosterol 5α,8α-endoperoxide) [24]. Many reviews discuss ergostane-type steroids as a part of fungal compositional diversity constituents [25–32].
Figure 1. 5α-Ergostane skeleton 1 and structure of ergosterol (2).

2. Sterols

2.1. Ergosterol

Detailed studies of the biological effects of fungi have shown that some of them can be attributed to ergosterol (2) [33–38]. That is why ergosterol itself has attracted considerable attention as a potential lead for the development of new therapeutics. Its anticancer properties were investigated on the lungs [39], liver [40,41], breast [42], human gastric [43], and prostate [44] cancer cell lines.

Ergosterol treatment of mice inoculated with breast cancer cells prolonged mouse survival [42]. Suppression of cancer cell viability was explained by apoptosis and by up-regulating Foxo3 and Foxo3 downstream molecules Bim, Fas, and Fas L.

The antitumor potential of ergosterol was studied upon its application with amphotericin B [40]. The latter is a macrolide antifungal agent that is also used to reverse chemotherapeutic drug resistance. The combined treatment of liver cancer cell lines with ergosterol followed by amphotericin B resulted in a significant decrease of their viability as a result of necrotic cell death.

Experiments on reversing multidrug resistance in cancer cells were also performed using drug-sensitive human gastric carcinoma cell line SGC7901 and its adriamycin-resistant counterpart SGC7901/Adr. Ergosterol at concentrations below 5 µM has been shown to enhance the cytotoxicity of adriamycin on SGC7901/Adr cells [43].

In experiments with Hep2 cancer cells, it was shown that ergosterol inhibited cell growth with IC₅₀ value of 40 µM/mL [41]. The observed effect was explained by the pro-oxidant properties of ergosterol on the Hep2 cells.

Different effects have been noted for androgen-dependent LNCaP and androgen-independent DU-145 prostate cancer cells [44]. While ergosterol exerted an antiproliferative action on LNCaP, it promoted cell proliferation on DU-145. The authors [44] suggested that the observed difference may be related to the ability of ergosterol to act as a ligand for the androgen receptor.

Experiments with rats fed with a diet containing 0.1% ergosterol have shown a certain bladder carcinogenesis-preventing effect [45]. It was supposed that the observed effect is due to an androgen receptor expression-reducing action of brassicasterol (metabolite of ergosterol) on bladder epithelial cells.

Several studies have reported the anti-inflammatory effects of ergosterol. Its treatment of RAW 264.7 macrophages inhibited lipopolysaccharide-induced inflammation by suppressing the production of tumor necrosis factor-α and expression of cyclooxygenase-2 [46]. The inhibitory effect of ergosterol on degranulation of mucosal-type murine bone marrow-derived mast cells [47] or basophilic leukemia (RBL-2H3) cells [48] was associated with inhibition of β-hexosaminidase and histamine release in antigen-stimulated cells and was of interest for the treatment of allergic diseases dependent on mast cells.

Pretreatment of mice with ergosterol at doses of 25 and 50 mg/kg reduced lipopolysaccharide-induced histopathological changes in the lungs [49]. In addition, inhibition of inflammatory cells and pro-inflammatory cytokines, including tumor necrosis factor-α and interleukin-6, was observed. Similar effects were found on cigarette smoke-induced chronic obstructive pulmonary disease (COPD) in mice [50]. Besides inhibiting pro-inflammatory cytokines, ergosterol restored the activities of superoxide dismutase and reduced the content of malondialdehyde in serum and in the lung. Another study of
ergosterol’s protective effect against the cigarette smoke extract-induced COPD suggested that protective effects may be related to the NF-κB/p65 signaling pathway [51].

The transcription factor Nrf2 plays an important role in controlling the expression of antioxidant genes, which ultimately leads to anti-inflammatory effects. Activation of the Nrf2 signaling pathway by ergosterol was shown to enhance cardiomyocyte resistance to oxidative stress in lipopolysaccharide- or isoproterenol-induced myocardial injury [52,53]. Oral administration of ergosterol (25 mg/kg/day) to mice for two weeks effectively delayed the progression of osteoarthritis through a mechanism involving activation of the Nrf2 pathway in primary chondrocytes [54].

Diabetic nephropathy is a chronic loss of kidney function in patients with diabetes mellitus. Ergosterol has been shown to attenuate kidney damage in diabetic mice [55,56]. It restored blood glucose and serum insulin levels and improved most biochemical and renal functional parameters. Xiong et al. [57] considered ergosterol as a potential hypoglycemic agent for the treatment of type 2 diabetes mellitus based on the discovery that it could promote glucose transporter type 4 translocation and expression, as well as glucose uptake via the PI3K (phosphatidylinositol 3-kinase) and Akt (protein kinase B) pathways. Hyperglycemia promotes the formation of advanced glycation end products (AGE) by crosslinking proteins and carbohydrates. Ergosterol prevented the suppression of oxidative stress in HSC-T6 cells and prevented age-related diseases such as liver fibrosis and diabetes [58].

An inhibitory effect of ergosterol against human recombinant aromatase (IC\textsubscript{50} 8.1 µM) was observed in aromatase inhibitory assay [59]. Potential beneficial effects against ethanol hepatotoxicity were predicted by density functional theory calculations based on the ability of ergosterol to scavenge the \( \bullet \text{CH(OH)}\text{CH}_3 \) radical [60].

The following pharmacokinetic parameters were measured after a single oral administration (100 mg/kg) of ergosterol to rats: the area under the plasma concentration versus time curve from time 0 h to 36 h (AUC\textsubscript{0–36}) was 22.3 µg h mL\(^{-1}\), peak plasma concentration (C\textsubscript{max}) was 2.27 µg/mL, the elimination half-life (t\textsubscript{1/2}) was 5.90 h, and time to C\textsubscript{max} (T\textsubscript{max}) was 8.00 h [61].

Ergosterol is an easily crystallized compound with low water and oil solubility. To increase its bioavailability, nano-sized delivery vehicles were suggested to overcome this limitation. Poly(lactide-co-glycolide) nanoparticle encapsulation allowed a 4.9-fold increase of oral bioavailability compared to free ergosterol [62]. The relative oral bioavailability of ergosterol-loaded nanostructured lipid carriers prepared using glyceryl monostearate and decanoyl/octanoyl glycerides by hot emulsification-ultrasonication was 277% higher than that of ergosterol itself [63].

In addition to being used as an active ingredient, ergosterol has also been tested as part of other drug delivery systems. The study of cellular uptake and in vitro cytotoxicity of cyclic arginine-glycine-aspartic and octa-arginine peptide-modified ergosterol-combined cisplatin liposomes showed their stability in serum and the strongest anti-lung cancer effect [39]. The encapsulation of chlorin e6 in self-assembled ergosterol nanoparticles resulted in a novel supramolecularly assembled photosensitizer [64]. When applied to cancer cells 4T1 and MCF-7, it showed remarkable in vitro phototoxicity with cell inhibition of about 73% and 92%, respectively. Evident in vitro antiproliferative activity was demonstrated for a mixture of sterols (consisting mainly of ergosterol and 22,23-dihydroergosterol) from popular edible mushroom \textit{Flammulina velutipes} [65]. Encapsulation of the mixture increased the relative bioavailability of ergosterol and 22,23-dihydroergosterol to 163 and 244%, respectively.

Another way to increase the bioavailability of ergosterol is the preparation of its derivatives. Direct esterification of ergosterol and lauric acid led to the coupling product ergosterol laurate (3a) (Figure 2) with solubility in vegetable oil above 5.7 g/100 mL, while for ergosterol it was below 0.9 g/100 mL [66]. Esters of unsaturated fatty acids, ergosterol oleate (3b), ergosterol linoleate, and ergosterol linolenate were prepared by transesterification reaction using \textit{Proteus vulgaris} K80 lipase [67]. Their solubility in the tricaprylin solvent
Molecules 2022, 27, 2103

was 11–16 times higher than that of the initial sterol. Another ergosterol ester, \( \alpha \)-linolenic acid derivative, was prepared using Candida sp. 99-125 lipase as a biocatalyst [68].

![Diagram](image-url)

**Figure 2.** Structures of ergosterol O-derivatives.

The glucopyranosyl derivative 4 showed slightly higher activity in inhibiting LPS-induced NO production than ergosterol (1) (IC\(_{50}\) 16.6 and 14.3 \( \mu \)M, respectively) [69]. On the other hand, COX-1 enzyme inhibitory activity of 4 was weaker compared with that of the aglycone 1 [70].

Ergosterol adduct, ferulate 5, was studied for the HMG-CoA reductase inhibitory activity, which was 1.93 times higher than that of oryzanol [71]. Another adduct 6, derived from 2-naphthoic acid and ergosterol, showed stronger anti-tumor [72] and antidepressant [73] activities in vivo compared to ergosterol.

The antiproliferative effects of some ergosterol dimers have been studied against the HT29 and MCF-7 cancer cell lines [74]. The most effective was dimer 7 for the HT29 cancer cell line with an IC\(_{50}\) value of 160 \( \mu \)M. Unfortunately, the results of comparing the activity with ergosterol itself were not reported.

2.2. Other Fungal Sterols

Sterol fraction of fungi is typically a mixture of sterols [75]. As a rule, ergosterol has been considered to be its dominant component. However, this is not true in all cases. There are at least four other taxon-specific sterols (cholesterol, 24-methylenecholesterol, 24-ethylcholesterol, and brassicasterol), which may be the main sterols in some fungal species [76]. Research on the biological or pharmaceutical uses of ergostane sterols has received much less attention compared to ergosterol or functionalized ergostanes. Only sterols that have attracted attention as objects for the further in-depth study will be considered here.

5,6-Dihydroergosterol or stellasterol (8) (Figure 3) is widely found as a minor ergostane constituent of many fungi, including sclerotia of Polyporus umbelatus [77], mycelium of Cordyceps jiangxiensis [78], Stereum insignis [79], Eurotium rubrum [80], fruiting bodies of Stropharia rugosoannulata [81], Amauroderma amoensis [82], Amauroderma subresinosum [83], Lasiosphaera fenzlii [84], Cortinarius xiphidipus [85], Pleurotus eryngii [59], Trametes versicolor [86]. For practical purposes, a more suitable source of stellasterol (8) is its chemical synthesis from ergosterol [69, 87].
Andrade et al. studied the effect of the purified *Marthasterias glacialis* extract and stellasterol (8) as its sterol constituent on inflammation in LPS-treated RAW 264.7 cells [88] and against human breast cancer (MCF-7) and human neuroblastoma (SH-SY5Y) cell lines [89]. The maximum anti-inflammatory effect was achieved when used in combination with unsaturated fatty acids [88]. In experiments with cancer cells, treatment with the extract markedly affected their growth, with stellasterol being responsible for the cell cycle arrest [89]. Yang et al. reported decreased NO production in LPS-treated RAW 264.7 cells with IC$_{50}$ value of 15.1 µM and inhibition of iNOS and COX-2 [90].

The oxygen radical antioxidant capacity (ORAC) assay of components of the edible mushroom *Meripilus giganteus* revealed the highest antioxidant activity (4.94 mmol TE/g) for stellasterol (8) [91].

The study of the mechanism of anti-diabetic activity of the cosmopolitan woody polypore fungus *Ganoderma austral* showed that this may be due to its major component, stellasterol [92]. Its IC$_{50}$ as an α-glucosidase inhibitor (315 µM) was close to that of acarbose (208 µM), which is an anti-diabetic drug used to treat diabetes mellitus.

Stellasterol was also isolated from fruiting bodies of *Ganoderma lucidum* as pentadecanoate ester (9), which at a dose 100 mg/kg bw demonstrated moderate anti-inflammatory activity (60% inhibition) in carrageenan-induced paw edema [93].

Kim et al. conducted an extensive study of the effects of synthetically obtained stellasterol glucoside (10) and its analogs on skin inflammation [69,94–96]. It has been shown that 10 exhibits strong inhibitory activity against the production of nitric oxide (NO), which is a molecular mediator involved in inflammation. In addition, glucoside 10 suppressed the production of Th2-type chemokines CCL17 and CCL22. It was not cytotoxic up to a concentration of 100 µM, which makes it possible to consider 10 as a potential therapeutic agent for atopic dermatitis. Further studies in this area led to the discovery of galactosyl Δ$^{(14)}$-ergostenol (11) as the best candidate for the treatment of arthritis [97].

Ergostatreniol 12 (also named as antrosterol or EK100) is a quite common steroid in fungal sources. In particular, it was isolated from *Antrodia camphorata* [98–100], *Coprinus septulosus* [101], *Cordyceps militaris* [102], *Ganoderma resinaceum* [103], *Nigrospora sphaerica* [104], *Xylaria nigripes* [105].

Shih et al. showed that antrosterol (12) may be useful in the treatment of type 2 diabetes associated with hyperlipidemia [98]. Its use has led to a decrease in blood glucose and total cholesterol and triglyceride levels, an increase in the GLUT4 protein in skeletal muscle, and an improvement in insulin resistance.

The anti-inflammatory properties of *Antrodia camphorata* mycelium, used in traditional Chinese medicine, are at least partially determined by the presence of antrosterol as one of its constituents. Similar to the action of corticosteroids, compound 12 reduced the expression of IL-6 and IL-1β in macrophages [106]. The mechanism of anti-inflammatory effect of 12 has also been studied by Kuo et al. [107]. Authors explained the observed effect by an increase in the activity of antioxidant enzymes such as catalase, superoxide dismutase,
and glutathione peroxidase in liver tissue, and the reduction of the expression of iNOS and cyclooxygenase-2. The studies [108,109] also noted a decrease in the expression of the inflammatory factor NF-κB and inflammatory cytokines IL-6 and TNF-α. The mechanism of anti-inflammatory action of 12 was also investigated in LPS-stimulated RAW264.7 cells and Drosophila [102].

In experimental acute ischemic stroke model, antrosterol (12) reduced ischemic brain damage by decreasing the expression of p65NF-κB and caspase 3 and promoted neurogenesis and neuroprotection by activating PI3k/Akt-associated inhibition of GSK3 and activation of β-catenin [110]. Compound 12 was proposed as a potential therapeutic agent in intracerebral hemorrhage [111]. It had an inhibitory effect on the activation of the microglial c-Jun N-terminal kinase and attenuated the expression of brain cyclooxygenase, activation of matrix metalloproteinase and brain injuries in a model of intracerebral hemorrhage in mice. Long-term daily administration of 12 was shown to be safe and can be used as a potential ergogenic aid [112].

Hu et al. showed a strong cytotoxic effect of 12 against human U2OS lung osteosarcoma cells with IC_{50} value of 0.93 µM [105].

Cholesterol is a vital component of eukaryotic cells and its trafficking is an important issue for their proper functioning. 9-Dehydroergosterol (13) has proven to be a very convenient biochemical tool for studying cholesterol transport in living cells [113–115]. First of all, this is due to its own fluorescence because no additional moieties covalently attached to cholesterol are required. Second, 9-dehydroergosterol (13) mimics cholesterol very well, which is a consequence of its ability to stand upright in the membrane, almost identical to cholesterol.

Ano et al. found that extracts of dairy products fermented with Penicillum candidum have potent anti-inflammatory effect on microglia [116]. Repeated purification of the extracts led to the isolation of 9-dehydroergosterol (13) as an active principle responsible for the observed effect. Compound 13 significantly inhibited neurotoxicity and neuronal cell death induced by over-activated microglia, making it a valuable agent for the prevention of dementia.

Dendritic cells play a key role in regulating the balance between tolerance and immune response. It has been shown that 14-dehydroergosterol (14) induces the transformation of dendritic cells in the bone marrow of mice and differentiates them into a tolerogenic type [117]. It can be helpful in preventing chronic inflammatory and autoimmune diseases.

She et al. isolated from the mangrove-derived fungus Aspergillus sp. two steroids having a 6/6/6/6/5 pentacyclic steroidal system [118]. Ergosteradiacid A (15) was supposed to be a natural Diels-Alder product derived from fumaric acid and ergostatetraene 14. In vitro experiments showed that adduct 15 was active against Mycobacterium tuberculosis tyrosine phosphatase B (IC_{50} 15.1 µM) and had a strong anti-inflammatory effect by suppressing NO production at 4.5 µM.

A number of hybrids of 9-dehydroergosterol with polyketides have been isolated from natural sources. Two anthraquinone derivatives, evantrasterol A and B (16 and 17) (Figure 4), have been found in the endophytic fungus Emericella variecolor [119].

Elsebai et al. isolated nitrogenous metabolites of phenalenone, conio-azasterol (18), and S-dehydroazasirosterol (19), from the marine endophytic fungus Coniothyrium cereal [120]. Another nitrogenous hybrid of 9-dehydroergosterol fused through the morpholine ring with alternariol, pestauvicomorpholine A (20), was isolated from the fermentation product of the fungus Pestalotiopsis uvicola [121]. No cytotoxicity was detected for any of the tested compounds 16–20.
3. Endoperoxides

Compounds containing a peroxide group are quite widespread among various natural substances, and steroids are not an exception [27]. Two 5α,8α-endoperoxides, ergosterol peroxide (EP, 21a) and 9,11-dehydroergosterol peroxide (DHEP, 22a) (Figure 5), are the most typical representatives of fungal steroids. Publications up to 2016 on the biological activity of EP (5a) have been thoroughly reviewed by Merdivan and Lindequist [24], and only the more recent literature regarding this compound will be discussed here.

Biological studies of endoperoxides 21a and 22a have been aimed primarily at assessing their cytotoxic potential. Both compounds revealed quite high level of cytotoxicity in a wide range of cancer cells (Table 1). It should be noted that measurements of cell toxicity often vary significantly from laboratory to laboratory. Thus, for EP and cell line MCF-7 the values of IC₅₀ varied from IC₅₀ 1.18 µM [122] to 151 µM [123].
Attempts have been made to understand the cytotoxicity mechanism for 21a, and some authors have concluded that more than one mechanism is at work. Obviously, the peroxide bridge plays a crucial role, bearing in mind that ergosterol is not cytotoxic. It was assumed that induction of apoptosis is the main cause of cytotoxicity [24]. Homolytic cleavage of the peroxide moiety in a reducing medium leads to the formation of reactive oxygen species (ROS), which are powerful internal stimuli for apoptosis. This has been confirmed, in particular, in experiments with MCF-7 cells [124]. Their treatment with 21a at concentrations of 40–80 µg/mL led to an increase in the production of ROS in a dose-dependent manner and to the induction of apoptosis. The inhibitory properties of 21a against A549 lung cancer cells were mediated by mitochondria-dependent apoptosis and autophagy [125]. EP also reduced LPS/ATP-induced proliferation and migration of A549 cells. A synergistic effect was observed when using EP with kinase inhibitor Sorafenib. Based on ID$_{50}$ values for the MCF-7 cell line (1.18 µM) compared to the MDA-MB-231 cell line (12.82 µM), EP (21a) was hypothesized to target estrogen receptors [122]. Its possible role as an ER$\alpha$ antagonist was suggested by Kim et al. based on the suppression of the increase in the viability of MCF-7 cells caused by 17$\beta$-estradiol [126].

Ergosterol peroxide (21a) and 9,11-dehydroergosterol peroxide (22a) were often isolated from the same fungal material, and on the whole both compounds exhibit similar biological properties. DHEP (22a) was slightly more cytotoxic than EP (21a) on the Hep 3B cell viability (IC$_{50}$ 16.7 and 19.4 µg/mL, respectively) [127]. In experiments with BV-2 microglia cells, compound 22a did not damage cell viability, although EP was cytotoxic to these cells [128]. Kobori et al. showed that 22a selectively inhibits the growth of HT29 human colon adenocarcinoma cells without affecting normal human WI38 fibroblasts [129]. The inhibition was attributed to the induction of expression of an inhibitor of cyclin-dependent kinase 1A, thus causing cell cycle arrest and apoptosis. The rather strong cytotoxic effect of 22a (IC$_{50}$ 8.58 µM) on HeLa human cervical carcinoma cells was associated with the regulated expression of stathmin 1, a protein that is critical for the regulation of the cell cytoskeleton [130]. The mechanisms of 22a cytotoxicity in A375 melanoma cells have been shown to be caspase-dependent and mediated via the mitochondrial pathway and include targeting of the induced differentiation protein of myeloid leukemia cells Mcl-1, release of cytochrome c, and activation of caspase-9 and -3 [131].

In experiments with a large number of cell lines EP possessed cytotoxic activity at the level of 1 µM and was more active in comparison with DHEP [132]. On the other hand, in the aromatase inhibitory assay 9(11)-double-bond enhances the inhibitory activity (IC$_{50}$ > 100 µM vs. 32.6 µM for EP and DHEP, respectively) [59]. EP was thought to be one of the main compounds responsible for the antiproliferative effect of an ethanolic extract of the native New Zealand mushroom *Hericium novae-zealandiae* [133]. Two possible mechanisms of the observed effect have been proposed: apoptosis based on upregulation of CASP3, CASP8, CASP9, and anti-inflammation, as follows from downregulation of IL6 and upregulation of IL24.

Studying the cytotoxic effects on renal cell carcinoma cells, Zhang et al. found that EP treatment suppressed cell growth, colonization, migration and invasion, arrested the cell cycle, and triggered apoptosis [134]. This also means that several mechanisms can act for the same effect.

A similar situation with multiple pathways was observed in experiments with ovarian cancer cells [135]. Their treatment with 21a inhibited nuclear $\beta$-catenin, thus decreasing the expression levels of cyclin D1 and c-Myc. Meanwhile, the level of protein tyrosine phosphatase SHP2 was increased in the treated cells, while the activity of Src kinase was suppressed. Thus, the antitumor effect of 21a on ovarian cancer cells is due to both the $\beta$-catenin and STAT3 signaling pathways.

Significant inhibition of the formation of experimental lung metastases in vivo was found for EP (21a) [136]. The effect was attributed to inhibition of the NF-$\kappa$B and STAT3 inflammatory pathways in 4T1 breast cancer cells.
Table 1. Cytotoxicity of fungal endoperoxides on different cell lines.

| Compound | Cell Line | Origin * | Effect [Ref.] |
|----------|-----------|----------|---------------|
| 21a      | HepG2     | Liver carcinoma | IC₅₀ 13.19 μM [137], IC₅₀ > 20 μM [139], IC₅₀ 35.2 μg/mL [144] |
| 21b      | 21d       | Liver carcinoma | IC₅₀ 13.6 μM [84], IC₅₀ > 20 μM [139], IC₅₀ 5.2 μg/mL [144] |
|          | HepG2     | Liver carcinoma | IC₅₀ 13.9 μM [138], IC₅₀ > 20 μM [139], IC₅₀ 23.15 μM [145], IC₅₀ 113 μM [123] |
|          | MDA-MB-231| Breast carcinoma | IC₅₀ 12.82 μM [122], IC₅₀ 18 μM [149], IC₅₀ 24.75 μM [146], IC₅₀ 44.6 μM [147] |
|          | SK-Hep1   | Liver cancer | IC₅₀ 19.25 μM [145], IC₅₀ 19.71 μM [146] |
|          | SK-HEP1   | Liver cancer | IC₅₀ 30 μM [134] |
|          | SUM-149   | Breast cancer | IC₅₀ 9 μM [149], IC₅₀ 20 μM [150] |
|          | T-47D     | Breast cancer | IC₅₀ 19 μM [149] |
|          | MCF-7     | Breast cancer | IC₅₀ 1.18 μM [122], IC₅₀ 9.01 μM [138], IC₅₀ 26 μM [140], IC₅₀ 26.06 μM [145,146], IC₅₀ 29 μM [125], IC₅₀ 38.2 μM [143], IC₅₀ 40 μM [124], IC₅₀ 98.12 μM [142], IC₅₀ > 100 μM [126,144], IC₅₀ 151 μM [123] |
|          | RCC       | Renal carcinoma | IC₅₀ 23.15 μM [123] |
|          | PC-3      | Prostatic carcinoma | IC₅₀ 42 μg/mL [133] |
|          | PC-3M     | Prostate cancer | IC₅₀ 23.15 μM [123] |
|          | SK-MEL-2  | Skin melanoma | IC₅₀ 9.01 μM [151] |
|          | SK-OV-3   | Ovary malignant ascites | IC₅₀ 15.11 μM [151] |
|          | U87       | Glioblastoma | 20.1% inhibition at 100 μM [152] |
| 21c      | HepG2     | Liver carcinoma | IC₅₀ 12.34 (n = 1), 9.46 (n = 2), 6.74 (n = 3) μM [145] |
|          | MCF-7     | Breast cancer | IC₅₀ 14.80 (n = 1), 13.70 (n = 2), 7.45 (n = 3) μM [145] |
|          | SUM-149   | Breast cancer | IC₅₀ 10.43 (n = 1), 11.70 (n = 2), 5.92 (n = 3) μM [145] |
|          | T-47D     | Breast cancer | 6.60 μM [145] |
|          | MDA-MB-231| Breast carcinoma | IC₅₀ 7 μM [149], IC₅₀ 2 μM [149], IC₅₀ 16 μM [149] |
Table 1. Cont.

| Compound | Cell Line | Origin * | Effect [Ref.] |
|----------|-----------|----------|---------------|
| 21f      | HCT-116   | Colon carcinoma | IC₅₀ 0.21 µM [153] |
| 21g      | SUM-149   | Breast cancer | EC₅₀ 12 µM [150] |
| 21h      | MDA-MB-231 | Breast carcinoma | EC₅₀ 10 µM [149] |
| 21i      | HepG2     | Liver carcinoma | IC₅₀ 0.85 µM [146] |
| 21j      | HepG2     | Liver carcinoma | IC₅₀ 2.83 µM [146] |
| 22a      | Hep 3B    | Hepatocellular carcinoma | IC₅₀ 16.7 µg/mL [127] |
| 22b      | A549      | Lung carcinoma | No cytotoxicity [156] |
| 27       | A549      | Lung carcinoma | No cytotoxicity [156] |
| 28       | A549      | Lung carcinoma | No cytotoxicity [156] |

* Human, if not stated otherwise.

Compound 21a can be used as a radiosensitizer in the treatment of cervical cancer to reduce the toxic effects that occur after ionizing radiation therapy. Loss of viability of the cervical cell lines HeLa and CaSki was observed with increasing dose of 21a [158].

Biological effects of EP (21a) and its Δ⁹,¹¹-counterpart 22a are not limited to their cytotoxic and anticancer properties. A detailed study on the bioactivity of the components of the truffle Reddolomyces parvulusporus revealed a number of EP activities, including anti-tyrosinase, anti-urease, anti-α-glucosidase, and anti-α-amylase ones [159]. Tyrosinase is an enzyme involved in the biosynthesis of melanin in humans, and its inhibitors are of interest for preventing excessive melanin production, as being active ingredients of...
skin whitening agents. Tyrosinase inhibitory activity (IC$_{50}$: 202.37 µg/mL) of EP was also detected by Bai et al. [160].

Ng et al. reported the antidiabetic effect of 21a that was due to the upregulation of glucose absorption and modulation of the PI3K/Akt, MAPK, and GLUT-4 signaling pathways [161]. EP was tested for its antileishmania activity against Leishmania donovani promastigotes and showed good activity with IC$_{50}$ values of 9.43 µM [162]. The EP trypanocidal activity has been associated with its interaction with CYP51 [163]. The key structural moiety responsible for this is the peroxide bridge, which mediates interaction with the CYP51 heme binding site. At a later stage, this can cause the appearance of free radicals through homolytic cleavage at the O-O site, the pharmacophore responsible for the biological activity of 21a.

Zhou et al. studied the immunoregulatory effect on inflammation caused by influenza A virus in human alveolar epithelial cells A549. EP (21a) was found to have anti-inflammatory effects and prevent virus-induced apoptosis by attenuating retinoic acid-inducible gene I signaling in infected cells [164]. Oral administration of EP to piglets infected with porcine delta-coronavirus resulted in a reduction in diarrhea, relief of intestinal damage, and a decrease in viral load in feces and tissues [165]. Wang et al. demonstrated that ergosterol peroxide prevents infection by suppressing porcine delta-coronavirus-induced autophagy via the p38 signaling pathway [166,167].

DHEP (22a) was found to exhibit strong anti-inflammatory effect in lipopolysaccharide-stimulated RAW264.7 cells [168–170]. It suppressed the production of NO even at 12.5 µM and pro-inflammatory cytokines interleukin 6 at 25 µM [168]. With age, mesenchymal stem cells in bone marrow tend to differentiate more into adipocytes than into osteocytes. Compounds 21a and 22a have been shown to inhibit the differentiation of mesenchymal stem cells toward adipocytes, which may be useful for the treatment of postmenopausal osteoporosis [171].

In experiments with 3T3-L1 mouse embryonic fibroblast cells, it was shown that EP inhibits triglyceride synthesis and reduces the accumulation of lipid droplets by suppressing adipogenesis [172]. The endoperoxides 21a and 22a were tested for their antibacterial activity [173–177]. The presence of a 9,11-double bond contributed to the increase in activity [173,177]. Thus, Δ$^{9,11}$-derivative 22a was more effective against M. tuberculosis H37Rv in comparison with 21a (MIC 16 µg/mL and 64 µg/mL, respectively) [173]. Antitubercular activity of the fungus Gliocladium sp. MR41., was tested on M. tuberculosis. It was found to be due to EP (21a) with MIC 0.78 µg/mL [178].

Kim et al. isolated glucosides 21b and 22b from the Korean wild fungus Xerula furfuracea and tested their effects on adipogenesis and osteogenesis in a mouse mesenchymal stem cell line [10]. Both compounds were found to inhibit the differentiation of stem cells into adipocytes, which is of interest in the treatment of syndromes associated with menopause.

Significant antifungal and cytotoxic activities were reported for EP decanoate (21f) [153]. In disk diffusion test against Candida albicans culture, its MIC value was found to be 8.3 µg/disc that was comparable to clotrimazole (MIC 5.1 µg/disc). Compound 21f showed also very good cytotoxicity against the HCT-116 cell line with IC$_{50}$ value of 0.21 µM compared to doxorubicin (IC$_{50}$ 0.06 µM).

In an attempt to improve antitumor activity, a number of derivatives of endoperoxide 21a have been studied. Ergosterol peroxide sulfonamide 21g was found to be more effective in reducing cancer cell viability than the parental endoperoxide 21a [150]. Significantly, its toxicity to normal human BJ fibroblasts was minimal, indicating that 21g targets cancer cells.

A series of EP analogs containing BODIPY or a biotin moiety was obtained by Rivas et al. as probes for cellular localization studies [149]. They demonstrated that EP is distributed across the cytosol with significant accumulation in the endoplasmic reticulum.
In addition, the resulting compounds were tested for antiproliferative activity in breast cancer cell models. The most active ones were analogs 21e and 21h (Table 1).

Several adducts of EP with 7-N,N-diethylaminocoumarins have been obtained by Bu et al. [145]. Analogues 21c and 21d exhibited increased cytotoxicity compared to 21a, which was explained by their localization mainly in mitochondria, as followed from fluorescence imaging. In addition, the piperazine derivative 21d suppressed the formation, invasion, and migration of cell colonies, induced arrest of HepG2 cells in the G2/M phase, and increased the level of intracellular reactive oxygen species.

A number of EP 3-carbamate derivatives were obtained by Hu et al. [146]. They exhibited antiproliferative activity, which was 6–28 times stronger than that of the initial endoperoxide 21a (Table 1). The most active compounds 21i and 21j contain piperazinyl and piperidinyl fragments.

A steroid-xanthone heterodimer, asperversin A (23), was isolated from the culture of Aspergillus versicolor, an endophytic fungus isolated from the marine brown alga Sargassum thunbergii [179]. Compound 23 was tested for biological activities against some bacterial and fungal strains with no noticeable effect.

Further structural modifications of steroidal molecule with retention of the 5α,8α-endoperoxide scaffold included changes in the carbon skeleton of the side chain [180,181]. Thus, 7-dehydrocholesterol peroxide, its acetate and hemisuccinate showed improved anticancer activity and selectivity over the corresponding derivatives of EP [180].

In comparison with the compounds 21a and 22a, 5α,9α-endoperoxides have been studied much less due to their lower availability. Compounds 24 and 25 (Figure 6) were isolated from the edible mushroom Grifola gargal and evaluated in the osteoclast-forming assay [182]. They inhibited osteoclast formation, which may be of interest for the prevention of osteoporosis. Endoperoxide 26, isolated from the fruiting bodies of Stropharia rugosoannulata, protected neuronal cells by attenuating endoplasmic reticulum stress caused by thapsigargin, an inhibitor of the Ca^{2+}-ATPase [81]. A significant cytotoxicity (Table 1) against A549 and MCF-7 cells was noted for the endoperoxide 27, isolated from the fruiting body of a medicinal macro fungus Ganoderma lingzhi [12]. Agarol (28) was isolated as a tumoricidal substance from the mushroom Agaricus blazei [157]. Its cytotoxicity was evaluated against four cancer lines (Table 1). Agarol (28) was shown to induce apoptosis by increasing generation of ROS and release of apoptosis-inducing factor from the mitochondria to the cytosol.

Figure 6. Structures of fungal 5α,9α-endoperoxides.

4. Epoxides

The majority of compounds of this group are 5α,6α epoxides (Figure 7). Almost all of them contain a hydroxy- or keto group at C-7, Δ^{8(9)}, or Δ^{8(14)}-double bond, and some 5α,6α-epoxides have a functionalized ring D. Other epoxides (4,5-, 5β,6β-, 8,9-, 8,14-, and 9,11-derivatives) are much less common in fungi (Figure 8). Compounds 29–59 were tested...
in various assays, including AChE inhibitory, cytotoxic, α-glucosidase inhibition, NO production inhibition, etc., (Table 2).

**Figure 7.** Structures of fungal 5,6-epoxides.

**Figure 8.** Structures of other fungal epoxides.
Bae et al. noted that the presence of an epoxyl group in the tetracyclic skeleton of ergosterol derivatives increases their cytotoxic properties [183]. Isolation of a series of 5α,6α-epoxides from the macrofungus *Omphalia lapidescens* allowed to establish some structure activity relationship correlations [15]. The greatest cytotoxicity against a human gastric cancer cell line, HGC-27, was noted for the compound 30a and 31a containing an α-oriented hydroxyl group at C-7 and Δ^{8(9)}- or Δ^{8(14)}-double bond (Table 2). The transition to 7-ketones 33 and 36 led to a decrease in activity, and of both compounds, the derivative 33 without a double bond in the BC cycles was less active. The diepoxide 52 showed the least activity, which indicates the importance of the double bond for cytotoxic activity. Epoxides 41, 43a, and 43b, isolated from the culture of Basidiomycete *Polyporus ellisi*., were evaluated for cytotoxicity against five human cancer cell lines [184]. The first two compounds were practically inactive, while epoxide 41 exhibited strong activity against all tested cell lines with IC_{50} in the range from 1.5 to 3.9 μM (Table 2).

Ferreira et al. performed virtual screening experiments on low-molecular weight fungal constituents as potential MDM2 inhibitors [185]. The latter is an important negative regulator of the p53 tumor suppressor, and its inhibitors have significant anti-tumor activity. From the compounds studied, epoxide 29 returned one of the best docking scores.

Epoxide 31b was found to exhibit potent inhibitory activity on the expression of mRNA of propionate convertase subtilisin/kexin type 9 (PCSK9) [186]. The latter affects the low density lipoprotein receptor on the surface of liver cells, resulting in high level of low density lipoprotein cholesterol (LDL-C). PCSK9 inhibitors have been proposed as novel LDL-C-lowering agents for the treatment of hyperlipidemia. Compound 31b showed activity with IC_{50} values of 8.23 μM, which was comparable with berberine (IC_{50} 8.04 μM) used as a positive control.

A number of epoxides were tested for their anti-inflammatory activity. As a rule, inhibition of TNF-α and NO production in LPS-stimulated RAW264.7 macrophage cells was used to evaluate anti-inflammatory effects. Epoxide 30c showed superior inhibitory activity on NO production with IC_{50} value of 3.24 μM [103]. In the same experiment, the positive control L-NMMA, nitric oxide synthase inhibitor, revealed IC_{50} value of 49.86 μM. TNF-α secretion decreased after treatment of macrophage cells with epoxide 49, which at 10 μM exhibited activity with inhibition value of 37.5% [187]. This was comparable to the positive control (52.5% at 1 μM) exerted by celecoxib, the cyclooxygenase-specific inhibitor.

### Table 2. Sources and biological activity of fungal epoxides.

| Compound | Fungal Source [Ref.] | Assays (Activity) [Ref.] |
|----------|-----------------------|--------------------------|
| 29 | *Hericium erinaceus* [187,188], Chaeumom sp. M453 [189], Colletotrichum sp. YM432 [190], Cordyceps sinensis [191], Stereum insigne CGMCC5.57 [79] | AChE inhibitory assay (IC_{50} 67.8 μM) [190], nematicidal and antibacterial assays (no activity) [79] |
| 30a | *Amauroderma subresinosum* [83], *Ganoderma lucidum* [147], G. resinaceum [103], Grifola frondosa [154], *Omphalia lapidescens* [15], *Simplicillium* sp. YZ-11 [192], *Stropharia rugosoannulata* [193], Pleurotus eryngii [6] | α-glucosidase inhibition assay (IC_{50} > 100 μM) [154], cytotocxic assay (HGC-27, IC_{50} 11.69 μM) [15], (MCF-7, IC_{50} 24.3 μM; NCI-H460, IC_{50} 19.8 μM; SF-268, IC_{50} 15.5 μM) [194], (A549, IC_{50} 35.99 μM; HepG2, IC_{50} 25.81 μM; MDA-MB-231, IC_{50} 29.73 μM) [154], (HepG2, IC_{50} 22.1 μM; MDA-MB-231, IC_{50} 20.3 μM) [147], lettuce hypocotyl growth assay (65–80% inhibition) [193], NO production inhibition assay (IC_{50} 12.4 μM) [6], (IC_{50} 19.77 μM) [103] |
| 30b | *Ganoderma resinaceum* [103], *Stropharia rugosoannulata* [81] | anti-fungal assay (MIC 250 μM) [81], NO production inhibition assay (IC_{50} 17.23 μM) [103], osteoclast-forming assay [81] |
| 30c | *Amauroderma amoensis* [82], *Ganoderma resinaceum* [103] | NO production inhibition assay (IC_{50} 3.24 μM) [103] |
| Compound | Fungal Source [Ref.] | Assays (Activity) [Ref.] |
|----------|----------------------|-------------------------|
| 31a      | Cortinarius glaucaus [105], Ganoderma lucidum [147], G. resinaceum [103], G. sinense [196], Grifola frondosa [154], Hygrocybe bistolens [193], Lepiota rhacodes [197], Omphalia lapidescens [15], Simplicillicium sp. [192], Stropharia rugosa [192], Phellinus linteus [198], Pleurotus eryngii [6], Termitomyces microcarpus [132] | α-glucosidase inhibition assay (IC50 > 100 µM) [154], cytotoxic assay (IC50 18.97 µM) [135], (MCF-7, IC50 > 50 µM; NCI-H460, IC50 > 50 µM); SF-268, IC50 > 50 µM) [194]; (A549, IC50 69.11 µM; HepG2, IC50 38.87 µM; MDA-MB-231, IC50 46.76 µM) [154]; (A549, IC50 15.3 µg/mL; XF498, IC50 15.1 µg/mL) [183]; (HepG2, IC50 50.6 µM; MDA-MB-231, IC50 46.7 µM) [147]; HNE inhibitory assay (IC50 28.2 µM) [198]; lettuce hypocotyl growth assay (61–78% inhibition) [193]; NCi 60 panel [132]; NO production inhibition assay (IC50 > 30 µM) [6]; (IC50 23.34 µM) [103]; (IC50 > 40 µM) [196] |
| 31b      | Ganoderma resinaceum [103], Hericium erinaceus [187,188], Sparassis crispa [186,199], Phellinus linteus [198], Pleurotus eryngii [6] | cytotoxic assay (MCF-7, IC50 > 50 µM) [194]; (NCI-H460, IC50 > 50 µM) [194]; (SF-268, IC50 > 50 µM) [194]; NO production inhibition assay (IC50 14.3 µM) [6]; (IC50 17.23 µM) [103]; PCSV9 mRNA expression (inhibition, IC50 8.23 µM) [186] |
| 31c      | Hericium erinaceus [200] | PPAR transactivation assay (EC50 8.2 µM) [200] |
| 31d      | Hericium erinaceus [200] | PPAR transactivation assay (EC50 6.4 µM) [200] |
| 32       | Pleurotus eryngii [59] | aromatase inhibitory assay (IC50 17.3 µM) [59] |
| 33       | Hericium erinaceus [187], Omphalia lapidescens [15] | cytotoxic assay (HGC-27, IC50 29.34 µM) [15], HNE inhibitory assay (IC50 75.1 µM) [198], TNF-α secretion assay (inhibition value of 37.5% at 10 µM) [187] |
| 34       | Grifola frondosa [182] | osteoclast-forming assay [182] |
| 35       | Amauroderma subresinosum [83] | cytotoxic assay (HL-60, IC50 32.1 µM; SMMC-7721, A549, MCF-7, SW480, IC50 > 40 µM) [184] |
| 36       | Omphalia lapidescens [15] | cytotoxic assay (HGC-27, IC50 23.41 µM) [15] |
| 37a      | Pleurotus eryngii [201] | cytotoxic assay (RAW264.7, IC50 > 30 µM) [201] |
| 37b      | Stropharia rugosa [81] | osteoclast-forming assay [81] |
| 38       | Grifola frondosa [182] | cytotoxic assay (HepG2, IC50 200.9 µM; MDA-MB-231, IC50 189.4 µM) [147], osteoclast-forming assay [182] |
| 39       | Amauroderma subresinosum [83], Polyporus ellisii [184] | cytotoxic assay (HL-60, IC50 32.1 µM; SMMC-7721, A549, MCF-7, SW480, IC50 > 40 µM) [184] |
| 40       | Pleurotus eryngii [201] | cytotoxic assay (RAW264.7, IC50 > 30 µM) [201], NO production inhibition assay (IC50 13.2 µM) [201] |
| 41       | Polyporus ellisii [184] | cytotoxic assay (HL-60, IC50 1.5 µM; SMMC-7721, IC50 3.9 µM; A549, IC50 2.7 µM; MCF-7, IC50 3.1 µM; SW480, IC50 2.9 µM) [184] |
| 42       | Phomopsis sp. [202] | α-glucosidase inhibition assay (IC50 > 100 µM) [202] |
| 43a      | Polyporus ellisii [184], Phomopsis sp. [202] | antibacterial assay (MIC 28.2 µM against Micrococcus luteus) [202], cytotoxic assay (HL-60, IC50 32.1 µM; SMMC-7721, A549, MCF-7, SW480, IC50 > 40 µM) [184] |
| 43b      | Ganoderma resinaceum [103], Polyporus ellisii [184], Phomopsis sp. [202] | cytotoxic assay (HL-60, IC50 18.8 µM; SMMC-7721, A549, MCF-7, SW480, IC50 > 40 µM) [184] |
| 44       | Grifola frondosa [182] | osteoclast-forming assay [182] |
| 45       | Pleurotus eryngii [6] | NO production inhibition assay (IC50 > 30 µM) [6] |
| 46       | Ganoderma lucidum [147] | cytotoxic assay (HepG2, IC50 138.3 µM; MDA-MB-231, IC50 176.1 µM) [147] |
| 47       | Amauroderma amoenis [82] | AChE inhibitory assay (14.63% inhibition at 100 µM) [82] |
| 48       | Trametes versicolor [168] | (NO inhibitory activity at 12.5 µM, IL-6 inhibitory effect at 25 µM) [168] |
| 49       | Hericium erinaceus [187,188], Stropharia rugosa [193] | TNF-α secretion assay (37.5% inhibition at 10 µM) [187] |
| 50       | Hericium erinaceus [187,188], Phellinus linteus [198], Stropharia rugosa [193] | HNE inhibitory assay (IC50 35.2 µM) [198], inhibition of lettuce hypocotyl growth (no activity) [193] |
| 51       | Ganoderma lucidum [147], Hericium erinaceus [187] | NO production inhibition assay (moderate activity) [187] |
| 52       | Aspergillus awamori [205], Omphalia lapidescens [15] | cytotoxic assay (HGC-27, IC50 58.43 µM) [15], (A549, IC50 64 µM) [203] |
| 53       | Hericium erinaceus [187], Pleurotus eryngii [6] | NO production inhibition assay (IC50 > 30 µM) [6] |
| 54       | Omphalia lapidescens [15] | cytotoxic assay (HGC-27, IC50 15.37 µM) [15] |
Table 2. Cont.

| Compound | Fungal Source [Ref.] | Assays (Activity) [Ref.] |
|----------|----------------------|-------------------------|
| 55       | Pleurotus eryngii [201] | cytotoxic assay (RAW264.7; IC₅₀ > 30 µM) [201] |
| 56       | Talaromyces stipitatus [204] | cytotoxic assay (Hep3B, IC₅₀ 4.75 µM; HepG2, IC₅₀ 8.85 µM; Huh-7, IC₅₀ 13.78 µM) [204] |
| 57       | Aspergillus penicillioides [205], Ganoderma lingzhi [12] | antibacterial assay (MIC 32 µg/mL against *Vibrio anguillarum*) [205], cytotoxic assay (A549, IC₅₀ 8.57 µM; MCF-7, IC₅₀ 6.09 µM) [12] |
| 58       | Chaetomium sp. [189] | AChE inhibitory assay (20–60% inhibition at 50 µg/mL) [189] |
| 59       | Colletotrichum sp. [206] | AChE inhibitory assay (18.2% inhibition at 100 µg/mL) [206] |

Human neutrophil elastase (HNE) is a serine protease that can degrade extracellular matrix proteins such as collagen, fibronectin, etc. Inhibition of this enzyme can prevent the loss of skin elasticity, thereby preventing skin aging. Yoo et al. reported the HNE-inhibitory properties of *Phellinus linteus* mycelium components [198]. All three tested epoxides 31a, 34, and 50 showed significant activity with ID₅₀ ranging from 28.2 to 75.1 µM.

Epoxides 30a, 31a, and 33 were isolated after anaerobic incubation of ergosterol peroxide (EP, 21a) with rat intestinal flora [207]. Two of them (30a and 33) were found to be more active against human colorectal cancer cells than the original EP. This means that EP’s strong anti-tumor properties may be (at least in part) due to its metabolic products.

A number of ergostane-type sterol fatty acid esters, including epoxides 31c and 31d, were isolated from the mushroom *Hericium erinaceum* and evaluated for their PPAR transactivational effects using a luciferase reporter system [200]. Oleyl and linoleyl esters 31c and 31d proved to be the most potent activators of the transcriptional activity of PPARs with EC₅₀ values down to 6.4 µM.

5. Polyols

It should be kept in mind that the structures of ergostane-type steroids with hydroxyl and/or carbonyl group(s) given below do not fully reflect their diversity in fungal sources. A large number of compounds have been isolated before 2010; for a number of compounds isolated later, no data on biological activity are given, and for this reason they are not included in this review.

Many fungal ergostanes of this class are 5α-alcohols containing (an)other hydroxy (or a functionalized hydroxy) group(s) at C-6, C-9, and/or C-14 (Figure 9). 5α,6α-Epoxides are their evident biosynthetic precursors. As a rule, rings A and B are trans-fused for most ergostanes of this group, with the exception of 5β-alcohols 77, 78, 84 (Figure 10). It should be noted that fomentarol B (84) has a cis-junction of ring B and C, which is rare among the ergostane type steroids [208].

Cerevisterol (60) is probably the best studied among 5α,6β-dihydroxy derivatives, as it is widespread in the fungal kingdom (Table 3). It should be noted that data on its cytotoxicity are inconsistent and sometimes contradictory. Thus, cerevisterol (60) showed significant activity with IC₅₀ values of 1.1–1.9 µM against the BT-549, KB, SK-MEL, and SKOV-3 cancer cell lines [209]. On the other hand, it was practically inactive toward A549, HeLa, HepG2, and MCF-7 cells [210]. This inconsistence may be partly due to the diverse cell lines used by different authors. But a large difference was also observed in experiments with the same cell lines (e.g., reported IC₅₀ values for HepG2 varied from 14.5 µM [211] to 174.6 µM [147]).
Figure 9. Structures of fungal steroids with a 5α,6-diol fragment and their O-derivatives.

Figure 10. Structures of other fungal polyols.
The results of studies of antimicrobial activity also vary quite a lot. Thus, in the course of searching for biologically active constituents of wood decaying mushrooms, *Trametes gibbosa* and *Trametes elegans*, Agyare et al. isolated cerevisterol (60) as a compound responsible for their antimicrobial activity [212]. It inhibited the growth of a number of bacteria with MICs ranging from 25 to 50 µg/mL (ciprofloxacin MICs were between 0.31 and 3.50 µg/mL). The sub-inhibitory concentration of 60 (3 µg/mL) modified the activity of commonly used antibiotics (either potentiating or reducing). Similar results with respect to antimicrobial activity of 60 were obtained by Zhou et al. [213]. On the other hand, no antimicrobial activity for cerevisterol (60) was reported in works [214,215].

To access the anti-inflammatory activity of cerevisterol (60), Lee et al. measured the levels of NO and PGE₂ and the production of cytokines TNF-α, IL-1, and IL-6 in LPS-stimulated macrophages [216]. It was shown that 60 suppressed the LPS-induced production of NO and PGE₂ and decreased the expression of pro-inflammatory cytokines.  

Table 3. Sources and biological activity of fungal alcohols.

| Compound | Fungal Source [Ref.] | Assays (Activity) [Ref.] |
|----------|----------------------|--------------------------|
| Aspergillus fumiatus [213], A. versicolor [179], Cladosporium sp. [217], Clitocybe nebularis [214], Eurotium rubrum [80], Fomes fomentarius [208], Fusarium chlamydosporum [209,218], F. equiseti [219], F. solani [216], Ganoderma sinense [196,220], Glomerella sp. [215], Gymnopilus clavatus [221], Hericium Erinaceum [222,223], Hypholoma lateritium [224], Leptographium qinlingensis [197], Leucocarpus mongolica [210], Meripilus giganteus [91], Mortchella esculenta [226], Omphalia lapidescens [15], Penicillium brasiliense [227], Pleurotus eryngii [6], P. tuber-regium [228], Polyporus umbellatus [77,211], Termitomyces microcarpus [132], Trametes gibbosa and T. elegans [212], Tricholoma populinum [229], Xylaria nigripes [105] | AChE inhibitory assay (0.4% inhibition at 100 µg/mL) [80], antibacterial assay (no activity against Streptococcus agalactiae, Staphylococcus epidermidis, Moraxella catarrhalis, Haemophilus influenzae, and Proteus mirabilis) [214], (S. typhi, S. aureus and A. niger, MICs 25 µg/mL each, E. faecalis, MIC 50 µg/mL) [212]. (Bacillus subtilis and Escherichia coli, MICs 64 µg/mL each; Staphylococcus aureus, MIC 32 µg/mL) [213], cytotoxic assay (A549, IC₅₀ 94.75 µM; HeLa, IC₅₀ 74.13 µM; HepG2, IC₅₀ 46.58 µM; MCF-7, IC₅₀ 63.76 µM) [210], (T47D, 50.2% inhibition at 30 µM) [229], (BT-549, 1.4 µM; KB, 1.90 µM; SK-MEL, 1.70 µM; SKOV-3, 1.1 µM) [229], (Caco-2, IC₅₀ 37.56 µM; MCF-7, IC₅₀ 32.4 µM; MDA-MB-231, IC₅₀ 41.5 µM) [219], (HGC-27, IC₅₀ 37.71 µM) [15], (MCF-7, IC₅₀ 37.2 µM; FC-3, IC₅₀ 80 µM) [221], (HepG2, IC₅₀ 14.5 µM) [211], (HepG2, IC₅₀ 174.6 µM; MDA-MB-231, IC₅₀ 148.8 µM) [147], (SW1990, IC₅₀ 32.81 µM; Vero, IC₅₀ > 100 µM) [220], NF-κB inhibitory assay (IC₅₀ 5.1 µM) [226], HIV-inhibitory assay (IC₅₀ 9.3 µM) [230], HNE inhibitory assay (IC₅₀ 77.5 µM) [198], DPPH free radical-scavenging assay (IC₅₀ 13.8 µM) [222], GIRQ channel inhibitory assay (13% inhibition at 10 µM) [224], lipoygenase inhibitory assay (IC₅₀ 5.46 µM) [218], NO production inhibition assay (IC₅₀ > 40 µM) [196], (IC₅₀ > 30 µM) [6]; ORAC assay (antioxidant activity 1.94 mmol TE/g) [81], PTP1B inhibitory activity assay (IC₅₀ 7.5 µg/mL) [77], toxicity to *Pinus armandi* seedlings (lethal rate 95% at 30 µg/mL) [197], trap activity assessment (reduction to 28.1% from 332% in control cells) [223] |
| Aspergillus penicillioides [205], A. usutus [231], Aspergillus versicolor [179], Eurotium rubrum [80], Ganoderma lucidum [352], G. sinense [233], Hericium Erinaceum [223], Omphalia lapidescens [15], Penicillium brasiliense [227], Pleurotus eryngii [6], Tricholoma populinum [229], Xylaria nigripes [105] | AChE inhibitory assay (2.7% inhibition at 100 µg/mL) [80], cytotoxic assay (T47D, 23.7% inhibition at 30 µM; MDA-MB-231, 54.7% inhibition at 30 µM) [229], (U2OS, IC₅₀ 6.0 µM) [105], (HGC-27, IC₅₀ 4.17 µM) [15], (HL-60, IC₅₀ 22.4 µM; LLC-IC₅₀ 55.5 µM; MCF-7, IC₅₀ > 100 µM) [225], HIV-inhibitory assay (IC₅₀ 3.8 µM) [230], HNE inhibitory assay (IC₅₀ 14.6 µM) [198], neuroprotective activity assay (20.9% increase in cell viability against Aβ₂₅₋₃₅-induced injury in SH-SY5Y neuroblastoma cells at the concentration 10 µM) [105], NO production inhibition assay (IC₅₀ 20.4 µM) [6], (108.2% inhibition rate at 10 µM) [230], trap activity assessment (reduction to 74.8% from 332% in control cells) [223] |
| Fomes fomentarius [208], Omphalia lapidescens [15] | cytotoxic assay (HGC-27, IC₅₀ 25.50 µM) [15] |
| Eurotium rubrum [80], Hericium Erinaceum [223] | AChE inhibitory assay (17.9% inhibition at 100 µg/mL) [80], trap activity assessment (reduction to 81.8% from 332% in control cells) [223] |
| Fusarium chlamydosporum [218] | lipoygenase inhibitory assay (IC₅₀ 3.06 µM) [218] |
| Hericium Erinaceum [223] | ORAC assay (antioxidant activity 8.01 mmol TE/g at 10 µM) [223] |
| Compound | Fungal Source [Ref.] | Assays (Activity) [Ref.] |
|----------|---------------------|--------------------------|
| 62a      | *Eurotium rubrum* [80], *Fomes fomentarius* [208], *Hericium erinaceum* [223], *Hypoglossum russula* [183], *Omphalia lapidescens* [15] | AChE inhibitory assay (2.4% inhibition at 100 µg/mL) [80], cytotoxic assay (HGIC-27, IC50 > 100 µM) [183], (HepG2, IC50 196.9 µM; MDA-MB-231, IC50 114.2 µM) [147], (A549, >30 µg/mL; XF498, >30 µg/mL) [183], trap activity assay (reduction from 138.9% from 332% in control cells) [223] |
| 62b      | *Hericium erinaceum* [200] | PPAR transactivation assay (EC50 18.7 µM) [200] |
| 62c      | *Hericium erinaceum* [200] | PPAR transactivation assay (EC50 20.6 µM) [200] |
| 63a      | *Ganoderma lucidum* [147], *Pleurotus eryngii* [6] | cytotoxic assay (HepG2, IC50 62.5 µM; MDA-MB-231, IC50 56.3 µM) [147], NO production inhibition assay (IC50 29.8 µM) [6] |
| 63b      | *Ganoderma sinense* [220] | cytotoxic assay (SW1990, IC50 5.05 µg/mL; Vero, IC50 22.59 µg/mL) [220] |
| 64       | *Fomes fomentarius* [208], *Ganoderma lucidum* [147], *Hericium erinaceum* [187] | antibacterial assay (no activity against Streptococcus agalactiae, Staphylococcus epidermidis, Haemophilus influenzae, and Proteus mirabilis, marginal activity against Moraxella catarrhalis) [214], anti-fungal assay (MIC 500 µM) [61], cytotoxic assay (MC8-7, MDA-MB-231, T47D, no activity) [229], (HepG2, IC50 129.7 µM; MDA-MB-231, IC50 148.5 µM) [147], (A549, 17.1 µg/mL; XF498, 16.5 µg/mL) [183], (A549, 10.83 µM; HCT-15, 13.2 µM; SK-MEL-2, 10.39 µM; SK-OV-3, 12.16 µM) [151] |
| 66       | *Ganoderma lucidum* [147] | cytotoxic assay (HepG2, IC50 286.4 µM; MDA-MB-231, IC50 216.5 µM) [147] |
| 67a      | *Omphalia lapidescens* [15] | cytotoxic assay (HGIC-27, IC50 12.71 µM) [15], (HepG2, IC50 184.6 µM; MDA-MB-231, IC50 224.2 µM) [147] |
| 67b      | *Hericium erinaceum* [200] | PPAR transactivation assay (EC50 22.3 µM) [200] |
| 68a      | *Omphalia lapidescens* [15] | cytotoxic assay (HGIC-27, IC50 26.74 µM) [15] |
| 68b      | *Fomes fomentarius* [208] | cytotoxic assay (A549, IC50 29.8 µM; MCF-7, IC50 26.1 µM; NUGC-3, IC50 24.1 µM) [206] |
| 69       | *Pleurotus eryngii* [6] | NO production inhibition assay (IC50 > 30 µM) [6] |
| 70       | *Hericium erinaceus* [187,188] | TNF-α secretion assay (25% inhibition at 10 µg/mL) [187] |
| 71       | *Penicillium granulatum* [234] | cytotoxic assay (no activity) [234] |
| 72       | *Hericium erinaceum* [187] | TNF-α secretion assay (36.7% inhibition at 10 µg/mL) [187] |
| 73       | *Cortinarius setulosus* [101], *Ganoderma lipsiensae* [235], *G. resinaceum* [103], *Xylaria nigripes* [105] | antibacterial assay (93.6% inhibition against Giardia duodenalis trophozoites) [235], NO production inhibition assay (IC50 27.6 µM) [103], (IC50 22.76 µM) [103], tyrosinase inhibitory assay (IC50 6.9 µM) [236] |
| 74       | *Eurotium rubrum* [80] | AChE inhibitory assay (23.1% inhibition at 100 µg/mL) [80] |
| 75       | *Ganoderma resinaceum* [103] | NO production inhibition assay (IC50 22.76 µM) [103] |
| 76       | *Penicillium granulatum* [234] | cytotoxic assay (no activity) [234] |
| 77       | *Omphalia lapidescens* [16] | cytotoxic assay (GES-1, IC50 > 50 µM; HGIC-27, IC50 12.82 µM; MDA-MB-231, IC50 11.33 µM) [16] |
| 78       | *Omphalia lapidescens* [16], *Pleurotus eryngii* [6] | cytotoxic assay (GES-1, IC50 28.0 µM; HGIC-27, IC50 > 50 µM; MDA-MB-231, IC50 24.85 µM) [16], NO production inhibition assay (IC50 > 30 µM) [6] |
| 79       | *Ganoderma duriport* [237], *Ganoderma lucidum* [232,238], *Phellinus linteus* [198] | cytotoxic assay (HL-60, IC50 12.7 µM; LLC, IC50 45.2 µM; MCF-7, IC50 > 100 µM) [232], (A549, MCF-7, PC-3, IC50 > 50 µM) [238], HNE inhibitory assay (IC50 > 100 µM) [198] |
| 80       | *Lasiodiplodia pseudotheciormae* [11] | AChE inhibitory assay (no activity) [11], α-glucosidase inhibition assay (no activity) [11] |
| 81       | *Penicillium granulatum* [234] | cytotoxic assay (A549, IC50 5.5 µM) [234] |
| 82       | *Penicillium granulatum* [234] | cytotoxic assay (A549, BEL-7402, SHG-44, IC50 > 20 µM; ECA-109, IC50 9.2 µM; HepG2, IC50 7.0 µM) [234] |
| 83       | *Omphalia lapidescens* [16] | cytotoxic assay (GES-1, HGIC-27, MDA-MB-231, IC50 > 50 µM) [16] |

Table 3. Cont.
Table 3. Cont.

| Compound | Fungal Source [Ref.] | Assays (Activity) [Ref.] |
|----------|----------------------|-------------------------|
| 84       | *Fomes fomentarius* [208], *Omphalia lapidescens* [16] | cytotoxic assay (MDA-MB-231, IC<sub>50</sub> 140.86 µM) [16], NO production inhibition assay (98.77% inhibitory activity at 50 µM) [208] |
| 85       | *Penicillium chrysogenum* [239], *Penicillium granulatum* [240] | anti-fungal assay (8 mm diameter at 20 µg/disk) [239], cytotoxic assay (HeLa, IC<sub>50</sub> 15 µg/mL; NCI-H460, IC<sub>50</sub> 40 µg/mL; SW1990, IC<sub>50</sub> 31 µg/mL) [239], (HepG2, IC<sub>50</sub> 8.2 µM) [240] |
| 86       | *Penicillium granulatum* [234] | cytotoxic assay (no activity) [234] |
| 87       | *Penicillium granulatum* [234] | cytotoxic assay (A549, IC<sub>50</sub> 8.0 µM; BEL-7402, IC<sub>50</sub> 8.5 µM; ECA-109, IC<sub>50</sub> 8.3 µM; HepG2, IC<sub>50</sub> 6.7 µM; SHG-44, IC<sub>50</sub> 4.8 µM) [234] |
| 88       | *Penicillium granulatum* [234] | cytotoxic assay (no activity) [234] |

Yoo et al. studied the HNE-inhibitory potency of ergostanes isolated from the mycelium of *Phellinus linteus* [198]. Methyl ether 61a revealed the highest activity among all tested compounds with an IC<sub>50</sub> 14.6 µM, which was comparable with the positive control (epigallocatechin gallate, IC<sub>50</sub> 12.5 µM). The corresponding alcohol 60 was five times less active than 61a.

Kim et al. studied the inhibitory activity of steroids isolated from *Hericium erinaceum* against tartrate-resistant acid phosphatase (TRAP) [223]. The latter has become a promising target for the development of new therapeutics for the treatment of osteoporosis and other bone-related diseases. Compounds 60, 61a, 61c, 62a at a concentration of 10 µM reduced TRAP activity in osteoclasts differentiated from RAW 264.7 cells, from 322% in control cells to 28–139% in treated cells.

Compared to 5α,6-diols, other fungal polyols (Figure 10) have been relatively less studied. As mentioned above, many ergostane steroids are found in both mushrooms and plants. In particular, this applies to triol 73 found in various fungal species [101,103,105,235]. Among sixty-three compounds isolated from bamboo *Sinocalamus affinis* and studied as inhibitors of estrogen biosynthesis, triol 73 showed the highest activity with an IC<sub>50</sub> value of 0.5 µM [241]. It reduced the level of expression of aromatase mRNA in granulosa-like cells of human ovaries without affecting the catalytic activity of aromatase. This discovery makes the steroid 73 an interesting lead compound in the development of new agents for the treatment of estrogen-dependent cancers.

Studying the cytotoxicity of compounds isolated from the fruiting bodies of a medicinal mushroom *Ganoderma lucidum*, Min et al. selected the 2β,3α,9α-triol 79 for a more detailed evaluation [232]. Treatment with 79 in a dose-dependent manner inhibited the growth of HL-60 human premyelocytic leukemia cells with the IC<sub>50</sub> value of 12.7 µg/mL. The effect was attributed to the induction of the apoptotic process, including activation of DNA fragmentation and caspase-3 activity.

6. Hydroxyketones

This group of ergostanes in the present review is divided into compounds containing two (Figure 11), three (Figure 12), and four or more (Figure 13) functional groups in the cyclic part of the steroid molecule. It should be borne in mind that such a classification is rather arbitrary and does not cover all the aspects that are relevant to these steroids.
Figure 11. Structures of fungal hydroxyketones with two functional groups.

Figure 12. Structures of fungal hydroxyketones with three functional groups.
Figure 13. Structures of fungal hydroxyketones with four or more functional groups.

The first 8β-hydroxyergosta-3-one type of steroid, cyathisterol (89), was isolated from the fruiting body of Calvatia cyathiformis [242]. Later, Ji et al. isolated from an algicolous strain of Aspergillus ustus a very similar but not identical compound called isocyathisterol (90) [231]. A detailed NMR study allowed to determine the configuration of all stereocenters in 90. The authors concluded that the difference between the compounds 89 and 90 was in the C-9 and/or C-14 configuration.

Li et al. reported theoretical and experimental results on the properties of isocyathisterol (90) as inhibitor of isocitrate dehydrogenase IDH1 [233]. Mutations in this enzyme are associated with certain brain tumors, that makes IDH1 inhibitors as potential anticancer therapeutics for glioma patients. Based on the results of molecular virtual screening, isocyathisterol (90) had a low equilibrium dissociation constant of 18.40 µM, which confirmed the strongest binding to the IDH1 mutant. Kinetic studies showed that 90 inhibited the mutant enzyme in a noncompetitive manner.

Qi et al. isolated from spores of a medicinal mushroom Ganoderma lucidum a number of steroids possessing a 4,6,8(14),22-tetraene-3-one unit [243,244]. The obtained compounds called as ganodermasides A-D 91, 93, 110, 95 were tested for their antiaging effect on the yeast replicative lifespan assay (Table 4). All of them increased the average lifespan compared to negative control and exhibited effect similar to the known anti-aging substance, resveratrol.

A number of ergosterol metabolites including hydroxyketones 91, 93, 109 were isolated from a non-pathogenic filamentous fungus Talaromyces stipitatus [204]. Compounds 91, 93, 109 showed remarkable cytotoxic activities against hepatoma cell lines with IC_{50} values ranging down to 5.26 µM.
Table 4. Sources and biological activity of fungal hydroxyketones.

| Compound | Fungal Source [Ref.] | Assays (Activity) [Ref.] |
|----------|----------------------|---------------------------|
| 89       | Calzatia cyathiformis [242] | antibacterial assay (against E. coli, S. aureus, and A. salina with inhibitory zones of 6.7, 5.7, and 5.1 mm, respectively, at 30 µg/disk) [231], cytotoxic assay (A549, IC₅₀ 12.3 µM; HL-60, IC₅₀ 18.7 µM; K562, IC₅₀ 27.2 µM; MCF-7, IC₅₀ 23.8 µM; SMMMC-7721, IC₅₀ 15.7 µM; SW480, IC₅₀ 19.1 µM) [245]. (MCF-7, IC₅₀ > 100 µM) [126], (A549, IC₅₀ 19.1 µM; HL-60, IC₅₀ 14.6 µM; MCF-7, IC₅₀ 20.4 µM; SMMMC-7721, IC₅₀ 19.0 µM; SW480, IC₅₀ 25.7 µM) [17], |
| 90       | Aspergillus ustus [231], Calzatia nipponica [126], Ganoderma sinense [233], Stereum hirsutum [17], Tricholoma imbricatum [245] | cytotoxic assay (Hep3B, IC₅₀ 9.67 µM; HepG2, IC₅₀ 11.83 µM) [204], lifespans assay (number of divisions of K6001 yeast strain cells before death: 8.2 in control, 8.9 at 1 µM, 9.4 at 100 µM) [244], |
| 91       | Ganoderma lucidum [243,244], Talaromyces stipitatus [204] | cytotoxic assay (A549, HL-60, MCF-7, SMMMC-7721, SW480, IC₅₀ > 40 µM; HL-60, IC₅₀ 22.8 µM) [184], |
| 92       | Polyporus ellisi [184] | cytotoxic assay (A549, HL-60, MCF-7, SMMMC-7721, SW480, IC₅₀ > 40 µM; HL-60, IC₅₀ 17.8 µM) [184], |
| 93       | Ganoderma lucidum [243,244], Talaromyces stipitatus [204] | cytotoxic assay (Hep3B, IC₅₀ 12.59 µM; HepG2, IC₅₀ 18.95 µM; Huh-7, IC₅₀ 32.81 µM) [204], lifespans assay (number of divisions of K6001 yeast strain cells before death: 8.2 in control, 9.1 at 1 µM, 11.1 at 10 µM, 9.6 at 100 µM) [244], |
| 94       | Polyporus ellisi [184] | cytotoxic assay (A549, HL-60, MCF-7, SMMMC-7721, SW480, IC₅₀ > 40 µM; HL-60, IC₅₀ 22.8 µM) [184], |
| 95       | Ganoderma lucidum [243], Phomopsis sp. [246] | antifungal assay (MIC 64 µg/mL against Fusarium oxysporum, MIC 128 µg/mL against Hormodendrum compactum) [246], lifespans assay (number of divisions of K6001 yeast strain cells before death: 7.5 in control, 10.0 at 3 µM, 10.7 at 10 µM, 9.2 at 30 µM) [243], |
| 96       | Chaetomium globosum [247] | cytotoxic assay (A549, MG-63, SMMMC-7721, IC₅₀ > 50 µg/mL) [247], |
| 97       | Colletotrichum sp. [206], Penicillium brasiliare [227], Pleurotus eryngii [6], Tricholoma imbricatum [245] | cytotoxic assay (A549, IC₅₀ 21.7 µM; HL-60, IC₅₀ 27.3 µM) [245], NO production inhibition assay (IC₅₀ 12.4 µM) [6], |
| 98       | Tricholoma imbricatum [245] | cytotoxic assay (HL-60, IC₅₀ 25.7 µM; SMMMC-7721, IC₅₀ 27.3 µM; SW480, IC₅₀ 17.7 µM) [245], |
| 99       | Fomes fomentarius [208], Grifola frondosa [48], Phellinus linteus [198] | β-hexosaminidase release assay (no activity) [48], HNE inhibitory assay (IC₅₀ > 100 µM) [198], NO production inhibition assay (IC₅₀ 32.87 µM) [208], |
| 100      | Hericium erinaceum [187] | TNF-α secretion assay (24.6% inhibition at 10 µg/mL) [187], |
| 101      | Tricholoma imbricatum [245] | cytotoxic assay (A549, IC₅₀ 12.4 µM; HL-60, IC₅₀ 12.2 µM; K562, IC₅₀ 13.8 µM; MCF-7, IC₅₀ 17.8 µM; SMMMC-7721, IC₅₀ 27.6 µM; SW480, IC₅₀ 19.7 µM) [245], |
| 102      | Chaetomium globosum [247], Phomopsis sp. [202], Tricholoma imbricatum [245] | α-glucosidase inhibition assay (IC₅₀ > 100 µM) [202], cytotoxic assay (A549, IC₅₀ 20.72 µg/mL; MG-63, IC₅₀ 15.34 µg/mL; SMMMC-7721, IC₅₀ 19.20 µg/mL) [247]. (A549, IC₅₀ 27.3 µM; HL-60, IC₅₀ 23.6 µM) [245], |
| 103      | Tricholoma imbricatum [245] | cytotoxic assay (A549, IC₅₀ 36.7 µM; HL-60, IC₅₀ 16.6 µM; K562, IC₅₀ 19.9 µM; MCF-7, IC₅₀ 21.3 µM; SMMMC-7721, IC₅₀ 23.5 µM) [245], |
| 104      | Pleurotus eryngii [248] | NO production inhibition assay (weak activity) [248], |
| 105      | Tricholoma imbricatum [245] | cytotoxic assay (A549, IC₅₀ 12.7 µM; HL-60, IC₅₀ 7.7 µM) [245], |
| 106      | Stereum hirsutum [17] | cytotoxic assay (A549, IC₅₀ 11.0 µM; HL-60, IC₅₀ 3.1 µM; MCF-7, IC₅₀ 12.3 µM; SMMMC-7721, IC₅₀ 9.0 µM; SW480, IC₅₀ 13.4 µM) [17], |
| 107      | Stereum hirsutum [17] | cytotoxic assay (A549, HL-60, MCF-7, SMMMC-7721, SW480, IC₅₀ > 40 µM) [17], |
| 108      | Gymnascus ressii [249], Polyporus ellisi [198], Phomopsis sp. [246] | antifungal assay (MIC 64 µg/mL against Fusarium oxysporum, MIC 256 µg/mL against Aspergillus niger and Trichophyton gypseum) [246], antimalarial assay (IC₅₀ 3.4 µg/mL against Plasmodium falciparum) [249], cytotoxic assay (KB, IC₅₀ 3.8 µM; MCF-7, IC₅₀ 7.9 µM; NCI-H187, IC₅₀ 1.9 µM; Vero, IC₅₀ 3.3 µM) [249], HNE inhibitory assay (IC₅₀ 20.5 µM) [198]. |
| Compound | Fungal Source [Ref.] | Assays (Activity) [Ref.] |
|----------|----------------------|--------------------------|
| 89       | Calvatia cyathiformis [242] |                           |
| 109      | Ganoderma resinaceum [103], Omphalia lapidescens [15], Talaromyces stipitatus [204] | cytotoxic assay (Hep3B, IC50 5.26 μM; HepG2, IC50 6.29 μM; HeLa, IC50 6.23 μM) [204], (HGC-27, IC50 16.93 μM) [19] |
| 110      | Ganoderma lucidum [243] | lifespan assay (number of divisions of K600 yeast strain cells before death: 7.5 in control, 8.8 at 3 μM, 10.8 at 10 μM, 9.4 at 30 μM) [245] |
| 111      | Colletotrichum sp. [206], Ganoderma sinense [196], Pleurotus eryngii [250], Psathyrella candolleana [251], Volvariella volvacea [123] | cytotoxic assay (HepG2, IC50 5.90 μM; SGC-7901, IC50 12.03 μM) [123], (A549, HL-60, MCF-7, SMMC-7721, SW480, IC50 > 40 μM) [251], (RAW264.7, IC50 > 100 μM) [250], NO production inhibition assay (IC50 28.5 μM) [196], (IC50 100 μM) [250] |
| 112      | Volvariella volvacea [123] | cytotoxic assay (HepG2, IC50 20.27 μM) [123] |
| 113      | Ganoderma resinaceum [103] | NO production inhibition assay (IC50 35.19 μM) [103] |
| 114      | Gliomastix sp. [252] | antiviral assay (EV-71 virus, IC50 17.8 μM) [252], cytotoxic assay (HL-60, IC50 1.75 μM; DU-145, IC50 7.37 μM; HeLa, IC50 12.1 μM; MOLT-4, IC50 6.53 μM) [252] |
| 115      | Ganoderma philippii [253] | AChE inhibitory assay (35.8% inhibition at 50 μg/mL) [253] |
| 116      | Ganoderma resinaceum [103] | NO production inhibition assay (IC50 32.87 μM) [103] |
| 117      | Pleurotus eryngii [6] | NO production inhibition assay (IC50 18.1 μM) [6] |
| 118      | Penicillium purpureogenum [254] | cytotoxic assay (A549, HepG2, MCF-7, IC50 > 100 μM) [254] |
| 119      | Gymnascus reessii [249], Phomopsis sp. [246], Talaromyces sp. [255] | antifungal assay (MIC 128 μg/mL against Candida albicans, MIC 256 μg/mL against Aspergillus niger and Hormodendrum compactum) [246], antimalarial assay (IC50 3.4 μg/mL against Plasmodium falciparum) [246], cytotoxic assay (KB, IC50 20.4 μM; MCF-7, IC50 > 50 μM; NCI-H187, IC50 12.1 μM; Vero, IC50 19.3 μM) [249] |
| 120      | Stereum hirsutum [17], Phomopsis sp. [246] | antifungal assay (MIC 64 μg/mL against Candida albicans and Hormodendrum compactum, MIC 128 μg/mL against Aspergillus niger) [246], cytotoxic assay (A549, IC50 27.8 μM; HL-60, IC50 14.4 μM; MCF-7, IC50 > 40 μM; SMMC-7721, IC50 32.0 μM; SW480, IC50 > 40 μM) [17] |
| 121      | Lasiodiplodia pseudotheobromae [11] | AChE inhibitory assay (no activity) [11], α-glucosidase inhibition assay (no activity) [11] |
| 122      | Phomopsis sp. [246] | antifungal assay (MIC 128 μg/mL against Candida albicans and Fusarium avenaceum, MIC 256 μg/mL against Hormodendrum compactum) [246] |

7. Ketones

Most compounds of this group of ergostane-type steroids contain keto functions at C-3 and C-6, as well as a number of double bonds (Figure 14). Ergone (124) is probably the best studied among them [256]. It is found in many fungal sources (Table 5), usually with a content of less than 10 μg/g of mushroom fruit bodies. *Polyporus umbellatus*, in comparison with other mushrooms, contains the highest amount of this compound, which, under optimized conditions, can reach 86.9 μg/g [257]. For practical purposes, ergone (124) can be easily obtained through a three-step chemical synthesis from ergosterol [258]. Ergone has been reported to possess various activities (Table 5), including cytotoxic, anti-bacterial [205], anti-inflammatory [228,259], anti-malarial [249], diuretic [260] abilities, and protective effects of early renal injury [261,262].
Attempts were made to study the mechanism of its action. A strong anticancer effect of 124 to HepG2 cells was associated with the induction of G2/M cell cycle arrest and apoptosis in a caspase-dependent manner [270].

Wang et al. studied the effect of ergone (124) on lipopolysaccharide-induced acute lung injury [272]. Pretreatment of mice with 124 was found to reduce neutrophil recruitment, regulate the release of inflammatory cytokines, reduce pulmonary edema, and correct pulmonary insufficiency. The observed effects were associated with inhibition of the NLRP3 signaling pathway.
Ergone (124) was found to inhibit signaling pathways STAT3 and Src in head and neck cancer-initiating cells [263] that results in the reduction of their stemness properties and tumorigenicity and is of interest for the treatment of head and neck squamous cell carcinoma.

The variety of pharmacological activities prompted scientists to study pharmacokinetic properties of ergone. Fan et al. investigated the interactions between ergone and human serum albumin [273]. The latter is a carrier protein for many endogenous and exogenous molecules in blood and greatly affects the pharmacokinetics of drugs. Fluorescence spectroscopy revealed the binding of ergone to albumin, in which hydrogen bonds and hydrophobic interactions play a dominant role.

The following pharmacokinetic parameters were measured after a single oral administration (20 mg/kg) of ergone to rats: the area under the plasma concentration versus time curve from time 0 h to indefinite time (AUC$_{0-\infty}$) was 19.6 µg h mL$^{-1}$, peak plasma concentration (C$_{\text{max}}$) was 1.5 µg/mL, the elimination half-life (t$_{1/2}$) was 5.90 h, and time to C$_{\text{max}}$ (T$_{\text{max}}$) was 3.8 h [266].

To improve the therapeutical effect of ergone, several drug delivery systems has been proposed [274,275]. The folate receptor is known to be overexpressed in a wide variety of cancers, which is the basis for the development of tumor-targeted drug delivery systems. One of them uses the most abundant protein in plasma, albumin. Folate-modified ergone bovine serum albumin nanoparticles showed increased cellular uptake, targeting ability and cytotoxicity toward KB cells [274]. An in vivo experiment showed a higher antitumor effect and less toxicity of ergone nanoparticles compared to free ergone. Another delivery system was based on the encapsulation of ergone in PEGylated liposomes [275]. Pharmacokinetic studies have shown that encapsulation provides a longer residence time of ergone in the blood, which leads to a more effective in vivo antitumor effect.

8. Fungal Steroids with a Transformed Side Chain

The metabolic transformations of the ergosterol side chain are not as diverse as those of the tetracyclic skeleton. As a rule, they include hydrogenation of the $\Delta^{22}$-double bond, its epoxidation, and hydroxylation of the terminal fragment (in most cases at C-25), as well as subsequent secondary transformations of the introduced functional groups.

Many steroids of this class of ergostanes are 25-hydroxy derivatives (Figure 15). Compounds 131–140 were tested in inflammatory, cytotoxic, and antibacterial assays, but showed no particular activity (Table 6).
The epoxide 143 (Figure 16) was isolated from a halotolerant fungus *Aspergillus flocculosus* PT05-1 cultured in a hypersaline medium [13]. It exhibited a moderate antibacterial and antifungal activity and a weak cytotoxicity against HL-60 and BEL-7402 cell lines.

![Figure 16. Structures of steroids with a transformed side chain.](image)

An ochratoxin-ergosteroid heterodimer, ochrasperfloroid (145), was isolated from the sponge-derived fungus *Aspergillus flocculosus* 16D-1 [276]. It showed potent inhibitory effects on IL-6 production in LPS-induced cells and NO production in LPS-activated macrophages (Table 6). Fungi of *Aspergillus* genus have been the source of three more steroids with the same side chain, including asperfloroid (146) [277], asperflosterol (148) [278], and compound 147 [279]. Anti-inflammatory properties were identified for asperfloroid (146) and asperflosterol (148) (Table 6).

Three 18,22-cyclosterols, including aspersteroid B (152) and aspersteroid C (153), were isolated from the culture extract of *Aspergillus ustus* NRRL 275 [280]. Both compounds exhibited no cytotoxicity against MCF-7, HeLa, A549, and HT-29 cells. When analyzing the immunosuppressive effect on the proliferation of T- and B-lymphocytes in vitro, they showed activity from moderate to weak.

Two bis-epoxides, favolon (149) and favolon C (150), were isolated from the cultures of basidiomycete *Favolaschia calocera* BCC 36684 [281]. They were evaluated for a number of activities such as antimalarial, antitubercular, cytotoxic, but a positive result was obtained only in the antifungal assay.
A pair of steroidal epimers, penijanthoids A and B (154 and 155), were isolated from the marine-derived fungus *Penicillium janthinellum* [246]. Both compounds showed weak anti-*Vibrio* activity against three pathogenic *Vibrio* spp.

**Table 6.** Sources and biological activity of fungal steroids with a transformed side chain.

| Compound | Fungal Source [Ref.] | Assays (Activity) [Ref.] |
|----------|----------------------|--------------------------|
| 131      | *Ganoderma sinense* [196] | NO production inhibition assay (IC\(_S_0\) 17.7 \(\mu\)M) [196] |
| 132      | *Ganoderma sinense* [196] | NO production inhibition assay (IC\(_S_0\) 32.4 \(\mu\)M) [196] |
| 133      | *Ganoderma sinense* [196] | NO production inhibition assay (IC\(_S_0\) 19.8 \(\mu\)M) [196] |
| 134      | *Fusarium chlamydosporum* [218] | lipoxygenase inhibitory assay (IC\(_S_0\) 7.23 \(\mu\)M) [218] |
| 136      | *Psathyrella candelana* [251] | cytotoxic assay (A549, HL-60, MCF-7, SMMC-7721, SW480, IC\(_S_0\) > 40 \(\mu\)M) [251] |
| 137      | *Psathyrella candelana* [251] | cytotoxic assay (A549, IC\(_S_0\) 23.4 \(\mu\)M; HL-60, IC\(_S_0\) 32.3 \(\mu\)M; MCF-7, IC\(_S_0\) 28.3 \(\mu\)M) [251] |
| 138      | *Conocybe siliginea* [282] | NO production inhibition assay (IC\(_S_0\) > 40 \(\mu\)M) [282] |
| 139      | *Conocybe siliginea* [282] | NO production inhibition assay (IC\(_S_0\) > 40 \(\mu\)M) [282] |
| 140      | *Aspergillus alabamensis* [283] | antimicrobial assay (MIC 32 \(\mu\)g/mL against *Edwardsiella ictaluri*, MIC 64 \(\mu\)g/mL against *Vibrio alginolyticus*) [283] |
| 141      | *Mahonia fortune* [265] | antibacterial assay (MIC 100 \(\mu\)g/mL against *Staphylococcus aureus*) [265] |
| 142      | *Hymenoscyphus fraxineus* [284] | antibacterial assay (MIC 16.7 \(\mu\)g/mL against *Bacillus subtilis*, *Micrococcus luteus* and *Staphylococcus aureus*) [284], cytotoxic assay (IC\(_S_0\) 1.929; IC\(_S_0\) 24 \(\mu\)g/mL) [284] |
| 143      | *Aspergillus flocculosus* [13] | antibacterial assay (MIC 3.3 \(\mu\)g/mL against *Candida albicans*, 3.3 \(\mu\)g/mL against *Pseudomonas aeruginosa*, 1.6 \(\mu\)g/mL against *Enterobacter aerogenes*) [13] |
| 144      | *Trichoderma sp.* [230] | HIV-inhibitory assay (IC\(_S_0\) 41.6 \(\mu\)M) [230], NO production inhibition assay (10\% inhibition at 10 \(\mu\)M) [230] |
| 145      | *Aspergillus flocculosus* [276] | cytotoxic assay (A549, IC\(_S_0\) 55.0 \(\mu\)M; HepG2, IC\(_S_0\) 23.6 \(\mu\)M) [276], IL-6 immune-suppressive activity assay (IC\(_S_0\) 2.02 \(\mu\)M) [276], NO inhibitory activity assay (IC\(_S_0\) 1.11 \(\mu\)M) [276] |
| 146      | *Aspergillus flocculosus* [277], *Chaetomium globosum* [285] | cytotoxic assay (A549, HepG2, THP-1, IC\(_S_0\) > 80 \(\mu\)M) [277], IL-6 immune-suppressive activity assay (IC\(_S_0\) 22 \(\mu\)M) [277] |
| 147      | *Aspergillus sp.* [279] | antiviral assay (no activity against H3N2 and EV71 viruses) [279] |
| 148      | *Aspergillus flocculosus* [278] | cytotoxic assay (A549, HepG2, THP-1, IC\(_S_0\) > 80 \(\mu\)M) [278], IL-6 immune-suppressive activity assay (IC\(_S_0\) 24 \(\mu\)M), TNF-\(\alpha\) secretion assay (IC\(_S_0\) 28 \(\mu\)M) [278] |
| 149      | *Favolaschia calocera* [281] | antifungal assay (active in the agar diffusion test) [281] |
| 150      | *Favolaschia calocera* [281] | antifungal assay (active in the agar diffusion test) [281] |
| 151      | *Albatrellus confluens* [286] | cytotoxic assay (HL-60, PAN-1, A549, SK-BR-3, SMMC-7721, no activity) [286] |
| 152      | *Aspergillus ustus* [280] | immunosuppressive assay (ConA-induced T-cell proliferation, IC\(_S_0\) 22.49 \(\mu\)M; LPS-induced B-cell proliferation, IC\(_S_0\) 22.49 \(\mu\)M) [280] |
| 153      | *Aspergillus ustus* [280] | immunosuppressive assay (ConA-induced T-cell proliferation, IC\(_S_0\) 69.68 \(\mu\)M; LPS-induced B-cell proliferation, IC\(_S_0\) 69.68 \(\mu\)M) [280] |
| 154      | *Penicillium janthinellum* [246] | antibacterial assay (MICs 25.0–50.0 \(\mu\)M against three pathogenic *Vibrio* spp.) [246] |
| 155      | *Penicillium janthinellum* [246] | antibacterial assay (MICs 25.0–50.0 \(\mu\)M against three pathogenic *Vibrio* spp.) [246] |
| 156      | *Phoma sp.* [287] | PTP inhibitory activity assay (PTP1B, IC\(_S_0\) 25 \(\mu\)M each) [287] |
9. Ergostanes with a Rearranged Tetracyclic Skeleton

Due to their intriguing structural complexity and promising biological activities, ergostanes with a rearranged tetracyclic carbon skeleton have become very attractive targets for chemists and biologists. A recent review [23] has covered this area quite thoroughly, but for consistency and completeness some results will be briefly discussed here.

Most ergostanes with a modified skeleton are highly functionalized compounds bearing three and more functional groups. A certain exception are aromatic 1(10→6)abeo-ergostane-type steroids 157–160 (Figure 17). Two of them, 157 and 158, exhibited significant cytotoxicity toward murine colorectal CT26 and human leukemia K562 cancer cell lines (Table 7). Citreoanthrasteroid B (158) was also tested for the neuroprotective effects on PC12 cells injured by glutamate (15 mM) [288]. Compound 158 showed potential neuroprotective activities by inhibiting the death of injured PC12 cells with EC_{50} value of 24.2 µM.

Figure 17. Structures of 1(10→6)abeo-ergostane-type steroids.

Another 1(10→6)abeo-steroid, aspersteroid A (161), was isolated from the culture extract of Aspergillus ustus [280]. It exhibited moderate cytotoxicity on four cancer cell lines, antimicrobial activity against Gram-negative and Gram-positive bacteria and immunosuppressive activities against the proliferation of T and B lymphocyte cells in vitro (Table 7).

Three anthrasteroid glycosides, malstersides A-C (162a–c), were isolated from the fungus Malbranchea filamentosus [289]. The sugar moiety in the side chain of all glycosides was found to be D-mannose and the glycoside 162c contained N-acetyl-D-glucosamine at the C-3 position. Cytotoxicity studies were performed with the A549 and Hela cancer cell lines. A moderate cytotoxicity in both lines was noted for malsteroside A (162a).

Two 1(10→6)-abeo-14,15-secosteroids, asperfloketals A (163) and B (164), were found in the sponge-associated fungus Aspergillus flacculosus 16D-1 [290]. They exhibited no cytotoxicity against three tested cancer cell lines. Promising results were obtained in anti-inflammatory assays. Compounds 163 and 164 displayed stronger activity in the CuSO_{4} induced transgenic fluorescent zebrafish than ibuprofen used as a positive control.

A-nor-B-homo steroid 165 (Figure 18) containing a 10(5→4)-abeo-ergostane fragment was isolated from culture of basidiomycete Polyporus ellisii [184] and from the mangrove-derived fungus Phomopsis sp. MGF222 [202]. Compound 165 exhibited inhibitory activities
against four out of five human cancer cell lines tested except A549 [184] (Table 7). It was also tested for the antibacterial activities against seven pathogenic bacteria and for the inhibitory activities against α-glucosidase, but no effect was observed [202].

Figure 18. Structures of ergostanes with a rearranged A-ring.

Another A-nor steroid 166 was isolated from the fungus of *Lasiodiplodia pseudotheobromae* [11]. A distinguished structural feature of this compound is an additional δ-lactone ring between C-3 and C-9.

Two nearly identical steroids 167 and 168 featured a bicyclo[3.3.1]nonane motif were discovered in the fungi *Phomopsis* sp. TJ507A [7] and *Stereum hirsutum* [17]. The only difference in their structures is the presence of a methoxy group in phomopsterone A (167) instead of an ethoxy one in steresterone A (168). Compound 167 was tested for NO inhibitory activity. Steresterone A (168) was evaluated for the cytotoxicity against five human cancer cell lines. Both compounds showed no activity in the respective tests.

Three C25 steroids, neocyclocitrinols E-G (169–171) were isolated from endophytic fungus *Chaetomium* sp. M453 [189]. All compounds were tested for AChE inhibitory activities and cytotoxicity, however, no effect was found.

Cheng et al. isolated from *Ganoderma theaecolum* ganotheaecolin A (173), having a naphtho[1,8-ef]azulene ring system steroid [291]. At a concentration of 10 µM, it showed activity to promote neurite growth in PC12 cells, comparable to that of nerve growth factor used as control.

A new steroid sarocladione (174) bearing a 5,10:8,9-diseco moiety was isolated from the deep-sea-derived fungus *Sarocladium kiliense* [292]. The initially proposed configuration at C-3 and C-7 proved to be incorrect and was revised to 3S,7R through the chemical synthesis [293]. Cytotoxic studies of compound 174 revealed no apparent cellular toxicities.
Lin et al. isolated from the sponge-derived fungus *Aspergillus flocculosus* 16D-1 two 11(9→10)-abeo-5,10-seco steroids, aspersecosteroids A (175) and B (176) [278], a characteristic structural feature of which was the presence of a dioxatetraheterocyclic ring system. Both compounds were non-cytotoxic at the concentrations up to 40 µM and showed a strong inhibitory effect on the production of TNF-α and IL-6.

Spiroseoflorsterol (177) (Figure 19), having a unique spiro[4.5]decan-6-one moiety, was isolated from the fruiting bodies of *Butyriboletus roseoflavus* [294]. It showed a strong cytotoxic effect on HepG2 cell line (IC₅₀ 9.1 µM), which was comparable to that of sorafenib (IC₅₀ 5.5 µM) used as a positive control. Moreover, spireseoflorsterol (177) was active against sorafenib-resistant Huh7/S cells with an IC₅₀ value of 6.2 µM, that makes it a promising candidate for antihepatoma drug development.

![Figure 19. Structures of ergostanes with a rearranged B-ring.](image)

Calvatanone (178), featuring a contracted tetrahydrofuran B-ring, was found in a rare mushroom *Calvatia nipponica* [126]. It showed a weak cytotoxicity against MCF-7 with IC₅₀ > 100 µM (Table 7).

Another compound with a five-membered B ring, laschiatron (179), was isolated from fermentations of *Favolaschia* sp. [281,295]. It was not active in antibacterial and cytotoxic assays, but exhibited antifungal activity in the agar diffusion test [281].

7-Nor-ergosterolide (180), featuring a pentalactone B-ring system, was found in the culture extract of an endophytic fungus *Aspergillus ochraceus* EN-31 [296] and a halotolerant fungus *Aspergillus flocculosus* PT05-1 [13]. Compound 180 showed pronounced cytotoxic and antibacterial properties.

A characteristic structural feature of erinarol J (181), isolated from the dried fruiting bodies of mushroom *Hericium erinaceum*, is the presence of 6,8-dioxabicyclo[3.2.1]oct-2-ene moiety [187]. Biotests have shown potent anti-inflammatory activity of 181 due to the inhibition of TNF-α secretion and NO production.

The first natural 5,6-seco steroid, eringiacetal A (182), was isolated from the fruiting bodies of mushroom *Pleurotus eryngii* [250]. Biological assays showed its modest cytotoxicity and ability to inhibit NO production.
Herbarulide (183) was first isolated from the endophytic fungus *Pleospora herbarum* as a compound having a campestane side chain [297]. Later the same structure was assigned to one of the constituents of the Taiwanese fungus *Antrodia camphorate* [298]. The correct structure of herbarulide (183) was proposed by Chen and Liu who isolated it from the fungus *Stereum hirsutum* [17]. The assignment was based rather on the assumption that the C-24 stereocenter of the starting ergosterol will remain unchanged during the transformations in the cyclic part. Finally, the correct structure of 183 was confirmed by its chemical synthesis [299]. Compound 184, structurally very close to herbarulide (183), was isolated from the fruiting bodies of *Ganoderma resinaceum* [103].

Solaniolic acid (185) is a degraded and rearranged steroid isolated from laboratory cultures of the fungus *Rhizoctonia solani* [300]. An important feature of its biological activity is antibacterial effect against methicillin-resistant *Staphylococcus aureus*. The latter is a cause of infection that is difficult to treat due to resistance to many antibiotics.

Tricholumin A (186) was isolated from the alga-endophytic fungus *Trichoderma asperellum* [301]. The only structural element of the parent ergosterol that remained after a number of metabolic stages of its biosynthesis is cycle A. The rest of the molecule, including a fragment of the side chain, has undergone deep transformations. Inhibitory properties of 186 against harmful microalgae and weak antibacterial activity against five aquatic pathogens were found.

Dankasterone A (187) (Figure 20) was first isolated from a fungal strain of *Gymnascella dankaliensis* derived from the sponge *Halichondria japonica* [302]. The initial erroneous assignment of stereochimistry at C-24 was corrected from S to R in a follow-up work by these authors [303]. Subsequently, compound 187 was repeatedly isolated from fungal sources as one of the ergostane constituents (Table 7). The only structural difference between 187 and dankasterone B (188) is the saturated ring A. From the endophytic fungus *Phomopsis* sp. TJ507A was also isolated phomopsterone B (190) differing from 187 by the presence of a methyl group at C-23 [7]. Dankasterone A (187) showed promising anticancer activities with IC\(_{50}\) down to 2.3 \(\mu M\) on a range of cancer cell lines (Table 7). Structure activity relationship studies of dankasterones A and B showed that the \(\Delta^4\)-double bond is essential for high cytotoxicity against the cancer cell lines tested. Carbonyl groups in dankasterone B (188) were other structural elements important for the high biological activity, because products of its NaBH\(_4\) reduction were not cytotoxic [17]. Phomopsterone B (190) was tested for inflammatory activity and showed promising results in iNOS inhibitory and NO production inhibition assays [7].

At first glance, the carbon skeleton of periconiastone A (189) [304] looks completely different from that of dankasterone B (188). In fact, compound 189 is available from 188 in one step via the intramolecular aldol reaction [305], which is also evidently realized in the course of its biosynthesis. So far, periconiastone A (189) has been tested for anti-inflammatory and antibacterial activities. Positive results were obtained in an antibacterial assay against Gram-positive bacteria [304].

An 8,14-seco-steroid, childinasterone A (191), was isolated from fruiting bodies of the ascomycete *Daldinia chilidiae* [306]. It showed no activity in cytotoxic studies and exhibited strong inhibition of NO production (IC\(_{50}\) value of 21.2 \(\mu M\) versus 41.5 \(\mu M\) for L-NMMA used as a positive control).

9,11-Secosteroids are quite common in sea sponges [22], but rather rare in fungal sources. The first such an ergostane 192 was isolated from king trumpet mushroom *Pleurotus eryngii* [6]. Compound 192 exhibited NO inhibitory activity similar to that of L-NMMA and revealed no cytotoxicity. Another 9,11-secoergostane (193), found in the fruiting bodies of *Pleurotus eryngii*, displayed similar profile of biological activity [6].
Figure 20. Structures of ergostanes with a rearranged C-ring.

Three steroids with a rearranged ring B, eringiacetal B (194), matsutakone (195), and pleurocin B (196), were isolated from the fruiting bodies of *Pleurotus eryngii* by Tanaka et al. [248]. All three compounds revealed inhibitory activity on production of NO which was stronger than that of L-NMMA. The 13,14-seco-13,14-epoxysteroid, eringiacetal B (194), was most active with an IC\textsubscript{50} of 13.0 µM compared to 23.9 µM for the L-NMMA positive control.

An 8(14→15)-abeo-steroid, asperflotone (197), was obtained from the solid culture of *Aspergillus flocculosus* 16D-1 [277]. Its characteristic structural feature is a rearranged bicyclo[4.2.1]non-2-ene ring system. Compound 197 was tested on three cancer cell lines with no cytotoxic effects. In immune-suppressive activity assay, asperflotone (197) exhibited inhibitory effects on IL-6 secretion.

The 15(14→22)abeo-steroid framework is common for ergostanes 198–203 (Figure 21), collectively referred to as strophasterols. It took some effort to establish the correct structures of these structurally related compounds. Strophasterols A–D (198–201) were first isolated from the mushroom *Stropharia rugosoannulata* [307]. The structure of strophasterin A (198) was established by X-ray crystallographic analysis. Comparison of the NMR data made it possible to assign the structure of 199 as the C-22 isomer of strophasterol A that was later confirmed by X-ray analysis [193]. Structure of strophasterol C (200) was proposed based on NOE correlations by Aung et al., who isolated it from the basidiomycete *Cortinarius glaucopus* together with glaucoposterol A (203) [195]. Additional evidence for the structure of 200 was obtained by its chemical synthesis [308]. Two more steroids with a strophastane skeleton, strophasterol E (202) and strophasterol F (203), were isolated from the fruiting bodies of *Pleurotus eryngii* [201]. Their structures were determined by X-ray analysis of the corresponding tris-p-bromobenzoate derivatives. Structural elucidation of strophasterol D (201) was done by comparing it with a synthetically prepared sample [309]. This work also showed that glaucoposterol A and strophasterol F are the same compound (203).
So far, the biological activity of strophasterols has been studied only marginally. Strophasterol A (198) showed a dose-dependent inhibitory effect on the toxicity of thapsigargin. The latter is known to disrupt the balance of the Ca$^{2+}$ concentration in the endoplasmic reticulum that is especially harmful to neuronal cells. Under the action of strophasterol A (198), an increase in cell viability by 10.3% compared with the control was noted [307]. Strophasterols E and F were tested for anti-inflammatory activity, but showed no promising results [201].

A 15(14→11)-abeo-ergostane, penicillitone (204), was isolated from the culture of the fungus *Penicillium purpurogenum* SC0070 [254]. It was evaluated for cytotoxicity against three cancer lines and showed good potency with IC$_{50}$ ranging from 4.44 to 5.98 µM. In addition, compound 204 was active in the inflammatory assay on the production of TNF-α and IL-6. At the concentration of 5 µM it reduced their secretion by 70.7% and 96.6%, respectively. For comparison, inhibition rates of the positive control dexamethasone at 100 µM were 87.3% and 96.7%, respectively. This makes promising further in-depth study of penicillitone (204) as an anti-inflammatory or antitumor agent.
| Compound   | Fungal Source [Ref.]                                                                 | Assays (Activity) [Ref.]                                                                                   |
|------------|--------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------|
| 157        | *Antrodia camphorata* [310], *Aspergillus ustus* [231], *Gibberella zae* [311]        | cytotoxic assay (CT26, IC₅₀ 15.3 µM; K562, IC₅₀ 19.9 µM) [310]                                             |
| 158        | *Antrodia camphorata* [310], *Penicillium citro-variæ* [312], *Phyllosticta capitalesiensis* [288] | cytotoxic assay (CT26, IC₅₀ 18.2 µM; K562, IC₅₀ 12.5 µM) [310], neuroprotective activity assay (IC₅₀ 24.2 µM) [288] |
| 159a       | *Aspergillus ustus* [231]                                                             |                                                                                                            |
| 159b       | *Aspergillus ustus* [231]                                                             |                                                                                                            |
| 160        | *Penicillium citro-variæ* [312]                                                      |                                                                                                            |
| 161        | *Aspergillus ustus* [280]                                                            | antimicrobial assay (Candida albicans, MIC₅₀ 17.24 µg/mL; Escherichia coli, MIC₅₀ 17.24 µg/mL; Staphylococcus aureus, MIC₅₀ 15.51 µg/mL) [280], cytotoxic assay (A549, IC₅₀ 40.32 µM; Hela, IC₅₀ 26.09 µM; HT-29, IC₅₀ 43.58 µM; MCF-7, IC₅₀ 32.03 µM) [280], immunosuppressive assay (ConA-induced T-cell proliferation, IC₅₀ 23.61 µM; LPS-induced B-cell proliferation, IC₅₀ 23.61 µM) [280] |
| 162a       | *Malbranchea filamentosa* [289]                                                      | cytotoxic assay (A549, IC₅₀ 38.6 µM; Hela, IC₅₀ 28.1 µM) [289]                                           |
| 162b       | *Malbranchea filamentosa* [289]                                                      | cytotoxic assay (A549, Hela, no activity) [289]                                                            |
| 162c       | *Malbranchea filamentosa* [289]                                                      | cytotoxic assay (Hela, IC₅₀ 76.9 µM) [289]                                                                 |
| 163        | *Aspergillus flocculosus* [290]                                                      | anti-inflammatory assay [290]                                                                                |
| 164        | *Aspergillus flocculosus* [290]                                                      | anti-inflammatory assay [290]                                                                                |
| 165        | *Phomopsis* sp. [202], *Polyporus ellisii* [184]                                     | α-glucosidase inhibition assay (IC₅₀ > 100 µM) [202], cytotoxic assay (A549, IC₅₀ > 40 µM; HL-60, IC₅₀ 17.1 µM; MCF-7, IC₅₀ 23.3 µM; SMMC-7721, IC₅₀ 21.3 µM; SW480, IC₅₀ 16.3 µM) [184] |
| 166        | *Lasiodiplodia pseudotheobromae* [11]                                                 |                                                                                                            |
| 167        | *Phomopsis* sp. [7]                                                                  | NO production inhibition assay (IC₅₀ > 25 µM) [7]                                                          |
| 168        | *Stereum hirsutum* [17]                                                              | cytotoxic assay (A549, HL-60, MCF-7, SMMC-7721, SW480, IC₅₀ > 40 µM) [17]                                |
| 169        | *Chaetomium* sp. [189]                                                               | cytotoxic assay (A549, HL-60, MCF-7, SMMC-7721, SW480, IC₅₀ > 40 µM) [189]                                |
| 170        | *Chaetomium* sp. [189]                                                               | cytotoxic assay (A549, HL-60, MCF-7, SMMC-7721, SW480, IC₅₀ > 40 µM) [189]                                |
| 171        | *Chaetomium* sp. [189]                                                               | cytotoxic assay (A549, HL-60, MCF-7, SMMC-7721, SW480, IC₅₀ > 40 µM) [189]                                |
| 172        | *Xylaria* sp. [313]                                                                 |                                                                                                            |
| 173        | *Ganoderma theaceolum* [291]                                                         | neurite outgrowth-promoting assay in PC12 cells (stimulated cell differentiation with a maximum effect at 10 µM) [291] |
| 174        | *Sarocladium kiliense* [292]                                                         | cytotoxic assay (Bel-7402, ECA-109, HeLa, PANC-1, SHG-44, no activity) [292]                             |
| 175        | *Aspergillus flocculosus* [278]                                                      | cytotoxic assay (A549, HepG2, THP-1, IC₅₀ > 80 µM) [278], IL-6 immune-suppressive activity assay (IC₅₀ 21 µM), TNF-α secretion assay (IC₅₀ 28 µM) [278] |
| 176        | *Aspergillus flocculosus* [278]                                                      | cytotoxic assay (A549, HepG2, THP-1, IC₅₀ > 80 µM) [278], IL-6 immune-suppressive activity assay (IC₅₀ 26 µM), TNF-α secretion assay (IC₅₀ 31 µM) [278] |
| 177        | *Butyriotheutus roseoflavus* [294]                                                   | cytotoxic assay (HepG2, IC₅₀ 9.1 µM; Huh7/S, IC₅₀ 6.2 µM; L02, IC₅₀ 22.8 µM) [294]                     |
| 178        | *Calvatia nipponica* [126]                                                           | cytotoxic assay (MCF-7, IC₅₀ > 100 µM) [126]                                                               |
| 179        | *Favolaschia calocera* [281], *Favolaschia sp.* [295]                                | antifungal assay (activity against Candida albicans, Cryptococcus neoformans, etc. at concentrations of 10–50 µg/mL) [295] |
| 180        | *Aspergillus flocculosus* [13], *Aspergillus ochraceus* [296]                        | antibacterial assay (MIC 1.9 µg/mL against Candida albicans, 7.5 µg/mL against Pseudomonas aeruginosa and Enterobacter aerogenes) [13], cytotoxic assay (BEL-7402, IC₅₀ 17.7 µM; HL-60, IC₅₀ 12.4 µM) [13], (NCI-H460, IC₅₀ 5.0 µg/mL; SMMC-7721, IC₅₀ 7.0 µg/mL; SW1990, IC₅₀ 28.0 µg/mL) [296] |
| Compound          | Fungal Source [Ref.] | Assays (Activity) [Ref.]                                                                 |
|-------------------|----------------------|----------------------------------------------------------------------------------------|
| 181               | *Hericium erinaceum* [187] | NO production inhibition assay (38.4% inhibition at 10 µg/mL) [187], TNF-α secretion assay (43.3% inhibition at 10 µg/mL) [187] |
| 182               | *Pleurotus eryngii* [250] | cytotoxic assay (RAW264.7, IC₅₀ 25.6 µM) [250], NO production inhibition assay (IC₅₀ 19.9 µM) [250] |
| 183               | *Antrodia camphorata* [298], *Gymnascus reessii* [249], *Stereo hirsutum* [17] | cytotoxic assay (A549, HL-60, MCF-7, SMMC-7721, SW480, IC₅₀ > 40 µM) [17], (KB, MCF-7, IC₅₀ > 50 µM; NC-I-H187, IC₅₀ 22.6 µM; Vero, IC₅₀ 43.8 µM) [249] |
| 184               | *Ganoderma resinaceum* [103] | antibacterial assay (MIC 1 µg/mL against the Gram-positive bacteria Bacillus subtilis, Staphylococcus aureus, and MRSA; MIC 16 µg/mL against the yeast Candida albicans; MIC 64 µg/mL against the Gram-negative bacteria Escherichia coli and Pseudomonas aeruginosa) [300] |
| 185               | *Rhizoctonia solani* [300] | antibacterial assay (against V. harveyi, V. splendidus, and P. citrea with inhibitory zones of 10, 7.5, and 8.0 mm, respectively, at 50 µg/disk) [301], antifungal assay (MIC 12 µg/mL against Glomerella cingulate) [301] |
| 186               | *Trichodema asperellum* [301] | antibacterial assay (against Gram-positive bacteria *Bacillus subtilis*, *Staphylococcus aureus*, and MRSA; MIC 16 µg/mL against the yeast *Candida albicans*; MIC 64 µg/mL against the Gram-negative bacteria *Escherichia coli* and *Pseudomonas aeruginosa*) [300] |
| 187               | *Antrodia camphorata* [310], *Arthritium sp.* [314], *Aspergillus penicilloides* [205], *Colletotrichum sp.* [206], *Conocybe siliginea* [315], *Gymnascus dahlkniensis* [303], *Nectaria flammea, N. tsunoda* [316], *Pestalotia sp.* [139], *Phomopsis sp.* [7], *Pleospora sp.* [317], *Streptomyces hirsutum* [17], *Talaromyces purpurogenus* [318], *Talaromyces sp.* [255] | cytotoxic assay (P388, ED₅₀ 2.2 µg/mL) [303], (A549, IC₅₀ 4.4 µM; HL-60, IC₅₀ 2.3 µM; MCF-7, IC₅₀ 2.7 µM; SMMC-7721, IC₅₀ 3.3 µM; SW480, IC₅₀ 3.5 µM) [17], (K562, IC₅₀ > 20 µM; ST26, IC₅₀ 6.7 µM) [310], (A549, IC₅₀ 21.3 µM; HL-60, IC₅₀ 7.9 µM; MCF-7, IC₅₀ 23.8 µM; SMMC-7721, IC₅₀ > 40 µM; SW480, IC₅₀ 14.2 µM) [318], cNOS inhibitory assay (IC₅₀ 6.58 µM) [7], NO production inhibition assay (IC₅₀ 13.04 µM) [7] |
| 188               | *Periconia sp.* [304] | antibacterial assay (MIC 4 µg/mL against *Staphylococcus aureus*, MIC 32 µg/mL against *Enterococcus faecalis*; MIC > 100 µg/mL against all four Gram-negative bacteria tested) [304], NO production inhibition assay (IC₅₀ > 40 µM) [304] |
| 189               | *Phomopsis sp.* [7] | cNOS inhibitory assay (IC₅₀ 1.49 µM) [7], NO production inhibition assay (IC₅₀ 4.65 µM) [7] |
| 190               | *Daldinia chiildae* [306] | cytotoxic assay (MCF-7, SMMC-7721, SW480, IC₅₀ > 40 µM) [306], NO production inhibition assay (IC₅₀ 21.2 µM) [306] |
| 192               | *Pleurotus eryngii* [6] | NO production inhibition assay (IC₅₀ 10.3 µM) [6] |
| 193               | *Pleurotus eryngii* [201] | NO production inhibition assay (NO produced 57.8% at 30 µM) [201] |
| 194               | *Pleurotus eryngii* [248] | NO production inhibition assay (IC₅₀ 13.0 µM) [248] |
| 195               | *Tricholoma matsutake* [319], *Pleurotus eryngii* [248] | AChE inhibitory assay (62.8% inhibition at 50 µg/mL) [319], NO production inhibition assay (IC₅₀ 25 µM) [248] |
| 196               | *Pleurotus eryngii* [248] | NO production inhibition assay (IC₅₀ 23.6 µM) [248] |
| 197               | *Aspergillus flocculosus* [277] | cytotoxic assay (A549, HepG2, THP-1, IC₅₀ > 80 µM) [277], IL-6 immune-suppressive activity assay (IC₅₀ 22 µM) [277] |
| 198               | *Stropharia rugosoannulata* [307] | antibacterial assay (RAW264.7, IC₅₀ > 30 µM) [201], cytotoxic assay (RAW264.7, IC₅₀ > 30 µM) [201] |
| 199               | *Stropharia rugosoannulata* [307] | antibacterial assay (RAW264.7, IC₅₀ > 30 µM) [201], cytotoxic assay (RAW264.7, IC₅₀ > 30 µM) [201] |
| 200               | *Stropharia rugosoannulata* [307] | antibacterial assay (RAW264.7, IC₅₀ > 30 µM) [201], cytotoxic assay (RAW264.7, IC₅₀ > 30 µM) [201] |
| 201               | *Cortinarius glaucopus* [195], *Stropharia rugosoannulata* [307] | antibacterial assay (RAW264.7, IC₅₀ > 30 µM) [201], cytotoxic assay (RAW264.7, IC₅₀ > 30 µM) [201] |
| 202               | *Pleurotus eryngii* [201] | antibacterial assay (RAW264.7, IC₅₀ > 30 µM) [201], cytotoxic assay (RAW264.7, IC₅₀ > 30 µM) [201] |
| 203               | *Pleurotus eryngii* [201] | antibacterial assay (RAW264.7, IC₅₀ > 30 µM) [201], cytotoxic assay (RAW264.7, IC₅₀ > 30 µM) [201] |
| 204               | *Penicillium purpurogenum* [254] | cytotoxic assay (A549, IC₅₀ 5.57 µM; HepG2, IC₅₀ 4.44 µM; MCF-7, IC₅₀ 5.88 µM) [254], IL-6 immune-suppressive activity assay (96.7% inhibition at 5 µg/mL) [254], NO production inhibition assay (70.7% inhibition at 5 µg/mL) [254] |
10. Degraded Sterols

The progressive degradation of ergostane-type steroids through 5,6- and 9,10-oxidative cleavages leads to the loss of ring A and the formation of highly degraded sterols (Figure 22). The most common and best studied among them is demethylincisterol A\textsubscript{3} (206). It demonstrated a potent activity against many cancer lines (Table 8). Cytotoxicity-guided investigation of Chinese mangrove \textit{Rhizophora mucronata} endophytic \textit{Pestalotiopsis} sp. yielded 206 as the most active compound with IC\textsubscript{50} values reaching nanomolar order [139].

![Figure 22. Structures of degraded sterols.](image)

Luo et al. examined a collection of secondary metabolites of endophytic fungi in search for inhibitors of SH2 containing protein tyrosine phosphatase-2 (SHP2) [320]. The latter is an oncogenic phosphatase participating in many signaling cascades and identified as a potential therapeutic target for cancer. It was found that demethylincisterol A\textsubscript{3} (206) inhibited the protein tyrosine phosphatase activity of SHP2 with an IC\textsubscript{50} of 6.75 µg/mL. In comparison, sodium orthovanadate used as a positive control showed an IC\textsubscript{50} value of 114 µg/mL.

Demethylincisterol A\textsubscript{3} (206) revealed significant antibacterial activities against a number of pathogenic bacteria with MICs values ranging from 3.13 to 12.5 µM (MICs of the positive control ciprofloxacin varied from 0.78 to 1.56 µM) [321].

\textit{Agrocybe chaxingu} extract was shown to have a very strong osteoclast suppression effect, useful in the prevention and control of osteoporosis. In search of the active components of this mushroom, Kawagishi et al. isolated a number of degraded sterols 208–212, collectively called as chaxines [322,323]. The initially assigned 2′\text{S},5′\text{S} stereochemistry of the A ring of
Molecules 2022, 27, 2103

chaxine B (209) was erroneous and was subsequently revised to 2'R,5'S [324,325]. Chaxines A-C were evaluated in the osteoclast-forming assay and were shown to suppress the rate of osteoclast formation with no cytotoxicity [322,323].

Chaxine C (211) was also isolated from traditional Chinese medicinal mushroom Cordyceps jiangxiensis under the name jiangxienone and showed promising results in inhibiting cancer cells [326]. Its IC_{50} values against A549 and SGC-7901 cells were six-fold lower than that of cisplatin.

Albocisterols A-C (219–221) isolated from cultures of Antrodia albocinnamomea were tested for inhibitory activities against protein tyrosine phosphatase [327]. A mixture of compounds 220 and 221 exhibited significant activity with IC_{50} value of 1.1 µg/mL (IC_{50} 1.2 µg/mL for ursolic acid used as a positive control). The corresponding C-27 alcohol, albocisterol A (219), was inactive at 50 µg/mL.

Table 8. Sources and biological activity of fungal degraded sterols.

| Compound | Fungal Source [Ref.] | Assays (Activity) [Ref.] |
|----------|----------------------|--------------------------|
| 205      | Fusarium solani [328] | cytotoxic assay (A549, HL-60, MCF-7, SMMC-7721, SW480, IC_{50} > 40 µM) [328], COX-2 inhibitory assay (IC_{50} > 20 µM) [328] |
| 206      | Agrocybe chaxingu [322], Anamulderia amoensis [82], Aspergillus sp. [321], Colletotrichum sp. [206], Gymnascella dankaliensis [329], Omphalista lapiodescens [16], Pestalotiopsis sp. [319,320], Pleosporales sp. [317], Termitomyces microcarpus [132], Tricholoma imbricatum [245], Xyliaria allantoida [330] | AChE inhibitory assay (<10% inhibition at 50 µg/mL) [82], antibacterial assay (MIC 12.5 µg against S. aureus, 3.13 µg against S. epidermidis, 3.13 µg against B. cereus) [321], cytotoxic assay (A549, IC_{50} 11.14 nM; HeLa, IC_{50} 0.17 nM; HepG2, IC_{50} 14.16 nM) [139], (A549, IC_{50} 27.2 µM; HL-60, IC_{50} 18.1 µM; K562, IC_{50} 13.6 µM; MCF-7, IC_{50} 10.9 µM; SMMC-7721, IC_{50} 21.7 µM; SW480, IC_{50} 19.2 µM) [245], (GES-1, IC_{50} 7.81 µM; HGC-27, IC_{50} 51.16 µM; MDA-MB-231, IC_{50} 16.48 µM) [16], (HeLa, IC_{50} 2.24 µg/mL; HCT-116, IC_{50} 2.51 µg/mL; HT-29, IC_{50} 3.00 µg/mL; MCF-7, IC_{50} 3.77 µg/mL; Vero, IC_{50} 3.65 µg/mL) [330], (P388, ED_{50} 1.0 µg/mL) [329], osteoclast differentiation assay (at 4.8 µM suppressed the rate of osteoclast formation to 55%) [322], protein tyrosine phosphatase assay (IC_{50} 6.75 µg/mL) [320] |
| 207      | Agrocybe chaxingu [322], Armillaria tabescens [170], Aspergillus acutatum [331], Aspergillus sp. [332], Pyropulastrus fomentarius [335], Tricholoma imbricatum [245] | AChE inhibitory assay (46.3% inhibition at 50 µg/mL) [82], cytotoxic assay (A549, IC_{50} 7.1 µM; HL-60, IC_{50} 22.1 µM; K562, IC_{50} 17.1 µM; MCF-7, IC_{50} 18.9 µM; SMMC-7721, IC_{50} 19.3 µM; SW480, IC_{50} 16.7 µM) [245], (A549, IC_{50} 18.2 µM; HL-60, IC_{50} 23.9 µM; K562, IC_{50} > 40 µM; MCF-7, IC_{50} 16.9 µM; SMMC-7721, IC_{50} 27.3 µM; SW480, IC_{50} > 40 µM) [333], NO production inhibition assay (IC_{50} 36.48 µM) [170] |
| 208      | Agrocybe chaxingu [322] | osteoclast differentiation assay (at 4.8 µM suppressed the rate of osteoclast formation to 67%) [322] |
| 209      | Agrocybe chaxingu [323] | osteoclast differentiation assay (at 3.1 µg/mL suppressed the rate of osteoclast formation to 66%) [323] |
| 210      | Agrocybe chaxingu [323] | |
| 211      | Agrocybe chaxingu [323], Cordyceps jiangxiensis [326], Tricholoma imbricatum [245], Xyliaria allantoida [330] | cytotoxic assay (A549, IC_{50} 7.9 µM; MCF-7, IC_{50} 10.2 µM) [245], (HeLa, IC_{50} 50.17 µg/mL; Vero, IC_{50} 76.57 µg/mL) [330], (A549, IC_{50} 2.93 µM; SGC-7901, IC_{50} 1.38 µM) [326], osteoclast differentiation assay (at 3.1 µg/mL suppressed the rate of osteoclast formation to 0%) [322] |
| 212      | Agrocybe chaxingu [323] | |
| 213      | Hericium alpestre [334] | cytotoxic assay (A549, IC_{50} 71.1 µM; HeLa, IC_{50} 69.6 µM; HT-29, IC_{50} 54.8 µM) [334] |
| 214      | Antrodia camphorata [335] | cytotoxic assay (A-2058, IC_{50} 31.1 µM; B16F10, IC_{50} 26.69 µM; HeLa, IC_{50} 43.03 µM; MCF-7, IC_{50} 77.39 µM) [335] |
| 215      | Ganoderma capense [8] | cytotoxic assay (BGC823, Daoy, HCT116, HepG2, NCI-H1650, IC_{50} > 50 µM) [8] |
| 216      | Ganoderma sinense [220] | cytotoxic assay (SW1990, Vero, IC_{50} > 100 µM) [220] |
| 217      | Daedaleopsis tricolor [336] | cytotoxic assay (A-549, HL-60, MCF-7, SMMC-7721, SW480, IC_{50} > 40 µM) [336] |
| 218      | Lenzites betulinus [337] | PTP1B inhibitory activity assay (IC_{50} 21.5 µg/mL) [337] |
Table 8. Cont.

| Compound | Fungal Source [Ref.] | Assays (Activity) [Ref.] |
|----------|----------------------|--------------------------|
| 219      | *Antrodiella albocinnamomea* [327] | PTP1B inhibitory activity assay (no activity against DPP-IV and PTP1B at 50 µg/mL) [327] |
| 220      | *Antrodiella albocinnamomea* [327] | PTP1B inhibitory activity assay (IC_{50} 1.1 µg/mL in a mixture with 10–46) [327] |
| 221      | *Antrodiella albocinnamomea* [327] | PTP1B inhibitory activity assay (IC_{50} 1.1 µg/mL in a mixture with 10–45) [327] |
| 222      | *Phomopsis tersa* [338] | cytotoxic assay (A549, HepG2, MCF-7, SF-268, IC_{50} > 100 µM) [338] |
| 223      | *Tricholoma matsutake* [319] | AChE inhibitory assay (40.3% inhibition at 50 µg/mL) [319] |

11. Conclusions

Fungi have been a traditional object of human practical interest throughout history. At first this was due to the nutritional value of mushrooms. Currently, fungi are attracting special attention as a source of a large number of biologically active compounds belonging to different classes: polyketides, terpenoids, peptides, alkaloids, etc., [339]. A wide variety of fungal secondary metabolites, their low content in natural material and the complexity of structural identification have led to the rapid development of research in this area only in the last two–three decades through the use of highly efficient methods of instrumental analysis and separation of complex natural compositions. A special place among fungi constituents is occupied by the metabolic products of ergosterol, the most important fungal sterol. Many of them are discussed in this review and some appear promising as leads for new medicines. At the same time, it is obvious that the described results not only characterize the achieved high level of research in this area, but also indicate directions for further scientific search, which is necessary for a better understanding of the content of the fungal metabolome and will allow revealing more fully the possibilities of practical use of its components in human healthcare.

Author Contributions: V.N.Z., P.D., and V.A.K. contributed equally. All authors have read and agreed to the published version of the manuscript.

Funding: The financial support by the Belarusian Foundation for Fundamental Research (projects X22ChI-025 and X22MC-004) is greatly appreciated.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: We would like to acknowledge the Molecules journal for providing the APC waiver.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

| Abbreviation | Definition |
|--------------|------------|
| AChE         | acetylcholinesterase |
| bw           | body weight |
| ConA         | concanavalin A |
| COX          | cyclooxygenase |
| DHEP         | 9,11-dehydroergosterol peroxide |
| DPP-IV       | dipeptidyl peptidase IV |
| DPPH         | 2,2-diphenyl-1-picrylhydrazyl radical |
| ED_{50}      | median effective dose |
| EP           | ergosterol peroxide |
| GIRK         | G protein-coupled inwardly-rectifying potassium channel |
| Galp         | galactopyranosyl |
| Glcp         | glucopyranosyl |
Molecules 2022, 27, 2103
40 of 53

HNE human neutrophil elastase
IC₅₀ half maximal inhibitory concentration
IDH isocitrate dehydrogenase
IL interleukin
iNOS inducible nitric oxide synthase
LDL-C low density lipoprotein cholesterol
L-NMMA N⁵-methyl-L-arginine acetate salt
LPS lipopolysaccharide
MDM2 mouse double minute 2 homolog
MIC minimum inhibitory concentration
MRSA methicillin resistant Staphylococcus aureus
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells
NO nitric oxide
NOE nuclear Overhauser effect
ORAC Oxygen Radical Antioxidant Capacity
PCSK9 proprotein convertase subtilisin/kexin type 9
PEG poly(ethylene glycol)
PGE₂ prostaglandin E₂
PTP protein tyrosine phosphatase
PTP1B protein tyrosine phosphatase 1B
ROS reactive oxygen species
PPAR peroxisome proliferator-activated receptor
SHP2 SH2-containing protein tyrosine phosphatase-2
TE Trolox equivalent
TNF-α tumor necrosis factor alpha
TRAP tartrate-resistant acid phosphatase

References
1. Öztürk, M.; Tel-Çayan, G.; Muhammad, A.; Terzioglu, P.; Duru, M.E. Mushrooms: A Source of Exciting Bioactive Compounds. In Studies in Natural Products Chemistry; Atta-ur, R., Ed.; Elsevier: Amsterdam, The Netherlands, 2015; Volume 45, pp. 363–456. [CrossRef] [PubMed]
2. Lindequist, U.; Niedermeyer, T.H.J.; Jülich, W.D. The pharmacological potential of mushrooms. eCAM 2005, 2, 285–299. [CrossRef]
3. Sanjai, S.; Manmohan, C.; Inder Pal, S. Fungal bioactive compounds in pharmaceutical research and development. Curr. Bioact. Compd. 2019, 15, 211–231. [CrossRef] [PubMed]
4. Rodrigues, M.L. The multifunctional fungal ergosterol. mBio 2018, 9, e01755-18. [CrossRef] [PubMed]
5. Zhang, B.-B.; Han, X.-L.; Jiang, Q.; Liao, Z.-X.; Wang, H.-S. Cytotoxic cholestane-type and ergostane-type steroids from the aerial parts of Euphorbia altotibetic. Steroids 2013, 78, 38–43. [CrossRef] [PubMed]
6. Kikuchi, T.; Maekawa, Y.; Tomio, A.; Masumoto, Y.; Yamamoto, T.; In, Y.; Yamada, T.; Tanaka, R. Six new ergostane-type steroids from king trumpet mushroom (Pleurotus eryngii) and their inhibitory effects on nitric oxide production. Steroids 2016, 115, 9–17. [CrossRef]
7. Hu, Z.; Wu, Y.; Xie, S.; Sun, W.; Guo, Y.; Li, X.-N.; Liu, J.; Li, H.; Wang, J.; Luo, Z.; et al. Phomopsterones A and B, two functionalized ergostane-type steroids from the endophytic fungus Phomopsis sp. TJ507A. Org. Lett. 2017, 19, 258–261. [CrossRef]
8. Tan, Z.; Zhao, J.L.; Liu, J.M.; Zhang, M.; Chen, R.D.; Xie, K.B.; Chen, D.W.; Dai, J.G. Lanostane triterpenoids and ergostane-type steroids from the cultured mycelia of Ganoderma capense. J. Asian Nat. Prod. Res. 2018, 20, 844–851. [CrossRef]
9. Happi, G.M.; Wouamba, S.C.N.; Ismail, M.; Kouam, S.F.; Frese, M.; Lenta, B.N.; Sewald, N. Ergostane-type steroids from the Cameroonian ‘white tiama’ Entandrophragma angolense. Steroids 2020, 156, 108584. [CrossRef] [PubMed]
10. Lee, S.R.; Choi, J.H.; Ryoo, R.; Kim, J.-C.; Pang, C.; Kim, S.-H.; Kim, K.H. Ergostane-type steroids from Korean wild mushroom Xerula furfuracea that control adipocyte and osteoblast differentiation. J. Microbiol. Biotechnol. 2020, 30, 1769–1776. [CrossRef]
11. Liang, Y.; Zhang, M.; Yu, M.; Wang, J.; Zhu, H.; Chen, C.; Zhang, Y. Four new ergostane-type steroids from Lasiodiplodia pseudotheobromae. Tetrahedron Lett. 2020, 61, 151735. [CrossRef]
12. Yu, J.H.; Yu, S.J.; Liu, K.L.; Wang, C.; Liu, C.; Sun, J.Y.; Zhang, H. Cytotoxic ergostane-type steroids from Ganoderma lingzhi. Steroids 2021, 165, 108584. [CrossRef]
13. Zheng, J.; Wang, Y.; Wang, J.; Liu, P.; Li, J.; Zhu, W. Antimicrobial ergosteroids and pyrrole derivatives from halotolerant Aspergillus flocculus PT05-1 cultured in a hypersaline medium. Extremophiles 2013, 17, 963–971. [CrossRef] [PubMed]
14. Han, J.-J.; Bao, L.; Tao, Q.-Q.; Yao, Y.-J.; Liu, X.-Z.; Yin, W.-B.; Liu, H.-W. Gloeophyllins A–J, cytotoxic ergosteroids with various skeletons from a Chinese Tibet fungus Gloeophyllum abietinum. Org. Lett. 2015, 17, 2538–2541. [CrossRef] [PubMed]
15. Wang, Y.; Dai, O.; Peng, C.; Su, H.G.; Miao, L.L.; Liu, L.S.; Xiong, L. Polyoxygenated ergosteroids from the macrofungus Omphalia lapidescens and the structure-cytotoxicity relationship in a human gastric cancer cell line. *Phytochem. Lett.* 2018, 25, 99–104. [CrossRef]

16. Liu, E.; Chen, J.-F.; Wang, Y.; Guo, L.; Zhou, Q.-M.; Peng, C.; Xiong, L. Cytotoxicity of lanostane-type triterpenoids and ergosteroids isolated from *Omphalia lapidescens* on MDA-MB-231 and HGC-27 cells. *Biomed. Pharmacother.* 2019, 118, 109273. [CrossRef]

17. Zhao, Z.-Z.; Han, K.-Y.; Li, Z.-H.; Feng, T.; Chen, H.-P.; Liu, J.-K. Cytotoxic ergosteroids from the fungus *Stereum hirsutum*. *Phytochem. Lett.* 2019, 30, 143–149. [CrossRef]

18. Lardy, H.; Partridge, B.; Neeve, N.; Wei, Y. Ergosteroids: Induction of thermogenic enzymes in liver of rats treated with steroids derived from dehydroepiandrosterone. *Proc. Natl. Acad. Sci. USA* 1995, 92, 6617–6619. [CrossRef]

19. Glottorini, E. Withanolides and related ergostane-type steroids. *Nat. Prod. Rep.* 1991, 8, 415–440. [CrossRef]

20. Chen, L.X.; He, H.; Qiu, F. Natural withanolides: An overview. *Nat. Prod. Rep.* 2011, 28, 705–740. [CrossRef]

21. Xu, Q.Q.; Wang, K.W. Natural bioactive new withanolides. *Mini Rev. Med. Chem.* 2020, 20, 1101–1117. [CrossRef]

22. Aiello, A.; Fattorusso, E.; Menna, M. Steroids from sponges: Recent reports. *Steroids* 1999, 64, 687–714. [CrossRef] [PubMed]

23. Duecker, F.L.; Reuß, F.; Heretsch, P. Rearranged ergostane-type natural products: Chemistry, biology, and medicinal aspects. *Org. Biomol. Chem.* 2019, 17, 1624–1633. [CrossRef] [PubMed]

24. Merdivan, S.; Lindequist, U. Ergosterol peroxide: A mushroom-derived compound with promising biological activities—a review. *Int. J. Med. Mushrooms* 2017, 19, 93–105. [CrossRef] [PubMed]

25. Choi, J.-H. Biologically functional molecules from mushroom-forming fungi. *Biosci. Biotechnol. Biochem.* 2018, 82, 372–382. [CrossRef]

26. Clericuzio, M.; Mellerio, G.G.; Finzi, P.V.; Vidari, G. Secondary metabolites isolated from *Tricholoma* species (Basidiomycota, Tricholomataceae): A review. *Nat. Prod. Commun.* 2018, 13, 1213–1224. [CrossRef]

27. Vil, V.A.; Gloriozova, T.A.; Poroikov, V.V.; Terent’ev, A.O.; Savidov, N.; Dembitsky, V.M. Peroxy steroids derived from plant and fungal and their biological activities. *Appl. Microbiol. Biotechnol.* 2018, 102, 7657–7667. [CrossRef]

28. Vil, V.A.; Terent’ev, A.O.; Savidov, N.; Gloriozova, T.A.; Poroikov, V.V.; Pounina, T.A.; Dembitsky, V.M. Hydroperoxy steroids and triterpenoids derived from plant and fungi: Origin, structures and biological activities. *J. Steroid Biochem. Mol. Biol.* 2019, 190, 76–87. [CrossRef]

29. Dai, Z.B.; Wang, X.; Li, G.H. Secondary metabolites and their bioactivities produced by *Paecilomyces*. *Molecules* 2020, 25, 5077. [CrossRef]

30. Xiao, J.; Gao, M.; Fei, B.; Huang, G.; Diao, Q. Nature-derived anticancer steroids outside cardia glycosides. *Fitoterapia* 2020, 147, 104757. [CrossRef]

31. Ha, J.W.; Kim, J.; Kim, H.; Jang, W.; Kim, K.H. Mushrooms: An important source of natural bioactive compounds. *Nat. Prod. Sci.* 2020, 26, 118–131. [CrossRef]

32. Savidov, N.; Gloriozova, T.A.; Poroikov, V.V.; Dembitsky, V.M. Highly oxygenated isoprenoid lipids derived from fungi and fungal endophytes: Origin and biological activities. *Steroids* 2018, 140, 114–124. [CrossRef]

33. Lorià-Kohen, V.; Lourenco-Nogueira, T.; Espinosa-Salinas, I.; Marin, F.R.; Soler-Rivas, C.; Ramirez de Molina, A. Nutritional and functional properties of edible mushrooms: A food with promising health claims. *J. Pharm. Nutr. Sci.* 2020, 10, 17832–17846. [CrossRef]

34. Nowak, R.; Nowacka-Jechalke, N.; Pietrzak, W.; Gawlik-Dziki, U. A new look at edible and medicinal mushrooms as a source of ergosterol and ergosterol peroxide—UHPLC-MS/MS analysis. *Food Chem.* 2022, 369, 130927. [CrossRef]

35. Shao, S.; Hernandez, M.; Kramer, J.K.; Rinker, D.L.; Tso, R. Ergosterol profiles, fatty acid composition, and antioxidant activities of button mushrooms as affected by tissue part and developmental stage. *J. Agric. Food Chem.* 2010, 58, 11616–11625. [CrossRef] [PubMed]

36. Schneider, I.; Kressel, G.; Meyer, A.; Krings, U.; Berger, R.G.; Hahn, A. Lipid lowering effects of oyster mushroom (*Pleurotus ostreatus*) in humans. *J. Funct. Foods* 2011, 3, 17–24. [CrossRef]

37. Gil-Ramirez, A.; Ruiz-Rodriguez, A.; Marin, F.R.; Reglero, G.; Soler-Rivas, C. Effect of ergosterol-enriched extracts obtained from *Agaricus bisporus* on cholesterol absorption using an in vitro digestion model. *J. Funct. Foods* 2014, 11, 589–597. [CrossRef]

38. Morales, D.; Tejedor-Calvo, E.; Jurado-Chivato, N.; Polo, G.; Tabernerio, M.; Ruiz-Rodriguez, A.; Largo, C.; Soler-Rivas, C. In vitro and in vivo testing of the hypocholesterolemic activity of ergosterol- and β-glucan-enriched extracts obtained from shiitake mushrooms (*Lentinula edodes*). *Food Funct.* 2019, 10, 7325–7332. [CrossRef] [PubMed]

39. Wu, M.; Huang, T.; Wang, J.; Chen, P.; Mi, W.; Ying, Y.; Wang, H.; Zhao, D.; Huang, S. Antilung cancer effect of ergosterol and cisplatin-loaded liposomes modified with cyclic arginine-glycine-aspartic acid and octa-arginine peptides. *Medicine* 2018, 97, e11916. [CrossRef]

40. Lin, Y.-C.; Lee, B.-H.; Alagie, J.; Su, C.-H. Combination treatment of ergosterol followed by amphotericin B induces necrotic cell death in human hepatocellular carcinoma cells. *OncoTarget* 2017, 8, 72727–72738. [CrossRef]

41. Sankaran, M.; Isabella, S.; Amaranath, K. Anti proliferative activity of ergosterol: A unique plant sterol on Hep2 cell line. *Int. J. Pharmu Res. Health Sci.* 2017, 5, 1736–1742. [CrossRef]

42. Li, X.; Wu, Q.; Xie, Y.; Ding, Y.; Du, W.W.; Sdri, M.; Yang, B.B. Ergosterol purified from medicinal mushroom *Amauroderma rude* inhibits cancer growth in vitro and in vivo by up-regulating multiple tumor suppressors. *OncoTarget* 2015, 6, 17832–17846. [CrossRef] [PubMed]
43. Hu, X.; Jiang, D.; Li, F.; Wu, Z.; Huang, Y.; Song, S.; Wang, Z. Ergosterol reverses multidrug resistance in SGC7901/Adr cells. *Pharmazie* 2014, 69, 396–400. [CrossRef] [PubMed]

44. Munoz-Fonsseca, M.B.; Vidal-Limon, A.; Fernandez-Pomares, C.; Rojas-Duran, F.; Hernandez-Aguilar, M.E.; Espinoza, C.; Trigos, A.; Suarez-Medellin, J. Ergosterol exerts a differential effect on AR-dependent LNCaP and AR-independent DU-145 cancer cells. *Nat. Prod. Res.* 2021, 35, 4857–4860. [CrossRef] [PubMed]

45. Yazawa, Y.; Ikarashi, N.; Hoshino, M.; Kikkawa, H.; Sakuma, F.; Sugiyama, K. Inhibitory effect of ergosterol on bladder carcinogenesis is due to androgen signaling inhibition by brassicasterol, a metabolite of ergosterol. *J. Nat. Med.* 2020, 74, 680–688. [CrossRef]

46. Kuo, C.-F.; Hsieh, C.-H.; Lin, W.-Y. Proteomic response of LAP-activated RAW 264.7 macrophages to the anti-inflammatory property of fungal ergosterol. *Food Chem.* 2011, 126, 207–212. [CrossRef]

47. Kageyama-Yahara, N.; Wang, P.; Wang, X.; Yamamoto, T.; Kadowaki, M. The inhibitory effect of ergosterol, a bioactive constituent of a traditional Japanese herbal medicine saineto on the activity of mucosal-type mast cells. *Biol. Pharm. Bull.* 2010, 33, 142–145. [CrossRef]

48. Kawal, J.; Higuchi, Y.; Hirota, M.; Hirasawa, N.; Mori, K. Ergosterol and its derivatives from *Grifola frondosa* inhibit antigen-induced degranulation of RBL-2H3 cells by suppressing the aggregation of high affinity IgE receptors. *Biosci. Biotechnol. Biochem.* 2018, 82, 1803–1811. [CrossRef]

49. Zhang, S.-Y.; Xu, L.-T.; Li, A.-X.; Wang, S.-M. Effects of ergosterol, isolated from *Sclerotinia polyrhizium* Pers., on lipopolysaccharide-induced inflammatory responses in acute lung injury. *Inflammation* 2015, 38, 1979–1985. [CrossRef]

50. Wang, H.; Zhang, T.; Li, Y.; Wang, S. Effects of ergosterol on COPD in mice via JAK3/STAT3/NF-κB pathway. *Inflammation* 2017, 40, 884–893. [CrossRef]

51. Sun, X.; Feng, X.; Zheng, D.; Li, A.; Li, C.; Li, S.; Zhao, Z. Ergosterol attenuates cigarette smoke extract-induced COPD by modulating inflammation, oxidative stress and apoptosis in vitro and in vivo. *Clin. Sci.* 2019, 133, 1523–1536. [CrossRef]

52. Xu, J.; Lin, C.; Wang, T.; Zhang, P.; Liu, Z.; Lu, C. Ergosterol attenuates LPS-induced myocardial injury by modulating oxidative stress and apoptosis in rats. *Cell. Physiol. Biochem.* 2018, 48, 583–592. [CrossRef] [PubMed]

53. Xie, Q.; Li, S.; Gao, Y.; Jin, L.; Dai, C.; Song, J. Ergosterol attenuates isoprostene-induced myocardial cardiotoxicity. *Cardiovasc. Toxicol.* 2020, 20, 500–506. [CrossRef] [PubMed]

54. Cai, D.; Yan, H.; Liu, J.; Chen, S.; Jiang, L.; Wang, X.; Qin, J. Ergosterol limits osteoarthritis development and progression through activation of Nrf2 signaling. *Exp. Ther. Med.* 2021, 21, 194. [CrossRef]

55. Dong, Z.; Sun, Y.; Wei, G.; Li, S.; Zhao, Z. Ergosterol ameliorates diabetic nephropathy by attenuating mesangial cell proliferation and extracellular matrix deposition via the TGF-β1/Smad2 signaling pathway. *Nutrients* 2019, 11, 483. [CrossRef]

56. Liu, C.; Zhao, S.; Zhu, C.; Gao, Q.; Bai, J.; Si, J.; Chen, Y. Ergosterol ameliorates renal inflammatory responses in mice model of diabetic nephropathy. *Biomed. Pharmacother.* 2020, 128, 110252. [CrossRef]

57. Xiong, M.; Huang, Y.; Liu, Y.; Huang, M.; Song, G.; Ming, Q.; Ma, X.; Yang, J.; Deng, S.; Wen, Y.; et al. Antidiabetic activity of ergosterol from *Pleurotus ostreatus* in KK-Ay mice with spontaneous type 2 diabetes mellitus. *Mol. Nutr. Food Res.* 2018, 62, 1700444. [CrossRef]

58. Tai, C.-J.; Choong, C.-Y.; Lin, Y.-C.; Shi, Y.-C.; Tai, C.-J. The anti-hepatic fibrosis activity of ergosterol depended on upregulation of PPARγ in HSC-T6 cells. *Food Funct.* 2016, 7, 1915–1923. [CrossRef]

59. Kikuchi, T.; Motoyashiki, N.; Yamada, T.; Shibatani, K.; Ninomiya, K.; Morikawa, T.; Tanaka, R. Ergostane-type sterols from king trumpet mushroom (*Pleurotus eryngii*) and their inhibitory effects on aromatase. *Mol. Nutr. Food Res.* 2018, 62, 1700444. [CrossRef]

60. Kageyama-Yahara, N.; Wang, P.; Wang, X.; Yamamoto, T.; Kadowaki, M. The inhibitory effect of ergosterol, a bioactive constituent of a traditional Japanese herbal medicine saineto on the activity of mucosal-type mast cells. *Biol. Pharm. Bull.* 2010, 33, 142–145. [CrossRef]

61. Zhao, Y.-Y.; Cheng, X.-L.; Liu, R.; Ho, C.C.; Wei, F.; Chen, Y.; Wang, X.; Qin, J. Ergosterol limits osteoarthritis development and progression through activation of Nrf2 signaling. *Exp. Ther. Med.* 2021, 21, 194. [CrossRef]

62. Dong, Z.; Sun, Y.; Wei, G.; Li, S.; Zhao, Z. Ergosterol ameliorates diabetic nephropathy by attenuating mesangial cell proliferation and extracellular matrix deposition via the TGF-β1/Smad2 signaling pathway. *Nutrients* 2019, 11, 483. [CrossRef]

63. Dong, Z.; Sun, Y.; Wei, G.; Li, S.; Zhao, Z. Ergosterol ameliorates diabetic nephropathy by attenuating mesangial cell proliferation and extracellular matrix deposition via the TGF-β1/Smad2 signaling pathway. *Nutrients* 2019, 11, 483. [CrossRef]

64. Dong, Z.; Sun, Y.; Wei, G.; Li, S.; Zhao, Z. Ergosterol ameliorates diabetic nephropathy by attenuating mesangial cell proliferation and extracellular matrix deposition via the TGF-β1/Smad2 signaling pathway. *Nutrients* 2019, 11, 483. [CrossRef]

65. Medina, M.E.; Galano, A.; Trigos, A. Scavenging ability of heterosidesic acid and ergosterol toward free radicals derived from ethanol consumption. *J. Phys. Chem. B* 2012, 116, 7514–7521. [CrossRef]

66. Zhao, Y.-Y.; Cheng, X.-L.; Liu, R.; Ho, C.C.; Wei, F.; Yan, S.-H.; Lin, R.-C.; Zhang, Y.; Sun, W.-J. Pharmacokinetics of ergosterol in rats using rapid resolution liquid chromatography-atmospheric pressure chemical ionization multi-stage tandem mass spectrometry and rapid resolution liquid chromatography/tandem mass spectrometry. *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.* 2011, 879, 1945–1953. [CrossRef]

67. Zhang, H.-Y.; Firempong, C.K.; Wang, Y.-W.; Xu, W.-Q.; Wang, M.-M.; Cao, X.; Zou, Y.; Tong, S.-S.; Yu, J.-N.; Xu, X.-M. Ergosterol-loaded poly(lactide-co-glycolide) nanoparticles with enhanced in vitro antitumor activity and oral bioavailability. *Acta Pharmacol. Sin.* 2016, 37, 834–844. [CrossRef] [PubMed]

68. Dong, Z.; Qiebal, S.; Zhao, Z. Preparation of ergosterol-loaded nanostructured lipid carriers for enhancing oral bioavailability and antidiabetic nephropathy effects. *AAPS PharmSciTech* 2020, 21, 64. [CrossRef] [PubMed]

69. Cheng, J.; Zhao, H.; Yao, L.; Li, Y.; Qi, B.; Wang, J.; Yang, X. Simple and multifunctional natural self-assembled sterols with anticancer activity-mediated supramolecular photosensitizers for enhanced antitumor photodynamic therapy. *ACS Appl. Mater. Interfaces* 2019, 11, 29498–29511. [CrossRef] [PubMed]

70. Yi, C.; Fu, M.; Cao, X.; Tong, S.; Zheng, Q.; Firempong, C.K.; Jiang, X.; Xu, X.; Yu, J. Enhanced oral bioavailability and tissue distribution of a new potential anticancer agent, *Flammulina velutipes* sterols, through liposomal encapsulation. *J. Agric. Food Chem.* 2013, 61, 5961–5971. [CrossRef]

71. He, W.-S.; Yin, J.; Xu, H.-S.; Qian, Q.-Y.; Jia, C.-S.; Ma, H.-L.; Feng, B. Efficient synthesis and characterization of ergosterol laurate in a solvent-free system. *J. Agric. Food Chem.* 2014, 62, 4997–5001. [CrossRef] [PubMed]
67. Park, S.H.; Kim, H.K. Antibacterial activity of emulsions containing unsaturated fatty acid ergosterol esters synthesized by lipase-mediated transesterification. Enzyme Microb. Technol. 2020, 139, 109581. [CrossRef]

68. He, W.S.; Li, L.; Zhao, J.; Xu, H.; Rui, J.; Cui, D.; Li, H.; Zhang, H.; Liu, X. Candidia sp. 99-125 lipase-catalyzed synthesis of ergosterol linolenate and its characterization. Food Chem. 2019, 280, 286–293. [CrossRef]

69. Park, H.G.; Lee, T.H.; Chang, F.; Kwon, H.J.; Kim, J.; Kim, H. Synthesis of ergosterol and 5,6-dihydroergosterol glycosides and their inhibitory activities on lipopolysaccharide-induced nitric oxide production. Bull. Korean Chem. Soc. 2013, 34, 1339–1344. [CrossRef]

70. Dissanayake, A.A.; Zhang, C.-R.; Mills, G.L.; Nair, M.G. Cultivated maitake mushroom demonstrated functional food quality as determined by in vitro bioassays. J. Funct. Foods 2018, 44, 79–85. [CrossRef]

71. Aziz, S.; Elafahmi; Soemardji, A.A. Molecular docking, synthesis and biological evaluation of ergosteryl-furate as a HMG-Coa reductase inhibitor. Pak. J. Pharm. Sci. 2020, 33, 997–1003.

72. Lin, M.; Li, H.; Zhao, Y.; Cai, E.; Zhu, H.; Gao, Y.; Liu, S.; Yang, H.; Zhang, L.; Tang, G. 2-Naphthoic acid ergosterol ester, an ergosterol derivative, exhibits anti-apoptosis activity by promoting apoptosis and inhibiting angiogenesis. Steroids 2017, 122, 9–15. [CrossRef] [PubMed]

73. Lin, M.; Li, H.; Zhao, Y.; Cai, E.; Zhu, H.; Gao, Y.; Liu, S.; Yang, H.; Zhang, L.; Tang, G.; et al. Ergosteryl 2-naphthoate, an ergosterol derivative, exhibits antidepressant effects mediated by the modification of GABAergic and glutamatergic systems. Molecules 2017, 22, 565. [CrossRef]

74. Karatavuk, A.O.; Karabulut, H.R.F. Synthesis of novel dimers containing cholesterol and ergosterol using click reaction and their anti-proliferative effects. Mon. Chem. 2020, 151, 837–844. [CrossRef]

75. Weete, J.D. Structure and Function of Sterols in Fungi. In Advances in Lipid Research; Paoletti, R., Kritchevsky, D., Eds.; Elsevier: Amsterdam, The Netherlands, 1989; Volume 23, pp. 115–167. [CrossRef]

76. Weete, J.D.; Abril, M.; Blackwell, M. Phylogenetic distribution of fungal sterols. PLoS ONE 2010, 5, e10899. [CrossRef]

77. Lee, H.S.; Hwang, I.H.; Kim, J.A.; Choi, J.Y.; Jang, T.-S.; Osada, H.; Ahn, J.S.; Na, M.; Lee, S.H. Isolation of protein tyrosine phosphatase 1B inhibitory constituents from the sclerotia of Polyporus umbelatus fries. Bull. Korean Chem. Soc. 2011, 32, 697–700. [CrossRef]

78. Xiao, J.-H.; Sun, Z.-H.; Pan, W.-D.; Zhong, J.-J. Secondary metabolite steroids isolated from medicinal entomogenous mushroom Cordyceps jiangxensis mycelium. Nat. Prod. Indian J. 2011, 7, 118–123.

79. Tian, M.-Q.; Wu, Q.-L.; Wang, X.; Zhang, K.-Q.; Li, G.-H. A new compound from Stereum insigne CGMCC5.7. Nat. Prod. Res. 2017, 31, 932–937. [CrossRef]

80. Qiao, M.-F.; Yi, Y.-W.; Deng, J. Steroids from an endophyte Eurotium rubrum strain. Chem. Nat. Compd. 2017, 53, 678–681. [CrossRef]

81. Wu, J.; Fushimi, K.; Tokuyama, S.; Ohno, M.; Miwa, T.; Koyama, T.; Yazawa, K.; Nagai, K.; Matsumoto, T.; Hirai, H.; et al. Functional-food constituents in the fruiting bodies of Stropharia rugosoannulata. Biosci. Biotechnol. Biochem. 2011, 75, 1631–1634. [CrossRef]

82. Zhang, S.S.; Ma, Q.Y.; Zou, X.S.; Dai, H.F.; Huang, S.Z.; Luo, Y.; Yu, Z.F.; Luo, H.R.; Zhao, Y.X. Chemical constituents from the fungus AmanoItera amoissis and their in vitro acetylcholinesterase inhibitory activities. Planta Med. 2013, 79, 87–91. [CrossRef]

83. Wang, Q.; Wang, Y.G.; Ma, Q.Y.; Huang, S.Z.; Kong, F.D.; Zhou, L.M.; Dai, H.F.; Zhao, Y.X. Chemical constituents from the fruiting bodies of AmanoItera subresinosum. J. Nat. Prod. Res. 2016, 18, 1030–1035. [CrossRef] [PubMed]

84. Gao, J.; Wang, L.W.; Zheng, H.C.; Damirin, A.; Ma, C.M. Cytotoxic constituents of Lasiosphaera fenzlii on different cell lines and the synergistic effects with paclitaxel. Nat. Prod. Res. 2016, 30, 1862–1865. [CrossRef] [PubMed]

85. Torres, S.; Cájas, D.; Palfrner, G.; Astuya, A.; Aballay, A.; Pérez, C.; Hernández, V.; Becerra, J. Steroidal composition and cytotoxic activity from fruiting body of Cortinarius xiphidipus. Nat. Prod. Res. 2017, 31, 473–476. [CrossRef]

86. Borlagdan, M.S.; De Castro, M.E.G.; van Altena, I.A.; Ragasa, C.Y. Sterols from Trametes versicolor. Res. J. Pharm. Biol. Chem. Sci. 2017, 8, 740–744.

87. Giroux, S.; Corey, E.J. An efficient, stereocontrolled synthesis of the 25-(R)-diastereomer of dafachronic acid A from β-ergosterol. Org. Lett. 2008, 10, 801–802. [CrossRef]

88. Pereira, D.M.; Correia-da-Silva, G.; Valenteo, P.; Teixeira, N.; Andrade, P.B. Anti-inflammatory effect of unsaturated fatty acids and ergosta-7,22-dien-3-ol from Marthasterias glaciialis: Prevention of CHOP-mediated ER-stress and NF-κB activation. PLoS ONE 2014, 9, e88341. [CrossRef]

89. Pereira, D.M.; Correia-da-Silva, G.; Valenteo, P.; Teixeira, N.; Andrade, P.B. Palmitic acid and ergosta-7,22-dien-3-ol contribute to the apoptotic effect and cell cycle arrest of an extract from Marthasterias glaciialis L. in neuroblastoma cells. Mar. Drugs 2014, 12, 54. [CrossRef]

90. Hong, Y.J.; Jang, A.R.; Jang, H.J.; Yang, K.S. Inhibition of nitric oxide production, iNOS and COX-2 expression of ergosterol derivatives from Phellinus pini. Nat. Prod. Sci. 2012, 18, 147–152.

91. Särközy, A.; Béni, Z.; Dékány, M.; Zomborszki, Z.P.; Rudolf, K.; Papp, V.; Hofmann, J.; Ványoló, A. Cerebrosides and steroids from the edible mushroom Meripilus giganteus with antioxidant potential. Molecules 2020, 25, 1395. [CrossRef]

92. Budipramana, K.; Junaidin, J.; Wirasutisna, K.R.; Pramana, Y.B.; Sukrasno, S. An integrated in silico and in vitro assays of dipetylpeptide-4 and α-glucosidase inhibition by stellasterol from Ganoderma austral. Sci. Pharm. 2019, 87, 21. [CrossRef]

93. Joseph, S.; Janardhanan, K.K.; George, V.; Baby, S. A new epoxide ganoderic acid and other phytoconstituents from Ganoderma lucidum. Phytochem. Lett. 2011, 4, 386–388. [CrossRef]
94. Jung, M.; Lee, T.H.; Oh, H.J.; Kim, H.; Son, Y.; Lee, E.H.; Kim, J. Inhibitory effect of 5,6-dihydroergosteryl-glucoside on atopic dermatitis-like skin lesions via suppression of NF-κB and STAT activation. *J. Dermatol. Sci.* 2015, 79, 252–261. [CrossRef] [PubMed]

95. Kim, T.K.; Cho, Y.K.; Park, H.; Lee, T.H.; Kim, H. Comparison of the inhibitory activities of 5,6-dihydroergosterol glycoside α- and β-anomers on skin inflammation. *Molecules* 2019, 24, 371. [CrossRef]

96. Park, Y.S.; Moon, H.J.; Ahn, K.H.; Lee, T.H.; Kim, H. Comparative study of the effect of 5,6-dihydroergosterol and 3-epi-5,6-dihydroergosterol on chemokine expression in human keratinocytes. *Molecules* 2020, 25, 522. [CrossRef]

97. Moon, H.; Ko, M.; Park, Y.; Kim, J.; Yoon, D.; Lee, E.; Lee, T.; Kim, H. Δ9(14)-Ergostenol glycoside derivatives inhibit the expression of inflammatory mediators and matrix metalloproteinase. *Molecules* 2021, 26, 4547. [CrossRef] [PubMed]

98. Kuo, Y.H.; Lin, C.H.; Shih, C.C. Ergostatrien-3β-ol from *Antrodia camphorata* inhibits diabetes and hyperlipidemia in high-fat-diet treated mice via regulation of related genes, glucose transporter 4, and AMP-activated protein kinase phosphorylation. *J. Agric. Food Chem.* 2015, 63, 2479–2489. [CrossRef] [PubMed]

99. Chang, Y.Y.; Liu, Y.C.; Kuo, Y.H.; Lin, Y.L.; Wu, Y.S.; Chen, J.W.; Chen, Y.C. Effects of antrostrol from *Antrodia camphorata* submerged whole broth on lipid homeostasis, antioxidation, alcohol clearance, and anti-inflammation in livers of chronic-alcohol fed mice. *J. Ethnopharmacol.* 2017, 202, 200–207. [CrossRef]

100. Kuo, Y.H.; Lin, T.Y.; You, Y.J.; Wen, K.C.; Sung, P.J.; Chang, H.M. Anti-inflammatory and antiphotodamaging effects of ergostatrien-3β-ol, isolated from *Antrodia camphorata*, on hairless mouse skin. *Molecules* 2016, 21, 1213. [CrossRef]

101. Ma, Q.-Y.; Yang, S.; Huang, S.-Z.; Kong, F.-D.; Xie, Q.-Y.; Dai, H.-F.; Yu, Z.-F.; Zhao, Y.-X. Ergostane steroids from *Coprinus setulosus*. *Chem. Nat. Compd.* 2018, 54, 710–713. [CrossRef]

102. Hsieh, W.T.; Hsu, M.H.; Lin, W.J.; Xiao, Y.C.; Lyu, P.C.; Liu, Y.C.; Lin, W.Y.; Kuo, Y.H.; Chung, J.G. Ergosta-7,9(11),22-trien-3β-ol interferes with LPS docking to LBP, CD14, and TLR4/MD-2 co-receptors to attenuate the NF-κB inflammatory pathway in vitro and *Drosophila*. *Int. J. Mol. Sci.* 2021, 22, 6511. [CrossRef]

103. Shi, Q.; Huang, Y.; Su, H.; Gao, Y.; Peng, X.; Zhou, L.; Li, X.; Qiu, M. C28 steroids from the fruiting bodies of *Ganoderma resinaceum* with potential anti-inflammatory activity. *Phytochemistry* 2019, 168, 112109. [CrossRef] [PubMed]

104. Metwaly, A.M.; Kadry, H.A.; El-Hela, A.A.; Mohammad, A.-E.I.; Ma, G.; Cutler, S.J.; Ross, S.A. Nigrosphearin A, a new isochromene derivative from the endophytic fungus *Nigrospora sphaerica*. *Phytochem. Lett.* 2014, 7, 1–5. [CrossRef] [PubMed]

105. Xiong, J.; Huang, Y.; Wu, X.-Y.; Liu, X.-H.; Fan, H.; Wang, W.; Zhao, Y.; Yang, G.-X.; Zhang, H.-Y.; Hu, J.-F. Chemical constituents from the fermented mycelia of the medicinal fungus *Xylaria nigripes*. *Heli. Chim. Acta* 2016, 99, 83–89. [CrossRef]

106. Kao, Y.T.; Kuo, Y.-H.; Wang, S.-D.; Hong, H.-J.; Lin, L.-J. Analogous corticosteroids, EK100, derived from solid-state-cultured mycelium of *Antrodia camphorata* inhibit proinflammatory cytokine expression in macrophages. *Cytokine* 2018, 108, 136–144. [CrossRef] [PubMed]

107. Huang, G.-J.; Huang, S.-S.; Lin, S.-S.; Shao, Y.-Y.; Chen, C.-C.; Hou, W.-C.; Kuo, Y.-H. Analgesic effects and the mechanisms of anti-inflammation of ergostatrien-3β-ol from *Antrodia camphorata* submerged whole broth in mice. *J. Agric. Food Chem.* 2010, 58, 7445–7452. [CrossRef]

108. Tsai, T.-C.; Tung, Y.-T.; Kuo, Y.-H.; Liao, J.-W.; Tsai, H.-C.; Chong, K.-Y.; Chen, H.-L.; Chen, C.-M. Anti-inflammatory effects of *Antrodia camphorata*, a herbal medicine, in a mouse skin ischemia model. *J. Ethnopharmacol.* 2015, 159, 113–121. [CrossRef]

109. Chao, T.Y.; Hsieh, C.C.; Hsu, S.M.; Wan, C.H.; Lian, G.T.; Tseng, Y.H.; Kuo, Y.H.; Hsieh, S.C. Ergostatrien-3β-ol (EK100) from *Antrodia camphorata* attenuates oxidative stress, inflammation, and liver injury in vitro and in vivo. *Prev. Nutr. Food Sci.* 2021, 26, 58–66. [CrossRef]

110. Wang, Y.H.; Chern, C.M.; Liou, K.T.; Kuo, Y.H.; Shen, Y.C. Ergostatrien-7,9(11),22-trien-3β-ol from *Antrodia camphorata* ameliorates ischemic stroke brain injury via downregulation of p65NF-κB and caspase 3, and activation of Akt/GSK3/β-catenin-associated neurogenesis. *Food Funct.* 2019, 10, 4725–4738. [CrossRef]

111. Hsieh, P.J.; Wang, W.H.; Hsioua, C.J.; Chen, C.K.; Lin, F.L.; Huang, S.H.; Yen, J.L.; Tsai, P.H.; Kuo, Y.H.; Hsiao, G. Ergosta-7,9(11),22-trien-3β-ol alleviates intracerebral hemorrhage-induced brain injury and bv-2 microglial activation. *Molecules* 2021, 26, 2970. [CrossRef]

112. Chen, Y.M.; Sung, H.C.; Kuo, Y.H.; Hsu, Y.J.; Huang, C.C.; Liang, H.L. The effects of ergosta-7,9(11),22-trien-3β-ol from *Antrodia camphorata* on the biochemical profile and exercise performance of mice. *Molecules* 2019, 24, 1225. [CrossRef]

113. Robalo, J.R.; do Canto, A.M.T.M.; Carvalho, A.J.P.; Ramalho, J.P.P.; Loura, L.M.S. Behavior of fluorescent cholesterol analogues dehydroergosterol and cholestatrienol in lipid bilayers: A molecular dynamics study. *J. Phys. Chem. B* 2013, 117, 5806–5819. [CrossRef] [PubMed]

114. Pourmousa, M.; Rog, T.; Mikkeli, R.; Vattulainen, I.; Solanko, L.M.; Wustner, D.; List, N.H.; Kongsted, J.; Karttunen, M. Dehydroergosterol as an analogue for cholesterol: Why it mimics cholesterol so well—or does it? *J. Phys. Chem. B* 2014, 118, 7345–7357. [CrossRef] [PubMed]

115. Chattopadhyay, A.; Biswas, S.C.; Rukmini, R.; Saha, S.; Samanta, A. Lack of environmental sensitivity of a naturally occurring fluorescent analog of cholesterol. *J. Fluoresc.* 2021, 31, 1401–1407. [CrossRef] [PubMed]

116. Ano, Y.; Kutsukake, T.; Hoshi, A.; Yoshida, A.; Nakayama, H. Identification of a novel dehydroergosterol enhancing microglial anti-inflammatory activity in a dairy product fermented with *Penicillium candidum*. *PLoS ONE* 2015, 10, e0116998. [CrossRef]

117. Ano, Y.; Ikado, K.; Shindo, K.; Koizumi, H.; Fujikawa, D. Identification of 14-dehydroergosterol as a novel anti-inflammatory compound inducing tolerogenic dendritic cells. *Sci. Rep.* 2017, 7, 13903. [CrossRef]
118. Liu, Z.; Dong, Z.; Qiu, P.; Wang, Q.; Yan, J.; Lu, Y.; Wasu, P.-A.; Hong, K.; She, Z. Two new bioactive steroids from a mangrove-derived fungus Astreuplicates sp. Steroids 2018, 140, 32–38. [CrossRef]
119. Liang, S.; Srisrinichan, S.; Pornpakakul, S. Anthraquinone-steroids, evanhtrasterol A and B, and a meroterpenoid, emericelleric acid, from endophytic fungus, Emericella varicelar. Steroids 2016, 106, 78–85. [CrossRef]
120. Elsebai, M.F.; Ghabbour, H.A.; Mehiri, M. Unusual nitrogenous phenalene derivatives from the marine-derived fungus Coniothyrium cereale. Molecules 2016, 21, 178. [CrossRef]
121. Hou, G.M.; Xu, X.M.; Wang, Q.; Li, D.Y.; Li, Z.L. Hybrid of dehydroergosterol and nitrogenous alternariol derivative from the fungus Pestalotiopsis wuicola. Steroids 2018, 138, 43–46. [CrossRef]
122. El-Sherif, N.F.; Ahmed, S.A.; Ibrahim, A.K.; Habib, E.S.; El-Fallal, A.A.; El-Sayed, A.K.; Wahba, A.E. Ergosterol peroxide from the egyptian red lingzhi or reishi mushroom, Ganoderma resinaceum (Agaricomycetes), showed preferred inhibition of MCF-7 over MDA-MB-231 breast cancer cell lines. Int. J. Med. Mushrooms 2020, 22, 389–396. [CrossRef]
123. Chen, P.; Qin, H.-J.; Li, Y.-W.; Ma, G.-X.; Yang, J.-S.; Wang, Q. Study on chemical constituents of an edible mushroom Volvariella volvacea and their antitumor activity in vitro. Nat. Prod. Res. 2020, 34, 1417–1422. [CrossRef] [PubMed]
124. Govindharaj, M.; Arumugam, S.; Nirmala, G.; Bharadwaj, M.; Murugiyann, K. Effect of marine basidiomycetes Fulvifomes sp.-derived ergosterol peroxide on cytotoxicity and apoptosis induction in MCF-7 cell line. J. Fungi 2019, 5, 16. [CrossRef]
125. Wu, H.-Y.; Yang, F.-L.; Li, L.-H.; Rao, Y.K.; Ju, T.-C.; Wong, W.-T.; Hsieh, C.-Y.; Pivkin, M.V.; Hua, K.-F.; Wu, S.-H. Ergosterol peroxide from the fungus Phoma sp. induces ROS-dependent apoptosis and autophagy in human lung adenocarcinoma cells. Sci. Rep. 2018, 8, 17956. [CrossRef] [PubMed]
126. Lee, S.; Lee, D.; Ryoo, R.; Kim, J.-C.; Park, H.B.; Kang, K.S.; Kim, K.H. Calvatianone, a sterol possessing a 6/5/6/5-fused ring system with a contracted tetrahydrofuran B-ring, from the fruiting bodies of Calvatia nipponica. J. Nat. Prod. 2020, 83, 2737–2742. [CrossRef]
127. Chen, Y.K.; Kuo, Y.H.; Chiang, B.H.; Lo, J.M.; Sheen, L.Y. Cytotoxic activities of 9,11-dehydroergosterol peroxide and ergosterol peroxide from the fermentation mycelia of Ganoderma lucidum cultured in the medium containing leguminous plants on Hep 3B cells. J. Agric. Food Chem. 2009, 57, 5713–5719. [CrossRef]
128. Lee, C.; Kim, S.; Li, W.; Bang, S.; Lee, H.; Lee, H.-J.; Noh, E.-Y.; Park, J.-E.; Bang, W.Y.; Shim, S.H. Bioactive secondary metabolites produced by an endophytic fungus Gaemumonnesy sp. JS0464 from a maritime halophyte Phragmites communis. J. Antibiott. 2017, 70, 737–742. [CrossRef]
129. Kobori, M.; Yoshida, M.; Ohnishi-Kameyma, M.; Takei, T.; Shinmoto, H. 5α,8α-Epoxysterol from Pestalotiopsis uvicola fungus sp. induces ROS-dependent apoptosis and autophagy in human lung adenocarcinoma cells. Molecules 2018, 23, 43–46. [CrossRef]
130. Kobori, M.; Yoshida, M.; Ohnishi-Kameyma, M.; Takei, T.; Shinmoto, H. 5α,8α-Epoxysterol from Pestalotiopsis uvicola fungus sp. induces ROS-dependent apoptosis and autophagy in human lung adenocarcinoma cells. Molecules 2018, 23, 43–46. [CrossRef]
131. Zheng, L.; Wong, Y.S.; Shao, M.; Huang, S.; Wang, F.; Chen, J. Apoptosis induced by 9,11-dehydroergosterol peroxide from Ganoderma Lucidum mycelium in human malignant melanoma cells is Mcl-1 dependent. Mol. Med. Rep. 2018, 18, 938–944. [CrossRef]
132. Cui, Y.J.; Guan, S.H.; Feng, L.X.; Song, X.Y.; Ma, C.; Cheng, C.R.; Wang, W.B.; Wu, W.Y.; Yue, Q.X.; Liu, X.; et al. Cytotoxicity and cell death by 9,11-dehydroergosterol peroxide isolated from Ganoderma Lucidum and its target-related proteins. Nat. Prod. Commun. 2010, 5, 1183–1186.
133. Zheng, L.; Wong, Y.S.; Shao, M.; Huang, S.; Wang, F.; Chen, J. Apoptosis induced by 9,11-dehydroergosterol peroxide from Ganoderma Lucidum mycelium in human malignant melanoma Cells is Mcl-1 dependent. Mol. Med. Rep. 2018, 18, 938–944. [CrossRef]
134. Njue, A.W.; Omolo, J.O.; Cheploogi, P.K.; Langat, M.K.; Mulholland, D.A. Cytotoxic ergostane derivatives from the edible mushroom Termitomyces microcarpus (Lyophyllaceae). Biochem. Syst. Ecol. 2018, 76, 12–14. [CrossRef]
135. Chen, Z.; Bishop, K.S.; Tanambell, H.; Buchanan, P.; Smith, C.; Quek, S.Y. Characterization of the bioactivities of a phytosterol extract and some of its constituents from the New Zealand native mushroom Hericium novae-zealandiae. Food Funct. 2019, 10, 6633–6643. [CrossRef] [PubMed]
136. He, L.; Shi, W.; Liu, X.; Zhao, X.; Zhang, Z. Anticancer action and mechanism of ergosterol peroxide from Paeclomyces cicaeae fermentation broth. Int. J. Mol. Sci. 2018, 19, 3935. [CrossRef]
137. Tan, W.; Pan, M.; Liu, H.; Tian, H.; Ye, Q.; Liu, H. Ergosterol peroxide inhibits ovarian cancer cell growth through multiple pathways. OncoTargets Ther. 2017, 10, 3467–3474. [CrossRef] [PubMed]
138. Shin, M.-K.; Sasaki, F.; Ki, D.-W.; Win, N.N.; Morita, H.; Hayakawa, Y. Anti-metastatic effects of ergosterol peroxide from the entomopathogenic fungus Ophiocordyces gracilipes on 4T1 breast cancer cells. J. Nat. Med. 2021, 75, 824–832. [CrossRef] [PubMed]
139. Yang, Y.; Luo, X.; Yasheng, M.; Zhao, J.; Li, J.; Li, J. Ergosterol peroxide from Pleurotus ferulae inhibits gastrointestinal tumor cell growth through induction of apoptosis via reactive oxygen species and endoplasmic reticulum stress. Food Funct. 2020, 11, 4171–4184. [CrossRef] [PubMed]
140. Zhao, F.; Xia, G.; Chen, L.; Zhao, J.; Xie, Z.; Qiu, F.; Han, G. Chemical constituents from Inonotus obliquus and their antitumor activities. J. Nat. Med. 2016, 70, 721–730. [CrossRef] [PubMed]
141. Zhou, J.; Li, G.; Deng, Q.; Zheng, D.; Yang, X.; Xu, J. Cytotoxic constituents from the mangrove endophytic Pestalotiopsis sp. induce G(0)/G(1) cell cycle arrest and apoptosis in human cancer cells. Nat. Prod. Res. 2018, 32, 2968–2972. [CrossRef]
142. Xiao, L.; Zhang, Y.; Zhang, H.-L.; Li, D.; Gu, Q.; Tang, G.-H.; Yu, Q.; An, L.-K. Spiroconyone A, a new phytosterol with a spiro [5,6] ring system from Coryza japonica. Org. Biomol. Chem. 2020, 18, 5130–5136. [CrossRef]
Shaker, S.; Sun, T.-T.; Wang, L.-Y.; Ma, W.-Z.; Wu, D.-L.; Guo, Y.-W.; Dong, J.; Chen, Y.-X.; Zhu, L.-P.; Yang, D.-P.; et al. Reactive oxygen species altering the metabolite profile of the marine-derived fungus Dichotomomyces ceiphi F31-1. *Nat. Prod. Res.* **2021**, *35*, 41–48. [CrossRef]

Le, B.V.; Nguyen, T.M.N.; Yang, S.Y.; Kim, J.H.; Le, T.V.; Huang, P.T.T.; Nguyen, V.T.; Nguyen, X.C.; Nguyen, H.N.; Chau, V.M.; et al. A new rearranged abietane diterpene from *Clereodendrum inermie* with antioxidant and cytotoxic activities. *Nat. Prod. Res.* **2018**, **32**, 2001–2007. [CrossRef]

Nguyen, T.T.; Nguyen, D.H.; Zhao, B.T.; Le, D.D.; Min, B.S.; Kim, Y.H.; Woo, M.H. Triterpenoids and sterols from the grains of *Echinocloa utilis* Ohwi & Yabuno and their cytotoxic activity. *Biomed. Pharmacother.* **2017**, *93*, 202–207. [CrossRef] [PubMed]

Hung, D.X.; Kuo, P.C.; Tuan, N.N.; Van Trung, H.; Tan Thanh, N.; Thu Ha, N.; Long Giang, B.; Quang Trung, N.; Thi Nhan, N.; Hai, H.V.; et al. Triterpenoids and sterols from the fruiting bodies of *Hexagonia tenuis* and their cytotoxicity. *Nat. Prod. Res.* **2021**, *35*, 251–256. [CrossRef] [PubMed]

Bu, M.; Li, H.; Wang, H.; Wang, J.; Lin, Y.; Ma, Y. Synthesis of ergosterol peroxide conjugates as mitochondria targeting probes for enhanced anticancer activity. *Molecules* **2019**, *24*, 3307. [CrossRef]

Bu, M.; Cao, T.; Li, H.; Guo, M.; Yang, B.B.; Zeng, C.; Hu, L. Synthesis of 5α,8α-ergosterol peroxide 3-carbamate derivatives and a fluorescent mitochondria-targeting conjugate for enhanced anticancer activities. *ChemMedChem* **2017**, *12*, 466–474. [CrossRef]

Chen, S.; Yong, T.; Zhang, Y.; Su, J.; Jiao, C.; Xie, Y. Anti-tumor and anti-angiogenic ergosterols from *Ganoderma lucidum*. *Front. Chem.* **2017**, *5*, 85. [CrossRef] [PubMed]

Nowak, R.; Drozd, M.; Mendyk, E.; Lemieszek, M.; Krakowiak, O.; Kisiel, W.; Szewczyk, K. A new method for the isolation of ergosterol and peroxyergosterol as active compounds of *Hygrophoropsis aurantiaca* and in vitro antiproliferative activity of isolated ergosterol peroxide. *Molecules* **2016**, *21*, 946. [CrossRef]

Ling, T.; Lang, W.H.; Martinez-Montemayor, M.M.; Rivas, F. Development of ergosterol peroxide probes for cellular localisation studies. *Org. Biomol. Chem.* **2019**, *17*, 5223–5229. [CrossRef] [PubMed]

Martinez-Montemayor, M.M.; Ling, T.; Suárez-Arroyo, I.J.; Ortiz-Soto, G.; Santiago-Negrón, C.L.; Lacourt-Ventura, M.Y.; Valentín-Acevedo, A.; Lang, W.H.; Rivas, F. Identification of biologically active *Ganoderma lucidum* compounds and synthesis of improved derivatives that confer anti-cancer activities in vitro. *Front. Pharmacol.* **2019**, *10*, 115. [CrossRef]

Kim, K.H.; Choi, S.U.; Noh, H.J.; Zee, O.; Lee, K.R. Cytotoxic ergosterol derivatives from the mushroom *Naematoloma fasciculare*. *Nat. Prod. Sci.* **2014**, *20*, 76–79.

Shi, X.-W.; Li, X.-J.; Gao, J.-M.; Zhang, X.-C. Fasciculols H and I, two lanostane derivatives from *Naematoloma fasciculare*. *Chem. Biodivers.* **2011**, *8*, 1864–1870. [CrossRef]

Ibrahim, S.R.M.; Mohamed, G.A.; Haari, R.A.A.; Abd-Elmonem, A.; El-Kholy, S.; Asfour, H.Z.; Zayed, M.F. Fusaristeroid A: A new cytotoxic and antifungal ergosterol fatty acid ester from the endophytic fungus *Fusarium* sp. associated with *Mentha longifolia* roots. *Pharmacogn. Mag.* **2018**, *14*, 308–313. [CrossRef]

Chen, S.; Yong, T.; Xiao, C.; Su, J.; Zhang, Y.; Jiao, C.; Xie, Y. Pyrrole alkaloids and ergosterols from *Grifola frondosa* exert anti-α-glucosidase and anti-proliferative activities. *J. Funct. Foods* **2018**, *43*, 196–205. [CrossRef]

Lee, S.; Lee, S.; Roh, H.-S.; Song, S.-S.; Ryoo, R.; Pang, C.; Baek, K.-H.; Kim, K.H. Cytotoxic constituents from the sclerotia of *Poria cocos* against human lung adenocarcinoma cells by inducing mitochondrial apoptosis. *Cells* **2018**, *7*, 116. [CrossRef]

Su, Z.; Wang, P.; Yuan, W.; Li, S. Chemical constituents from the fruit body of *Chlorophyllum molybdites*. *Nat. Prod. Commun.* **2013**, *8*, 1227–1228. [CrossRef]

Shimizu, T.; Kawai, J.; Ouchi, K.; Kikuchi, H.; Osima, Y.; Hidemi, R. Agarol, an ergosterol derivative from *Agaricus blazei*, induces caspase-independent apoptosis in human lung cancer cells. *Int. J. Oncol.* **2016**, *48*, 1670–1678. [CrossRef]

Meza-Menchaca, T.; Poblete-Naredo, I.; Albores-Medina, A.; Pedraza-Chaverri, J.; Quiroz-Figueroa, F.R.; Cruz-Gregorio, A.; Zepeda, R.C.; Melgar-Lalanne, G.; Lagunes, I.; Trigos, A. *Naematoloma fasciculare* sp. associated with *Olea europaea* L. fruits and *Boerhaavia segetalis* with antioxidant and cytotoxic activities. *Nat. Prod. Res.* **2017**, *31*, 2705. [CrossRef]

Cayan, F.; Tel-Cayan, G.; Deveci, E.; Duru, M.E.; Tuerk, M. A detailed study on multifaceted bioactivities of the extracted and isolated compounds from *Reddellomyces parvulosporus*. *Int. J. Food Sci. Technol.* **2022**, *57*, 1411–1419. [CrossRef]

Li, F.; Guo, S.; Zhang, S.; Peng, S.; Cao, W.; Ho, C.-T.; Bai, N. Bioactive constituents of *F. esculentum* bee pollen and quantitative analysis of samples collected from seven areas by HPLC. *Molecules* **2019**, *24*, 2705. [CrossRef]

Wu, S.-J.; Tung, Y.-J.; Ng, L.-T. Anti-diabetic effects of *Grifola frondosa* bioactive compound and its related molecular signaling pathways in palmitate-induced C2C12 cells. *J. Ethnopharmacol.* **2020**, *260*, 112962. [CrossRef]

Wonakam, A.K.N.; Ngansop, C.A.N.; Tchuenmogne, M.A.T.; Tchegnitegni, B.T.; Bitchagno, G.T.M.; Awantu, A.F.; Bankeu, J.J.K.; Boyom, F.F.; Sewald, N.; Lenta, B.N. Chemical constituents from *Baphia leptobotrys* *D* (Fabaceae) and their chemophenetic significance. *Biochem. Syst. Ecol.* **2021**, *96*, 104260. [CrossRef]

Meza-Menchaca, T.; Ramos-Ligonio, A.; Lopez-Moneaon, A.; Limon, A.V.; Kaluzhskiy, L.A.; Shkel, T.V.; Strushkevich, N.V.; Jimenez-Garcia, L.F.; Moreno, L.T.A.; Gallegos-Garcia, V.; et al. Insights into ergosterol peroxide’s trypanocidal activity. *Biomolecules* **2019**, *9*, 484. [CrossRef]

Zhou, B.; Liang, X.; Feng, Q.; Li, J.; Pan, X.; Xie, P.; Jiang, Z.; Yang, Z. Ergosterol peroxide suppresses influenza A virus-induced pro-inflammatory response and apoptosis by blocking RIG-I signaling. *Eur. J. Pharmacol.* **2019**, *860*, 172543. [CrossRef] [PubMed]
165. Duan, C.; Wang, J.; Liu, Y.; Zhang, J.; Si, J.; Hao, Z.; Wang, J. Antiviral effects of ergosterol peroxide in a pig model of porcine deltacoronavirus (PDCoV) infection involves modulation of apoptosis and tight junction in the small intestine. *Vet. Res.* 2021, 52, 86. [CrossRef] [PubMed]

166. Duan, C.; Liu, Y.; Hao, Z.; Wang, J. Ergosterol peroxide suppresses porcine deltacoronavirus (PDCoV)-induced autophagy to inhibit virus replication via p38 signaling pathway. *Vet. Microbiol.* 2021, 257, 109068. [CrossRef] [PubMed]

167. Duan, C.; Ge, X.; Wang, J.; Wei, Z.; Feng, W.-h.; Wang, J. Ergosterol peroxide exhibits antiviral and immunomodulatory abilities against porcine deltacoronavirus (PDCoV) via suppression of NF-κB and p38/MAPK signaling pathways in vitro. *Int. Immunopharmacol.* 2021, 93, 107317. [CrossRef] [PubMed]

168. Jin, M.; Zhou, W.; Jin, C.; Jiang, Z.; Diao, S.; Jin, Z.; Li, G. Anti-inflammatory activities of the chemical constituents isolated from *Trametes versicolor*. *Nat. Prod. Res.* 2019, 33, 2422–2425. [CrossRef]

169. Lee, S.; Lee, D.; Park, J.Y.; Seok, S.; Jang, T.S.; Park, H.B.; Shim, S.H.; Kang, K.S.; Kim, K.H. Antigastriitis effects of *Armillariella tabescens* (Scop.) Singh. and the identification of its anti-inflammatory metabolites. *J. Pharm. Pharmacol.* 2018, 70, 404–412. [CrossRef]

170. Lee, S.; Choi, E.; Yang, S.-M.; Ryoo, R.; Moon, E.; Kim, S.-H.; Kim, K.H. Bioactive compounds from sclerotia extract of *Trametes versicolor*. *BMC Complement Altern. Med.* 2016, 16, 2298–2306. [CrossRef] [PubMed]

171. Lee, S.; Choi, E.; Yang, S.-M.; Ryoo, R.; Moon, E.; Kim, S.-H.; Kim, K.H. Bioactive compounds from sclerotia extract of *Trametes versicolor*. *BMC Complement Altern. Med.* 2016, 16, 2298–2306. [CrossRef] [PubMed]

172. Jeong, Y.-U.; Park, Y.-J. Ergosterol peroxide from the medicinal mushroom *Hygrophorus russula* inhibits lipopolysaccharide-induced cytokine production in macrophages. *Vet. Immunol. Immunopathol.* 2016, 172, 1583. [CrossRef] [PubMed]

173. Cateni, F.; Doljak, B.; Zacchigna, M.; Anderluh, M.; Piltaver, A.; Scialino, G.; Banfi, E. New biologically active epidioxysterols from *Sparassis crispa* LPS-stimulated RAW264.7 cells. *Molecules* 2017, 22, 1583. [CrossRef] [PubMed]

174. Zhai, M.M.; Qi, F.M.; Li, J.; Jiang, C.X.; Hou, Y.; Shi, Y.P.; Di, D.L.; Zhang, J.W.; Wu, Q.X. Isolation of secondary metabolites from *Clonostachys rosea* YRS-06, a biological control agent, and evaluation of antibacterial activity. *Br. J. Nutr.* 2018, 117, 6576–6581. [CrossRef] [PubMed]

175. Sadorn, K.; Saepua, S.; Boonyuen, N.; Laksanacharoen, P.; Rachtawee, P.; Prabpai, S.; Kongsaeree, P.; Pittayakhajonwut, P. Identification of novel *Stereum hirsutum* polyketides with antifungal activity. *Bioorg. Med. Chem. Lett.* 2017, 27, 5498–5501. [CrossRef] [PubMed]

176. Duan, C.; Liu, Y.; Hao, Z.; Wang, J. Ergosterol peroxide suppresses porcine deltacoronavirus (PDCoV)-induced autophagy to inhibit virus replication via p38 signaling pathway. *Vet. Microbiol.* 2021, 257, 109068. [CrossRef] [PubMed]

177. Wang, A.; Li, P.; Han, P.; Gu, G.; Shan, T.; Lai, D.; Zhou, L. New nitrogen-containing metabolites from cultures of rice false smut pathogen *Fusarium oxysporum*. *Bioorg. Chem.* 2017, 70, 27–34. [CrossRef]

178. Uc-Cachon, A.; Gamboa-Angulo, M.M.; Borges-Argaez, R.; Reyes-Estebanez, M.; Said-Fernandez, S.; Molina-Salinas, G. Antitu-
217. Pang, X.; Lin, X.; Wang, J.; Liang, R.; Tian, Y.; Salendra, L.; Luo, X.; Zhou, X.; Yang, B.; Tu, Z.; et al. Three new highly oxygenated sterols and one new dihydroisocoumarin from the marine sponge-derived fungus Cladosporium sp. SCSIO41007. Steroids 2018, 129, 41–46. [CrossRef]

218. Al-Rabia, M.W.; Mohamed, G.A.; Ibrahim, S.R.M.; Asfour, H.Z. Anti-inflammatory ergosterol derivatives from the endophytic fungus Fusarium chlamydosporum. Nat. Prod. Res. 2021, 35, 5011–5020. [CrossRef]

219. Wang, H.; Liu, T.; Xin, Z. A new glucitol from an endophytic fungus Fusarium equiseti Salicorin 8. Eur. Food Res. Technol. 2014, 239, 365–376. [CrossRef]

220. Bao, F.; Yang, K.; Wu, C.; Gao, S.; Wang, P.; Chen, L.; Li, H. New natural inhibitors of hexokinase 2 (HK2): Steroids from Penicillium granulatum. J. Antibiot. 2018, 71, 1028–1035. [CrossRef] [PubMed]

221. Guo, J.; Yuan, Y.; Lu, D.; Du, B.; Xiong, L.; Shi, J.; Yang, L.; Liu, W.; Yuan, X.; Zhang, G.; et al. New natural compounds from the deep-sea-derived fungus Penicillium granulatum MCCC 3A00475 induced apoptosis via retinoid X receptor (RXR)-α pathway. Mar. Drugs 2019, 17, 178. [CrossRef] [PubMed]

222. Niu, S.; Wang, N.; Xie, C.-L.; Fan, Z.; Luo, Z.; Chen, H.-F.; Yang, X.-W. Roquefortine J, a novel roquefortine alkaloid, from the deep-sea-derived fungus Penicillium granulatum MCCC 3A00475. J. Antibiot. 2018, 71, 658–661. [CrossRef]

223. Guo, J.; Yuan, Y.; Lu, D.; Du, B.; Xiong, L.; Shi, J.; Yang, L.; Liu, W.; Yuan, X.; Zhang, G.; et al. Two natural products, trans-phytol and (22E)-ergosta-6,9,22-triene-3β,5α,8α-triol, inhibit the biosynthesis of estrogen in human ovarian granulosa cells by aromatase (CYP19). Toxicol. Appl. Pharmacol. 2014, 279, 23–32. [CrossRef]

224. Kawahara, N.; Sekita, S.; Satake, M. Steroids from Calvatia cyathiformis. Phytochemistry 1994, 37, 213–215. [CrossRef]
294. Su, L.H.; Geng, C.A.; Li, T.Z.; Huang, X.Y.; Ma, Y.B.; Zhang, X.M.; Wu, G.; Yang, Z.L.; Chen, J.J. Spirosofostanol, a rearranged ergostane-sterol from the fruiting bodies of Butyriboletus roseoflavus. J. Nat. Prod. 2020, 83, 1706–1710. [CrossRef] [PubMed]

295. Anke, T.; Werle, A.; Kappe, R.; Sterner, O. Laschiatrion, a new antifungal agent from a Favolaschia species (Basidiomycetes) active against human pathogens. J. Antimicrob. Chemother. 2004, 53, 496–501. [CrossRef]

296. Cui, C.-M.; Li, X.-M.; Meng, L.; Li, C.-S.; Huang, C.-G.; Wang, B.-G. 7-Nor-ergosterolide, a pentalactone-containing norsterol and related steroids from the marine-derived endophytic Aspergillus oryzae EN-31. J. Nat. Prod. 2010, 73, 1780–1784. [CrossRef]

297. Krohn, K.; Biele, C.; Aust, H.J.; Draeger, S.; Schulz, B. Herbarulide, a ketodivinyllactone steroid with an unprecedented homo-6-oxaergostane skeleton from the endophytic fungus Plespora herbarum. J. Nat. Prod. 1999, 62, 629–630.

298. Tong, Z.B.; Cui, X.H.; Wang, J.; Zhang, C.L.; Zhang, Y.Y.; Ren, Z. Constituents from solid-cultured Antrodia camphorata. Nat. Prod. Res. 2017, 31, 2564–2567. [CrossRef]

299. Duecker, F.L.; Heinze, R.C.; Mueller, M.; Zhang, S.; Heretsch, P. Synthesis of the alleged structures of fortisterol and herbarulide and structural revision of herbarulide. Org. Lett. 2020, 22, 1585–1588. [CrossRef]

300. Ratnaweera, P.B.; Williams, D.E.; Patrick, B.O.; de Silva, E.D.; Andersen, R.J. Solanieic acid, an antibacterial degraded steroid produced in culture by the fungus Rhizoctonia solani isolated from tubers of the medicinal plant Cyperus rotundus. Org. Lett. 2015, 17, 2074–2077. [CrossRef]

301. Song, Y.-P.; Shi, Z.-Z.; Miao, F.-P.; Fang, S.-T.; Yin, X.-L.; Ji, N.-Y. Tricholumin A, a highly transformed ergosterol derivative from the alga-endophytic fungus Trichoderma asperellum. Org. Lett. 2018, 20, 6306–6309. [CrossRef]

302. Nakada, T.; Yamamura, S. Three new metabolites of hybrid strain KO 0231, derived from Penicillium citreo-viride IFO 6200 and related steroids from the marine-derived endophytic Talaromyces purpurogenus strain. J. Nat. Prod. 2017, 80, 3749–3754. [CrossRef]

303. Amagata, T.; Tanaka, M.; Yamada, T.; Doi, M.; Minoura, K.; Ohishi, H.; Yamori, T.; Numata, A. Dankasterone, a new class of cytotoxic steroid produced by a marine fungus Gymnascella dankaliensis. Phytochemistry 2019, 162, 127–132. [CrossRef]

304. Gao, W.; Chai, C.; He, Y.; Li, F.; Hao, X.; Cao, F.; Gu, L.; Liu, J.; Hu, Z.; Zhang, Y. Periconiastone A, an antibacterial ergosterol with a pentacyclo[8.7.0.0^{2,14}.10]heptadecane system from Periconia sp. TJ403-rc01. Org. Lett. 2019, 21, 8469–8472. [CrossRef] [PubMed]

305. Duecker, F.L.; Heinze, R.C.; Heretsch, P. Synthesis of swinhoeststerol A, dankasterone A and B, and periconiastone A by radical framework reconstruction. J. Am. Chem. Soc. 2020, 142, 104–108. [CrossRef] [PubMed]

306. Zhao, Z.Z.; Chen, H.P.; Huang, Y.; Zhang, S.B.; Li, Z.H.; Feng, T.; Liu, J.K. Bioactive polyketides and 8,14-seco-ergosterol from the alga-endophytic fungus Tricholoma matsutake. Org. Lett. 2020, 22, 1072–1075. [CrossRef] [PubMed]

307. Wang, W.; Wan, X.; Liu, J.; Wang, J.; Zhu, H.; Chen, C.; Zhang, Y. Two new terpenoids from Talaromyces purpurogenus. Mar. Drugs 2018, 16, 150. [CrossRef]

308. Yang, X.-Y.; Li, Z.-H.; Dong, Z.-J.; Feng, T.; Liu, J.-K. Three new sesquiterpenoids from the sponge-derived endophytic fungus Arthrinium sp. Phytochem. Lett. 2017, 20, 246–251. [CrossRef]

309. Kumla, D.; Aung, T.S.; Buttachon, S.; Dethoup, T.; Gales, L.; Pereira, J.A.; Inacio, A.; Costa, P.M.; Lee, M.; Sekeroglu, N.; et al. A new dihydrochromone dimer and other secondary metabolites from cultures of the marine sponge-associated fungi Neosartorya fennelliae KUFA 0811 and Neosartorya tsunodae KUFC 9213. Mar. Drugs 2017, 15, 375. [CrossRef]

310. Lee, T.-H.; Chen, C.-C.; Chen, J.-J.; Liao, H.-F.; Chang, H.-S.; Sung, P.-J.; Tseng, M.-H.; Wang, S.-Y.; Ko, H.-H.; Kuo, Y.-H. New and cytotoxic components from Antrodia camphorata. Molecules 2014, 19, 21378–21385. [CrossRef]

311. Duecker, F.L.; Heinze, R.C.; Heretsch. P. Synthesis of swinhoeststerol A, dankasterone A and B, and periconiastone A by radical framework reconstruction. J. Am. Chem. Soc. 2020, 142, 104–108. [CrossRef] [PubMed]

312. Nakada, T.; Yamamura, S. Three new metabolites of hybrid strain KO 0231, derived from Penicillium citreo-viride IFO 6200 and related steroids from the marine-derived endophytic Talaromyces purpurogenus strain. J. Nat. Prod. 2017, 80, 3749–3754. [CrossRef] [PubMed]

313. Anke, T.; Werle, A.; Kappe, R.; Sterner, O. Laschiatrion, a new antifungal agent from a Favolaschia species (Basidiomycetes) active against human pathogens. J. Antimicrob. Chemother. 2004, 53, 496–501. [CrossRef]

314. Cui, C.-M.; Li, X.-M.; Meng, L.; Li, C.-S.; Huang, C.-G.; Wang, B.-G. 7-Nor-ergosterolide, a pentalactone-containing norsterol and related steroids from the marine-derived endophytic Aspergillus oryzae EN-31. J. Nat. Prod. 2010, 73, 1780–1784. [CrossRef]

315. Krohn, K.; Biele, C.; Aust, H.J.; Draeger, S.; Schulz, B. Herbarulide, a ketodivinyllactone steroid with an unprecedented homo-6-oxaergostane skeleton from the endophytic fungus Plespora herbarum. J. Nat. Prod. 1999, 62, 629–630.

316. Tong, Z.B.; Cui, X.H.; Wang, J.; Zhang, C.L.; Zhang, Y.Y.; Ren, Z. Constituents from solid-cultured Antrodia camphorata. Nat. Prod. Res. 2017, 31, 2564–2567. [CrossRef] [PubMed]

317. Duecker, F.L.; Heinze, R.C.; Mueller, M.; Zhang, S.; Heretsch, P. Synthesis of the alleged structures of fortisterol and herbarulide and structural revision of herbarulide. Org. Lett. 2020, 22, 1585–1588. [CrossRef] [PubMed]

318. Ratnaweera, P.B.; Williams, D.E.; Patrick, B.O.; de Silva, E.D.; Andersen, R.J. Solanieic acid, an antibacterial degraded steroid produced in culture by the fungus Rhizoctonia solani isolated from tubers of the medicinal plant Cyperus rotundus. Org. Lett. 2015, 17, 2074–2077. [CrossRef] [PubMed]

319. Song, Y.-P.; Shi, Z.-Z.; Miao, F.-P.; Fang, S.-T.; Yin, X.-L.; Ji, N.-Y. Tricholumin A, a highly transformed ergosterol derivative from the alga-endophytic fungus Trichoderma asperellum. Org. Lett. 2018, 20, 6306–6309. [CrossRef]

320. Nakada, T.; Yamamura, S. Three new metabolites of hybrid strain KO 0231, derived from Penicillium citreo-viride IFO 6200 and related steroids from the marine-derived endophytic Talaromyces purpurogenus strain. J. Nat. Prod. 2017, 80, 3749–3754. [CrossRef] [PubMed]
321. Chen, M.; Wang, K.L.; Liu, M.; She, Z.G.; Wang, C.Y. Bioactive steroid derivatives and butyrolactone derivatives from a gorgonian-derived Aspergillus sp. fungus. Chem. Biodivers. 2015, 12, 1398–1406. [CrossRef]
322. Kawagishi, H.; Akachi, T.; Ogawa, T.; Masuda, K.; Yamaguchi, K.; Yazawa, K.; Takahashi, M. Chaxine A, an osteoclast-forming suppressing substance, from the mushroom Agrocybe chaxingu. Heterocycles 2006, 69, 253–258. [CrossRef]
323. Choi, J.-H.; Ogawa, A.; Abe, N.; Masuda, K.; Koyama, T.; Yazawa, K.; Kawagishi, H. Chaxines B, C, D, and E from the edible mushroom Agrocybe chaxingu. Tetrahedron 2009, 65, 9850–9853. [CrossRef]
324. Hirata, Y.; Nakazaki, A.; Kawagishi, H.; Nishikawa, T. Biomimetic synthesis and structural revision of chaxine B and its analogues. Org. Lett. 2017, 19, 560–563. [CrossRef][PubMed]
325. Niki, M.; Hirata, Y.; Nakazaki, A.; Wu, J.; Kawagishi, H.; Nishikawa, T. Biomimetic synthesis of chaxine and its related compounds. J. Org. Chem. 2020, 85, 4848–4860. [CrossRef][PubMed]
326. Xiao, J.H.; Sun, Z.H.; Pan, W.D.; Lü, Y.H.; Chen, D.X.; Zhong, J.J. Jiangxienone, a new compound with potent cytotoxicity against tumor cells from traditional Chinese medicinal mushroom Cordyceps jiangxiensis. Chem. Biodivers. 2012, 9, 1349–1355. [CrossRef][PubMed]
327. Chen, Z.-M.; Yang, X.-Y.; Fan, Q.-Y.; Li, Z.-H.; Wei, K.; Chen, H.-P.; Feng, T.; Liu, J.-K. Three novel degraded steroids from cultures of the Basidiomycete Antrodiella albocinnamomea. Steroids 2014, 87, 21–25. [CrossRef][PubMed]
328. Chen, K.; Sun, W.; Bie, Q.; Liu, X.; Chen, C.; Liu, J.; Xue, Y.; Wang, J.; Luo, Z.; Zhu, H.; et al. Fusopolitide A and fusosterede A, A polyketide with a pentalenoi,2-ctpyran ring system and A degraded steride, from the fungus Fusarium solani. Tetrahedron Lett. 2018, 59, 2679–2682. [CrossRef]
329. Amagata, T.; Tanaka, M.; Yamada, T.; Chen, Y.-P.; Minoura, K.; Numata, A. Additional cytotoxic substances isolated from the sponge-derived Gymnascella dankaliensis. Tetrahedron Lett. 2013, 54, 5960–5962. [CrossRef]
330. McCloskey, S.; Noppawan, S.; Mongkolthanaruk, W.; Suwannasai, N.; Senawong, T.; Prawat, U. A new cerebroside and the cytotoxic constituents isolated from Xylaria allantoidea SWUF76. Nat. Prod. Res. 2017, 31, 1422–1430. [CrossRef]
331. Wu, J.; Zhang, H.; He, L.-M.; Xue, Y.-Q.; Jia, J.; Wang, S.-B.; Zhu, K.-K.; Hong, K.; Cai, Y.-S. A new fusicoccane-type norditerpene and a new indene from the marine-derived fungus Aspergillus aculeatinus WHUF0198. Chem. Biodivers. 2021, 18, e2100562. [CrossRef]
332. An, C.L.; Kong, F.D.; Ma, Q.Y.; Xie, Q.Y.; Yuan, J.Z.; Zhou, L.M.; Dai, H.F.; Yu, Z.F.; Zhao, Y.X. Chemical constituents of the marine-derived fungus Hericium alpestre. J. Asian Nat. Prod. Res. 2018, 21, 735–741. [CrossRef][PubMed]
333. Huang, H.-C.; Liaw, C.-C.; Yang, H.-L.; Hseu, Y.-C.; Kuo, H.-T.; Tsai, Y.-C.; Chien, S.-C.; Amagaya, S.; Chen, Y.-C.; Kuo, Y.-H. Lanostane triterpenoids and sterols from Antrodia camphorata. Phytochemistry 2012, 84, 177–183. [CrossRef][PubMed]
334. Zhao, J.-Y.; Feng, T.; Li, Z.-H.; Dong, Z.-J.; Zhang, H.-B.; Liu, J.-K. Sesquiterpenoids and an ergosterol from cultures of the fungus Daedaleopsis tricolor. Nat. Prod. Bioprospect. 2013, 3, 271–276. [CrossRef]
335. Chen, S.; Liu, Z.; Chen, Y.; Tan, H.; Zhu, S.; Liu, H.; Zhang, W. Phostoid A, a highly oxygenated norsteroid from the deep-sea-derived fungus Phomopsis tersa FS441. Tetrahedron Lett. 2020, 61, 151555. [CrossRef]
336. Liu, Z.; Zhao, J.-Y.; Sun, S.-F.; Li, Y.; Liu, Y.-B. Fungi: Outstanding source of novel chemical scaffolds. J. Asian Nat. Prod. Res. 2020, 22, 99–120. [CrossRef]